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Abstract 
 
 To prevent re-replication of DNA in a single cell cycle, the licensing of 
replication origins by Mcm2-7 is prevented during S and G2 phases. Metazoans 
achieve this by cell cycle regulated proteolysis of the essential licensing factor 
Cdt1 and formation of an inhibitory heterohexameric complex of Cdt1 with a 
small protein called geminin. The consequences of either stabilising Cdt1 or 
ablating geminin in synchronised human U2OS cells are investigated in this 
PhD Thesis to elucidate the possible contribution of re-replication in gene 
amplifications or rearrangements commonly seen in human tumours.  
 I show that following geminin loss, cells complete an apparently normal 
S-phase, but a proportion arrests at the G2/M boundary. When Cdt1 starts to 
accumulate in these cells, DNA re-replicates, suggesting that the key role of 
geminin is to prevent re-licensing in G2. Inhibition of cell cycle checkpoints in 
cells lacking geminin promotes progression through mitosis without detectable 
levels of re-replication. Checkpoint kinases thereby amplify re-replication into an 
all-or-nothing response by delaying geminin depleted cells in G2 phase. 
Comparative Genomic Hybridisation (CGH) array and Solexa Deep DNA 
sequencing revealed that re-replication after geminin depletion does not appear 
at preferential genomic regions within the human genome. This is consistent 
with a recent observation that G2 cells have lost their replication timing 
information and reduplicate their genome stochastically. In contrast, when Cdt1 
is stabilised by the neddylation inhibitor MLN4924, re-replication starts directly 
from within S-phase raising the question whether alternative mechanisms of re-
replication may cause distinct genomic consequences.  
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I.  1.  Milestones in Molecular Biology-  
  A brief journey through history  
 The focus of this PhD Thesis is the process of deoxyribonucleic acid (DNA) 
replication, thus it seems natural that it starts with the discovery of DNA. It was in 1869 
when Friedrich Miescher isolated nuclei from leukocytes and found an unexpected, 
acidic and phosphorus rich substance he called ‘nuclein’ (Miescher, 1871). 
 Although chromosomes were initially discovered by Walter Flemming in the 
1870s, the chromosome theory of inheritance was a result of observations from Boveri 
and Sutton in 1902 suggesting that the association of paternal and maternal 
chromosomes in pairs and their subsequent separation during cell division may 
constitute the physical basis of the Mendelian law of heredity (Boveri, 1902; Sutton, 
1902). In 1924 Robert Feulgen utilized microscopic dyes to show that chromosomes 
contain both proteins and nucleic acids (Feulgen and Rossenbeck, 1924), starting a 
race to identify the heredity molecule. Mainly because scientists wanted to believe that 
proteins are carrier of the genetic material, it was 20 years later before Oswald Avery 
and co-workers used infectious and non-infectious Pneumococcus strains and found 
that DNA is the transforming material (Avery et al., 1944). Avery’s discovery came too 
early for the scientific community and its great significance was never rewarded as 
deserved. In contrast, when Alfred Hershey and Martha Chase in 1952 used the 
bacteriophage T2 to infect bacteria and showed that it is the P32-labelled phage DNA 
which is found in the bacteria and not the S35-labelled coat protein, researchers 
accepted that DNA is the hereditary material (Hershey and Chase, 1952). A year later, 
James D. Watson and Francis H. C. Crick proposed the double helix structure of the 
DNA molecule using x-ray diffraction data collected by Rosalind Franklin and revealed 
the base pairing suggesting a possible copying mechanism for the genetic material 
(Franklin and Gosling, 1953; Watson and Crick, 1953).  
 After the discovery of the DNA structure one could say the next breakthrough 
came with the description of the semiconservative nature of replication by Meselson 
and Stahl. They designed a very clever experiment where bacterial DNA was labelled 
Chapter I                                                                                            Introduction     
	   19 
with heavy nitrogen (N15), bacteria subsequently grown on medium containing N14 in 
excess and after ultracentrifugation in a Caesium Chloride gradient the density of DNA 
was monitored over several generations. Consistent with the semiconservative 
replication hypothesis the results revealed that the heavy nitrogen is distributed evenly 
to each daughter molecule (Meselson and Stahl, 1958).  
 DNA polymerase 1, the first enzyme involved in DNA replication had already 
been described in 1955 (Kornberg et al., 1955) but it was in 1977, after some very 
laborious and inefficient techniques were developed, when Frederick Sanger came up 
with the dideoxy chain- termination method revolutionising the method of DNA 
sequencing (Sanger et al., 1977). Amplification of specific DNA templates became 
possible with the invention of the polymerase chain reaction (PCR) by Kary Mullis in 
1983 (Mullis and Faloona, 1987) thus starting a new era in molecular biology and 
medical diagnostics.   
 Thanks to those findings biologists were able to synthesise and manipulate 
recombinant DNA encoding proteins of interest, thus identifying their function in cellular 
processes and potential pathological implications in very great detail. Molecular Biology 
developed faster than any other field in Biology enabling scientists to sequence the 
whole human genome in several hours or analyse single cells by microscopy or flow 
cytometry, techniques which made the work presented in this Thesis a challenging and 
rewarding experience. 
 
I.  2.  The Mammalian Cell Cycle  
 A eukaryotic cell divides via alternation of two central processes: the precise 
doubling of the genome in S-phase and the segregation of the sister chromatids during 
mitosis. When cells exit mitosis they enter the G1 phase, which is characterised by cell 
growth and increased metabolic activity. However, the central cell cycle function is to 
prepare for DNA replication in S-phase and if necessary activate G1/S cell cycle 
checkpoints to prevent or delay progression into S-phase. Cells can be synchronised in 
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G1-phase by serum starvation. In response to DNA damage or other stress situations 
cells can irreversibly enter a senescent state, which represents an exit from the cell 
cycle. Alternatively, in the absence of proliferative stimuli cells can temporarily 
withdraw from the cell cycle and enter a G0 or quiescent state. During S-phase the 
initiation of DNA replication from multiple sites leads to the precise doubling of the 
genetic material. DNA replication can be monitored microscopically or by flow 
cytometry via incorporation of nucleotide analogues such a BrdU or EdU. DNA damage 
is detected and fixed during S-phase by activation of intra S-phase checkpoints. Cells 
can be synchronised in S-phase by addition of replication inhibitors such as thymidine, 
hydroxyurea or aphidicolin. Only after the complete genome is replicated do the cells 
enter G2-phase and prepare for cell division. The most important feature of the G2 
phase is the G2/M checkpoint, which prevents entry into mitosis in response to DNA 
damage or genotoxic stress thus inhibiting proliferation of damaged cells. After a cell 
enters mitosis it segregates the genetic material and undergoes cytokinesis to create 
two identical daughter cells, which then enter into the next G1 phase. 
 
I.  3.  How to ensure complete genome duplication? 
 Eukaryotic genomes contain a very large amount of DNA that is divided 
amongst a number of chromosomes. To allow rapid duplication of the genome 
replication must initiate from multiple sites along each chromosome. For complete 
duplication eukaryotes utilise between 103-105 replication origins, that are typically 
spaced 30-100 kB apart (Blow and Dutta, 2005). At present it is not clear what 
determines the position of replication origins in animal cells. In S. cerevisiae replication 
initiation has been shown to start within or very close to autonomously replicating 
sequences (ARSs) (Bielinsky and Gerbi, 1999; Brewer and Fangman, 1987; Huberman 
et al., 1987) which contain an 11 bp ARSs consensus sequence (ACS) that is essential 
for origin function (Diffley, 1996). In contrast, experiments by Harland and Laskey 
(1980) showed that numerous DNA sequences from viruses or prokaryotes replicate 
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efficiently and once-per cell cycle when injected into Xenopus laevis eggs, arguing 
against the requirement for specific sequences for initiation (Harland and Laskey, 
1980). This was confirmed by experiments using the Xenopus cell free system and the 
2D gel electrophoresis approach developed by Brewer and Fangman and showed that 
plasmids carrying ribosomal Xenopus DNA initiated and terminated at multiple, random 
locations (Hyrien and Mechali, 1992; Mahbubani et al., 1992). Those studies have 
raised the ‘random completion problem’: to avoid under-replication a random 
distribution would require origins to be spaced less than 1 kb apart (Blow et al., 2001; 
Laskey, 1985). Further studies pointed out that such random distribution is unlikely as 
Xenopus laevis origin recognition complex (XlORC), an essential replication protein 
(see Section I. 5. 1), saturated sperm chromatin at about one copy per 8-15 kb (Rowles 
et al., 1996). DNA fiber analysis revealed that origins are spaced 5-15 kb apart and 
that they are activated in clusters of approximately 5-10 origins (Blow et al., 2001), 
suggesting some sort of sequence independent origin spacing. 
 
 In mammalian cells the DNA replicated from a single origin, the replicon, ranges 
in size between 20-150 kb with a maximum of ~450 kb (Jackson and Pombo, 1998). 
Replicon clusters contain up to 10 adjacent origins, typical encompass less than 1 Mb 
of DNA (Figure I. 1)(Gillespie and Blow, 2010). When replication is initiated within a 
cluster, the replicons become associated with multiple proteins forming the replication 
machinery, turning the cluster into a replication factory or foci. In a human cell 
approximately ~50,000 replicons within ~10,000 foci replicate the entire genome in 
about 9 h, suggesting that a focus needs approximately 75 min to complete replication 
(Maya-Mendoza et al., 2010). That suggests that there are ~1400 active foci at any 
time during S-phase and this is indeed quite close to the 1230 active sites observed by 
high-resolution light microscopy (Cseresnyes et al., 2009). Interestingly, replication 
factories are not activated randomly but follow a predetermined timing program.  
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Figure I. 1. How to ensure complete genome duplication. Shown is a segment of DNA (black 
line) with five inactive origins and five activated origins/ replicons which form a replication bubble 
with fork moving bidirectional away from the origin. Those ten origins form an active cluster 
(green dots) of replicons. Human cells have approximately 10000 of those clusters with ~50000 
replicons during there S-phase. When a cluster is enganged in sythesis it becomes associated 
with the replication machinery and is also termed replication factory or foci. A foci needs about 75 
min to complete replication resulting in ~1400 active foci (green dots) any time during the 9h 
human S-phase. To ensure complete replication S-phase follows a strict spatial and temporal 
replication timing program estabished during G1 phase (blue and red dots) of the cell cycle and 
lost (grey dots) after S-phase is completed. In general euchromatin (red dot) replicates early 
(Pattern I and II) while heterochromatin (blue dot) replicates late (Pattern III,IV and V).
G1 G2
regions containing heterochromatin
regions containing euchromatin
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 At the Timing Decision Point in early G1 phase subchromosomal domains move 
to reproducible positions within the nucleus thus establishing the replication timing 
program (Dimitrova and Gilbert, 1999). The positioning correlates with chromatin 
organisation and the underlying transcriptional activity, with the transcriptionally active 
euchromatin localised in the nuclear interior and the inactive heterochromatin in the 
periphery or around the nucleoli (Figure I. 1) (Goren and Cedar, 2003; Zink, 2006). 
Once S-phase starts the execution of the timing program drives cells through 5 discrete 
phases of replication: bulk nucleoplasmic, peripheral and perinuclear-perinucleolar 
localisation precede replication first in small and then large, intranuclear patches 
(O'Keefe et al., 1992). It has recently been shown that replication induced in G2 nuclei 
does not follow the replication timing program suggesting that replication in S-phase 
erases the timing determinants leaving the G2 chromatin without timing information (Lu 
et al., 2010).  
 
 Initiation of replication origins must occur throughout S-phase to allow rapid, 
spatial and temporally determined duplication of the genome. It is therefore of crucial 
importance that initiation is a very tightly controlled event that can only occur once per 
origin. Figure I. 2. shows the dramatic consequence of deregulated origin usage. If 
origins fail to fire, portions of the genome may remain un-replicated as cells progress 
into mitosis, potentially causing problems during sister chromatid segregation leading 
to chromosome breaks and loss of genetic information. In contrast, if an origin initiates 
more than once a section of the genome would be re-replicated, which may have a 
range of deleterious effects such as a gene amplification (Green et al., 2010), a 
common feature in tumourigenesis, or cell death (Klotz-Noack et al., 2012; Melixetian 
et al., 2004; Zhu et al., 2004). Eukaryotes developed a mechanism called ‘licensing’ of 
replication origins that occurs in late mitosis and early G1, and is controlled by a 
licensing checkpoint, to prevent cells from re-replicating DNA during a single cell cycle. 
This depends on the licensing machinery being inactive during S-phase and G2 to 
inhibit re-firing of origins. 
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Figure I. 2. Consequences of deregulated origin usage. A section of chromosomal DNA with 
three replication clusters, each replicating from three origins is shown at different stages of the cell 
cycle. A whole chromosom containing the section is shown in mitosis. Panel B illustrates how the 
correct usage of all origins mediates complete DNA duplication. Panel A demonstrates the conse-
quence of a failure to initiate origins leading to under-replication and potentially to chromosome 
breaks in mitosis. In panel C an origin fires more then once, leading to rereplication of a portion of 
the genome causing irreversible genetic changes.
Figure I. 2.
Reproduced from Blow et al. 2011
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I.  4.  The replication licensing Factor 
I. 4. 1.  Discovery of the licensing factor 
 The first experimental evidence that the initiation of DNA replication is indeed a 
tightly regulated process came from Rao and Johnson in 1970 who fused somatic cells 
in different cell cycle stages together such that the cytoplasm is shared. They found an 
accelerated replication in G1 nuclei when fused with an S-phase cell, which replicated 
normally. When G1 nuclei were fused with a G2 cell, they replicated normally while the 
G2 nuclei failed to enter S-phase. When G2 nuclei were fused with a S-phase cell the 
S-phase cell replicated normally while the G2 cell did not initiate replication. This 
suggests that initiation of replication requires a diffusible S-phase promoting activity 
that G1 but not G2 cells can respond to (Rao and Johnson, 1970). 
 Blow and Laskey (1988) extended this using the Xenopus cell free system, 
revealing that G1, S-phase or G2 nuclei did not re-replicate after transfer into fresh G1 
extract. They found that re-replication could be induced in G2 nuclei after 
permeabilisation of the nuclear envelope, indicating the presence of an essential 
licensing factor that binds to origins after nuclear envelope breakdown in late mitosis 
allowing initiation of replication after formation of the nuclear envelope (Blow and 
Laskey, 1988). They proposed that the licensing factor is removed from origins upon 
initiation and cannot rebind due to exclusion by the nuclear envelope. Further 
experiments in other in vitro systems confirmed that the nuclear membrane is essential 
in preventing re-licensing and re-firing of replication origins (Coverley et al., 1993; 
Crevel and Cotterill, 1991; Leno et al., 1992). 
 
I. 4. 2.  Identification of MCM2-7 as licensing factor 
 A screening in S. cerevisiae identified mutants that are defective in 
maintenance of minichromosomes (Maine et al., 1984). One of them was the 
previously identified cell division cycle 46 (Cdc46)/MCM5 accumulating in the nucleus 
in late mitosis and disappearing upon entry into S-phase. Six MCM proteins (MCM2-7), 
Chapter I                                                                                            Introduction     
	   26 
displaying the same cell cycle dependent subcellular localisation as Cdc46/MCM5, 
were subsequently found to be essential for DNA replication (reviewed in (Chong et al., 
1996). Experiments by John Diffley in 1994 showed that origins exist in either a post-
replicative state, with only the origin recognition complex (ORC)(see Section I. 5. 1) 
bound to the origin, or in a pre-replicative state, with ORC and additional proteins 
bound, supporting the idea of a licensing factor. 
 
Meanwhile, biochemical experiments in Xenopus extracts showed that the activation of 
licensing factor in metaphase extract is dependent on cyclin-dependent kinase (Cdk) 
activity and is inhibited by the protein kinase inhibitor, 6-dimethylaminopurine (6-
DMAP) (Blow, 1993). Thus provided a clever assay for licensing activity in different 
chromatographic fractions of Xenopus egg extracts (Chong et al., 1995). First sperm 
was incubated in whole 6-DMAP treated extract for decondensation, isolated and 
incubated with different purified fractions of extract and then again incubated in 6-
DMAP egg extracts. Two of the fractions (namely replication licensing factor M (RLF-M) 
and RLF-B) allowed DNA replication with RLF-M containing a complex of proteins that 
included MCM2 and MCM3 (Chong et al., 1995; Kubota et al., 1995) and RLF-B later 
shown to contain Cdc10 dependent transcript 1 (Cdt1) (Tada et al., 2001). Further 
studies identified all six MCM proteins in the RLF-M fraction (Kubota et al., 1997; 
Thommes et al., 1997). Microscopic analysis of human cells revealed that MCMs are 
equally distributed throughout the entire nucleus in G1 and early S-phase and 
displaced from their site on chromatin once the site has finished replication. They were 
not associated with DNA in G2 cells or on condensed chromosomes in early mitosis 
(Krude et al., 1996) fulfilling the requirements demanded for the licensing factor. 
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I. 4. 3.  The MCM2-7 protein complex 
The MCM protein complex consists of six highly related subunits MCM2- MCM7, which 
are conserved throughout eukaryotic evolution and are also present in Archaea. 
Despite their sequence homology each subunit possesses unique sequences 
conserved in all species, indicating a universal and essential function for each 
individual MCM. This idea is supported by experiments in S. cerevisiae and S. pombe 
revealing that deletion of each single MCM is lethal (reviewed by (Dutta and Bell, 1997; 
Kelly and Brown, 2000). All six subunits contain a 250 aa region encoding an ATPase 
active site (ATPase associated with a variety of activities (AAA+) domain) (Koonin, 
1993) and form a 600 kDa (Fujita et al., 1997; Kubota et al., 1997) doughnut like 
heterohexameric complex (Figure I. 3 A). The positively charged central channel that is 
large enough to encircle the DNA double helix (Fletcher et al., 2003; Sato et al., 2000).  
 
A number of observations suggest that beside their role in initiation of replication at the 
origins, the MCM2-7 complex functions as the replicative helicase unwinding the DNA 
in front of the replication forks. A MCM4, 6, 7 complex purified from HeLa cells has 
been shown to posses limited ATP dependent 3’-5’ helicase activity in vitro (Ishimi, 
1997), while in combination with the fork proteins Cdc45 and GINS (from the Japanese 
go-ichi-ni-san meaning 5-1-2-3, after the four related subunits of the complex Sld5, 
Psf1, Psf2 and Psf3), the MCM2-7 complex displays strong helicase activity (Moyer et 
al., 2006). Furthermore degradation of MCM2-7 proteins after initiation of replication 
rapidly inhibits replication fork progression (Labib et al., 2000). Chromatin- 
immunoprecipitation experiments in S. cerevisiae and Xenopus showed that MCM 
complexes travel with the replication fork strongly supporting the helicase hypothesis 
and providing an elegant solution to how origins become ‘unlicensed’ upon initiation to 
prevent re-replication (Aparicio et al., 1997; Pacek et al., 2006). 
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I. 4. 4.  The MCM ‘paradox’ 
The so-called ‘MCM paradox’ summarises observations that questioned the idea that 
MCM2-7 function simply as the replicative helicase. First of all it has been shown that 
instead of the expected two MCM2-7 per replication origin, there are a total of 10-40 
molecules of MCM2-7 associated with chromatin for each origin that normally fires 
during S-phase (Burkhart et al., 1995; Edwards et al., 2002; Lei et al., 1996; 
Mahbubani et al., 1997).  Interestingly not all of these complexes are in close proximity 
to the origins, in fact some are distributed at least 1 kb from the ORC (Edwards et al., 
2002; Harvey and Newport, 2003; Ritzi et al., 1998). Supporting these findings, 
immunofluorescence studies showed that most MCM2-7 complexes do not co-localise 
with sites of replication (Dimitrova et al., 1999; Krude et al., 1996; Madine et al., 1995). 
The finding that the number of MCMs can be reduced to 1-2 copies per origin without 
inhibiting replication efficiency (Edwards et al., 2002; Mahbubani et al., 1997; 
Oehlmann et al., 2004) raised questions about additional functions of the excess MCM. 
A study suggested a role in intra-S-phase checkpoint activation by binding of MCM7 to 
ATR-interacting protein (ATRIP), a protein involved in activation of ataxia-
telangiectasia and Rad3 related (ATR) kinase (Cortez et al., 2004). However, the main 
function of excess licensed origins, named dormant origins, is to fire under replication 
stress to ensure the complete replication of the genome. 
 
I. 4. 4. 1.  Dormant origins- an essential function for excess MCM’s  
 In all organisms examined to date, there is a significant 3- to 20-fold excess of 
MCM2-7 double hexamers over the number of origins typically active in any one S-
phase. It has been reported that the excess MCMs can provide dormant origins that, in 
response to replicative stress, can fire and allow a complete replication of the genome 
(Blow et al., 2011; Ge and Blow, 2010; Ge et al., 2007; Ibarra et al., 2008; Woodward 
et al., 2006). As licensing can only occur in late mitosis and early G1 no MCM’s can be 
loaded when cells encounter problems during S-phase, for example, when DNA 
damage or tightly bound proteins cause an irreversible fork arrest. Loading an excess 
Chapter I                                                                                            Introduction     
	   29 
of MCM’s during the licensing period can therefore provide a mechanism to rescue 
replication of a segment of the genome when two converging forks stall (Figure I. 7 
middle panel). Mechanisms that activate dormant origins are not fully understood but 
the increased density of replication forks seen in active clusters by DNA fiber analysis 
(Ge et al., 2007) are consistent with dormant origins initiating in active replication 
clusters as a consequence of stochastic origin firing (Blow and Ge, 2009). In this 
scheme, once a chromosomal domain becomes competent to support initiation during 
S-phase, the origins (MCM2-7 double hexamers) that actually undergo initiation are 
selected by some non-deterministic process. If replication fork progression is inhibited, 
nearby licensed origins that would otherwise be eliminated by passive replication have 
an increased probability of undergoing initiation. Computer simulation of this simple 
model shows that it can account for the increased density of origins observed after HU 
treatment of U2OS cells if they contain 3-4 licensed origins for each origin that actually 
initiates in an unperturbed S phase (Blow and Ge, 2009).  
Previous work has shown that when replication forks stall, the ATR and Chk1 kinases 
suppress the global rate on initiation. This provides a potential difficulty in explaining 
how replicative stress can lead to dormant origin activation under conditions where 
Chk1 is suppressing global rates of initiation. A recent study showed that when 
replication stress is induced by treatment of cell with low levels of hydroxyurea or 
aphidicolin, the DNA damage checkpoint kinases ATR and Chk1 preferentially inhibit 
activation of new replication factories while allowing firing of dormant origins within 
active clusters (Ge and Blow, 2010). A study by Thomson and colleagues revealed that 
modest reduction of Cdk activity inhibits activation of new replication factories without 
significantly affecting initiation within clusters (Thomson et al., 2010). Chk1 could 
directly lower Cdk activity (Figure I. 8) or alternatively could inhibit only the Cdk 
substrates that are essential for factory activation (Gillespie and Blow, 2010; Thomson 
et al., 2010). A lack of dormant origins has recently been shown to promote 
tumourigenesis and will be discussed in Section I. 7. 1.  
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I.  5.  The licensing reaction and its components 
 Origin licensing involves the stepwise assembly of ‘pre-Replicative Complex’ 
(pre-RC) proteins onto DNA, and has been reconstituted in vitro with pre-RC proteins 
from Xenopus eggs (Gillespie et al., 2001) and budding yeast (Evrin et al., 2009; 
Remus et al., 2009) (Figure I. 3. B). ORC, the origin recognition complex (Coleman et 
al., 1996; Rowles et al., 1996), first binds DNA, then recruits Cdc6 (Cocker et al., 1996; 
Coleman et al., 1996) and Cdt1 (Maiorano et al., 2000; Nishitani et al., 2000). Two 
Cdt1 molecules recruit MCM2-7 proteins to ORC/Cdc6 on chromatin where they can 
act together to load Mcm2-7 onto DNA (Takara and Bell, 2011). Unlike MCM2-7, ORC, 
Cdc6 and Cdt1 are dispensable for replication after licensing is completed suggesting 
their only role in replication is to facilitate the loading of MCM2-7 complex (Donovan et 
al., 1997; Hua and Newport, 1998; Maiorano et al., 2000; Nishitani et al., 2000; Rowles 
et al., 1999). This reaction probably involves the opening of the MCM2-7 
heterohexameric ring and clamping it around DNA (Evrin et al., 2009; Remus et al., 
2009). MCM2-7 complexes are loaded onto origins as double hexamers, providing a 
configuration capable of initiating a pair of bidirectional replication forks (Evrin et al., 
2009; Gambus et al., 2011; Remus et al., 2009). 	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Figure I. 3. Stucture and chromatin 
loading of the MCM2-7 complex.  The 
position of the MCM2-7 protein within 
the complex (top left) is shown as well 
as a three-dimensional EM reconstruc-
tion of budding yeast MCM2-7 double 
hexamer. Bottom shows the represen-
tations while top right shows a cross 
section with DNA. AAA+= AAA+ ATP 
binding domain. B. Proposed model 
for the licensing reaction. ORC binds 
to DNA and recruits Cdc6 to the origin 
of replication. It has recently been 
proposed that two Cdt1 molecules 
recruit two MCM2-7 complexes to 
ORC/Cdc6 (Takara and Bell, 2011). 
Subsequently the pre- RC complex is 
formed by the loading of the MCM2-7 
double hexamer onto chromatin.   
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I. 5. 1.  The Origin Recognition Complex (ORC) 
 The ORC was first identified by Bell and Stillman in S. cerevisiae binding to a 
conserved Autonomously Replicating Sequence (ARS consensus sequence (Bell and 
Stillman, 1992). ORC is a five- or six- subunit protein complex (ORC1-5 or ORC1-6) 
(Gossen et al., 1995; Rowles et al., 1996) being a conserved feature of chromosomal 
replication in all eukaryotes studied so far. Deletion of ORC genes is lethal in 
Drosophila and S. pombe (Gavin et al., 1995; Grallert and Nurse, 1996; Landis et al., 
1997; Leatherwood et al., 1996) and depletion of the ORC1-5 blocks licensing and 
DNA replication in Xenopus (Coleman et al., 1996; Romanowski et al., 1996; Rowles et 
al., 1996) . 
 In S. cerevisiae ORC6 is not required for DNA binding but remains essential for 
DNA replication and cell viability (Li and Herskowitz, 1993), while it is shown to be 
indispensable for both processes in D. melanogaster (Chesnokov et al., 2001). 
Furthermore it has been shown that ORC6 is not required for the licensing activity of 
ORC1-5 in Xenopus (Gillespie et al., 2001) and is not part of the human ORC (Dhar et 
al., 2001).  A crucial function of ORC is the binding and hydrolysis of ATP and studies 
of S. cerevisiae ORC (ScORC) and D. melanogaster ORC (DmORC) indicated that 
ATP binding by ORC1 is required for DNA binding (Brauchle et al., 2003). ORC1 also 
promotes ATP hydrolysis, which if inactivated does not interfere with DNA binding but 
with MCM loading (Bowers et al., 2004). 
 ORC1 protein has been shown to exhibit a replication independent function in 
controlling centriole and centrosome copy number in human cells (Hemerly et al., 
2009), possibly explaining recent findings showing that ORC1 binds to chromatin 
independently of ORC2-5 (Sonneville et al., 2012). 
 
I. 5. 2.  The Cdc6 protein 
 The Cell Division Cycle 6 Protein (Cdc6) was first identified in a screen for S. 
cerevisiae mutants with defects in cell cycle progression (Hartwell et al., 1973). Cdc6 
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has been found in many eukaryotes and plays a crucial role in assembly of the pre-RC, 
where it acts after ORC and is required for MCM2-7 loading onto chromatin (Bell et al., 
1995; Coleman et al., 1996; Grallert and Nurse, 1996; Leatherwood et al., 1996; Saha 
et al., 1998). Cdc6 is highly related to ORC1 and with a limited extent to ORC4, ORC5 
and MCM2-7 proteins (Neuwald et al., 1999) and belongs to the family of AAA+ 
ATPase containing proteins. Mutations in this motif block MCM loading and 
consequently DNA replication (Perkins and Diffley, 1998; Weinreich and Stillman, 
1999a). Cdc6 binding to chromatin requires ORC binding (Coleman et al., 1996), while 
its ATP binding and hydrolysis does not require ATP binding and hydrolysis by ORC 
(Randell et al., 2006). Interestingly, destabilisation of Cdc6 on chromatin after licensing 
seems to be essential for Cdc7 kinase mediated phosphorylation of MCM4 and 
therefore required for initiation of DNA replication in S-phase (Kundu et al., 2010). 
 Cdc6 has also been found to play an important role outside DNA replication, as 
a mitotic substrate of polo-like kinase1, in regulating chromosomal segregation 
mediated by Cdk1 and separase (Yim and Erikson, 2010). Studies in S. pombe and 
Xenopus egg extracts also indicated that Cdc6 is required for activation and 
maintenance of the ATR/ Chk1 mediated S-phase checkpoint in response to replication 
inhibition or presence of apparent DNA structures (Murakami et al., 2002; Oehlmann et 
al., 2004). In human cells mitotic entry can be inhibited by Cdc6 mediated activation of 
Chk1 kinase thus preventing cyclin B/ Cdk1 mediated progression through the G2/M 
boundary (Clay-Farrace et al., 2003).  
 
I. 5. 3.  The Cdt1 protein 
The Cdc10 dependent transcript 1 (Cdt1) protein is another key factor in assembling 
the pre-RC and was first identified in S. pombe (Sp) as a gene that is regulated by the 
Cdc10 transcription factor (Hofmann and Beach, 1994). The same study revealed that 
mutation in SpCDT1 resulted in a failure of DNA replication and defects in the S-phase 
checkpoint. Nishitani et al. (2000) showed that SpCdt1 forms a complex with SpCdc6 
and is required for MCM loading onto chromatin. Cdt1 homologues have been reported 
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in Xenopus, Drosophila, human cells, (Maiorano et al., 2000; Nishitani et al., 2000; 
Whittaker et al., 2000; Wohlschlegel et al., 2000) and later in S. cerevisiae and C. 
elegans (Tanaka and Diffley, 2002; Zhong et al., 2003). Similar to the situation in S. 
pombe, the chromatin binding of Xenopus Cdt1 is dependent on ORC and Cdc6 
binding to the DNA (Gillespie et al., 2001; Maiorano et al., 2000). Furthermore, XlCdt1 
as well as Mus musculus Cdt1 (MmCdt1) have been shown to directly interact with 
MCM2-7 complexes via a domain at the C-terminus (Ferenbach et al., 2005; Yanagi et 
al., 2002) indicating a role in recruiting MCM2-7 to the origins. As shown in Figure I. 3, 
it has been shown in three independent studies that MCM2-7 complexes are loaded 
onto chromatin as double hexamers (Evrin et al., 2009; Gambus et al., 2011; Remus et 
al., 2009). Recent studies revealed that two Cdt1 molecules facilitate the loading of the 
MCM2-7 double hexamer, suggesting a model in which origin-bound ORC and Cdc6 
recruit two Cdt1 molecules to initiate double-hexamer formation prior to helicase 
loading (Takara and Bell, 2011). In metazoans Cdt1 has been shown to be the key 
regulatory protein for the licensing machinery and its regulation will be explained in 
more detail in Section I. 6. 1. 
 
I.  6.  Regulation of Replication licensing 
 
 Tight regulation of the licensing system is essential to ensure that MCM2-7 
complexes can only be loaded in late mitosis and early G1. In yeast, down regulation of 
the licensing machinery is achieved by Cdk activity and its inhibition in G2/M cells 
results in a full re-replication of the genome (Broek et al., 1991; Dahmann et al., 1995; 
Green et al., 2010; Nishitani and Nurse, 1995). In S. cerevisiae and S. pombe ORC 
function is inhibited by Cdk mediated phosphorylation of ORC2 (Nguyen et al., 2001; 
Vas et al., 2001), while Cdc6 is degraded in a Cdk dependent manner (Drury et al., 
2000; Elsasser et al., 1999; Jallepalli et al., 1997). Additionally, Cdks phosphorylate 
MCM2-7 and Cdt1 leading to their nuclear export during S-phase, G2 and mitosis 
(Hennessy et al., 1990; Labib et al., 1999; Nguyen et al., 2001; Tanaka and Diffley, 
2002).  
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 However in metazoans regulation of the licensing system is more complex and 
although Cdk activity plays a role in the mitotic regulation of the licensing system, the 
main route to prevent re-licensing during S phase and G2 is by down-regulation of 
Cdt1 activity (Figure I. 4.). In addition, ORC and Cdc6 are also subject to cell cycle 
regulation, though this appears to play a relatively minor role in preventing re-
replication. The experiments and results described in the next Chapters of this 
dissertation show how re-replication of the genome is induced by down regulation of 
Cdt1 activity, therefore the next sections provide insight into the regulation of the 
licensing system in metazoans focusing on Cdt1. 
 
ORC. In several human cell lines the level of chromatin bound ORC1 has been 
shown to be cell cycle regulated with a peak in G1 and a subsequent decrease during 
S-phase (Kreitz et al., 2001; Mendez et al., 2002). Over-expressed ORC1 binds and is 
ubiquitinated by the F-box protein S-phase kinase-associated protein 2 (Skp2), a 
component of the Skp1/Cul1-F-box E3 ubiquitin ligase (SCFSkp2), known to mediate 
proteasomal degradation of numerous cell cycle proteins. Interestingly, depletion of 
Skp2 increases endogenous levels of ORC1 suggesting a regulation via that pathway 
(Mendez et al., 2002). Studies in Xenopus extracts revealed that the affinity of ORC1 
and 2 to chromatin is reduced following licensing (Rowles et al., 1999) and DNA 
binding of ORC1 is inhibited during metaphase by Cdk phosphorylation (Romanowski 
et al., 2000) 
 
Cdc6. Although humans possess the SCFhcdc4 ubiquitin ligase machinery, it 
appears that Cdk phosphorylation in S-phase promotes nuclear export of Cdc6 (Fujita 
et al., 1999; Jiang et al., 1999; Petersen et al., 2000; Saha et al., 1998) instead of 
proteolysis such as seen in yeast. Instead Cdc6 degradation has been reported to take 
place in mitosis and is mediated by N-terminal destruction motifs (KEN-box and a D-
box) that are recognised by the anaphase promoting complex with cadherin 1 APCCDH1 
ubiquitin ligase (Mendez and Stillman, 2000; Petersen et al., 2000). In Xenopus, Cdc6 
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is removed from chromatin upon binding of MCM2-7 in late mitosis and early G1 and 
reloads in S-phase when MCM2-7 is displaced from the origin of replication and plays 
a role in the activation of the intra-S-phase checkpoint (Oehlmann et al., 2004).    
 
I. 6. 1.  Regulation of the licensing factor Cdt1 
 
I. 6. 1. 1. Proteolysis 
 
 In all cell types studied so far (S. pombe, C. elegans, Drosophila, Xenopus and 
human cells), Cdt1 protein levels oscillate during the cell cycle, with high levels in late 
mitosis and G1, and low levels in S and G2 phase (Figure I. 4 A). Three pathways of 
Cdt1 degradation have been identified so far.  
 
 Proliferating Cell Nuclear Antigen (PCNA) dependent Cul4/Ddb1/Cdt2 
ubiquitin ligase. In Xenopus efficient Cdt1 ubiquitination and degradation has been 
shown to be mediated by chromatin-bound PCNA, which binds Cdt1 via its PCNA 
interaction protein	   (PIP) domain (Figure I. 4 B) and subsequently recruits the Cul4/	  
DNA damage-binding protein 1 (Ddb1)/Cdt2 ubiquitin ligase.  
PCNA binds to DNA as part of the replication fork providing a mechanism to specifically 
degrade Cdt1 during S phase (Arias and Walter, 2005; Arias and Walter, 2006; Jin et 
al., 2006a). However, during the first cell cycles of the early Xenopus embryo, the 
nuclear/cytoplasmic ratio is too low for Cdt1 to be quantitatively degraded by this 
mechanism, so that Cdt1 levels remain high throughout the cell cycle (Kisielewska and 
Blow, 2012). 
 The PCNA/Cul4/Ddb1/Cdt2 pathway has also been shown to be crucial in C. 
elegans where siRNA mediated knockdown of Cul4 results in elevated Cdt1 levels with 
the consequence of extensive re-replication of DNA (Zhong et al., 2003).  
 In human cells it has been observed that the Cdt1 mRNA levels remained 
constant throughout the cell cycle (Nishitani et al., 2001) while Cdt1 levels decrease 
upon entry into S-phase, suggesting a post-translational regulation of Cdt1 (Nishitani et 
al., 2001; Wohlschlegel et al., 2000).  It has later been found that the PCNA/Cul4/Ddb1 
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pathway is the main route for Cdt1 down-regulation during DNA replication and in 
response to DNA damage (Higa et al., 2003; Jin et al., 2006b; Nishitani et al., 2006; 
Senga et al., 2006) (Figure I. 4). When re-replication occurs the DNA damage 
response is activated in human and Drosophila cells, Cdt1 as well as Cdc6 degradation 
is increased providing a mechanism to inhibit re-licensing and thereby limiting the 
extent of re-replication (Hall et al., 2008). In contrast, the same group found that Cdt1 is 
protected from degradation by Mitogen-activated protein (MAP) kinase induced 
phosphorylation in unperturbed G2 phase and during acute cellular stress response, 
such as exposure to toxins, osmotic shock or inflammatory cytokines (Chandrasekaran 
et al., 2011). In addition to the stabilisation of Cdt1, its phosphorylation blocks MCM2-7 
binding thus functionally inactivating Cdt1, providing a controlled environment to cope 
with stress while entering mitosis and holding enough Cdt1 to start licensing.  
 After DNA damage PCNA is loaded onto chromatin followed by dynamic 
recruitment of Cul4/Ddb1/Cdt2 and Cdt1 to the site of damage prior to Cdt1 
ubiquitination and degradation (Ishii et al., 2010; Roukos et al., 2011). How Cdt1 is 
recruited is not yet solved but a recent study provided evidence that Cul4/Ddb1/Cdt2 is 
recruited to PCNA by the clamp loader complex replication factor C in complex with 
chromosome cohesion factor Ctf18 (Ctf18-RFC) (Shiomi et al., 2012). 
 The hexameric (AAA+) ATPase p97, involved in endoplasmic reticulum- 
associated protein degradation and other relevant cellular processes, has recently 
been shown to mediate the release of PCNA/Cul4/Ddb1 ubiquitinated Cdt1 from 
chromatin which is essential for its proteasomal degradation in response to UV 
irradiation (Raman et al., 2011). C. elegans embryos deficient of p97 (Cdc48) not only 
show accumulation of Cdt1 on mitotic chromatin but also a persistent chromatin 
association of Cdc45/GINS leading to defects in S-phase progression and a reduced 
DNA content (Franz et al., 2011). 
 
 Cdk dependent SCFSkp2 ubiquitin ligase. The Cdk dependent SCFSkp2 
pathway provides an additional mechanism for Cdt1 degradation in S-phase and G2 (Li 
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et al., 2003; Nishitani et al., 2004; Sugimoto et al., 2004). This is a replication 
independent process that requires Cdk binding at residues 65-72 and subsequent 
phosphorylation of Threonine 29 (Liu et al., 2004; Takeda et al., 2005) (Figure I. 4 B).  
 In Drosophila the SCFSkp2 pathway has been shown to be a major pathway for 
Cdt1 proteolysis (Thomer et al., 2004). Direct evidence for the existence of the 
Cul4/Ddb1 pathway is missing but mutations of replication proteins inhibit Cdt1 
degradation suggesting a role of a replication dependent mechanism (May et al., 
2005). In agreement with this, abolition of Cdk phosphorylation does not fully stabilise 
Drosophila Cdt1, which contains the PIP motif required for PCNA dependent 
degradation. 
 
 APC/ CDH1 ubiquitin ligase. The APC/ CDH1 ubiquitin ligase is active from 
anaphase until late G1 and has been shown target Cdt1 for proteasomal degradation 
(Li and Blow, 2005; Sugimoto et al., 2008). Although APC mediated degradation of 
Cdt1 is not as efficient as for geminin but its impairment causes re-replication and 
chromosomal damage (Sugimoto et al., 2008). This pathway may prevent an excessive 
accumulation of Cdt1 before S-phase onset and geminin accumulation (Blow and 
Gillespie, 2008b) and plays a role in clearance of Cdt1 upon cell cycle exit (Sugimoto 
et al., 2008). 
 Besides the complex network of Cdt1 degradation, metazoans express a Cdt1 
inactivating protein called Geminin, indicating the importance of strict regulation for 
Cdt1. 
 
I. 6. 1. 2. The Cdt1 inhibitor - Geminin 
     
 Geminin is a 25 kDa protein that was initially identified using the Xenopus cell-
free system in a screen for targets of the APC performed by McGarry and Kirschner in 
1998. APC is a multi-subunit E3 ubiquitin ligase that is active from anaphase until the 
beginning of S-phase ensuring the exit from mitosis by ubiquitination of various 
substrates such as mitotic cyclins and proteins involved in spindle function and sister 
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chromatin cohesion (Uhlmann et al., 1999). Geminin transcription is driven by the E2F 
transcription factor (Yoshida and Inoue, 2004) whereas protein levels are regulated by 
APC, with high abundance in S-phase and G2, and low abundance upon entry into 
anaphase (McGarry and Kirschner, 1998)(Figure I. 4 A). Interestingly the same study 
revealed that geminin functions as a potent inhibitor of MCM2-7 loading in Xenopus 
egg extract. McGarry and Kirschner also reported the sequence of human geminin and 
Wohlschlegel et al. produced the first antibody targeting human geminin (McGarry and 
Kirschner, 1998; Wohlschlegel et al., 2000). However, the target of geminin inhibition 
was unknown until Wohlschlegel et al. and Tada et al. showed that geminin binds and 
inhibits Cdt1 (Tada et al., 2001; Wohlschlegel et al., 2000). Since then geminin 
homologues have been identified in C. elegans (Yanagi et al., 2005) and Drosophila  
(Quinn et al., 2001).  
 
 A number of studies have investigated the functional domains of Cdt1 
responsible for geminin, MCM2-7 and DNA binding. In Figure I. 4 B those findings are 
taken together and presented in a schematic overview of human Cdt1 and geminin and 
their functional domains. The N-terminus of Cdt1 has been shown to contain the motifs 
required for Cdt1 degradation as well as a nuclear localisation sequence. The central 
region contains a coiled-coil domain that is required for interaction with geminin 
(Ballabeni et al., 2004; Ferenbach et al., 2005; Saxena et al., 2004) although it also 
has been reported that the N-terminus can weakly interact with geminin (Ferenbach et 
al., 2005; Lee et al., 2004; Saxena et al., 2004). Ferenbach et al showed that the C-
terminal 377 residues are required for licensing and that the extreme C-terminus 
contains the domain that interacts with MCM2-7.  
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Figure I. 4. Cell cycle regulation of Cdt1 and geminin protein and a schematic representa-
tion of both proteins. A. Cell cycle phases are indicated and protein levels of Cdt1 (orange) and 
geminin (green) throughout the cell cycle are shown. B. Cdt1 and geminin protein with essential 
domains for poteolysis and licensing or licensing inhibition are shown. The domain architecture 
for Cdt1 is based on studies of Ferenbach et al.,2005 and reproduced from Davidson, 2007. PIP- 
PCNA binding motif, Cy- Cyclin/Cdk binding modif, T29- Cdk phosphorylation site. The geminin 
binding domain is pink, the MCM binding domain violet and the region required for licensing is 
yellow. The domain architecture for geminin is based on Thepaut et al., 2004. NLS- Nuclear 
localisation sequence, D-box- Destruction box required for APC/C binding. The functional essen-
tial coiled-coil domain is shown in green and the region required for licensing inhibition is grey.
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 While geminin degradation is dependent on a 9 aa destruction box near the N-
terminus, a central 80 aa coiled-coil domain is responsible for its role as an inhibitor of 
DNA replication (Figure I. 4 B).  
 The mechanism by which geminin inhibits Cdt1 is not clear; it does not prevent 
binding of Cdt1 to the DNA but prevents the binding of Cdt1 to MCM2-7 (Gillespie et 
al., 2001; Kim et al., 2007). Several studies have shown that geminin exists as a 
homodimer (Ferenbach et al., 2005; Lee et al., 2004; Saxena et al., 2004; Thepaut et 
al., 2004) and binds Cdt1 in a ratio of 2 geminin to 1 Cdt1 forming a heterotrimer 
(Ferenbach et al., 2005; Lee et al., 2004). However, the ratio between geminin and 
Cdt1 may functions as a non-linear molecular switch between controlled licensing and 
complete inhibition of licensing. This is based on an accumulation of evidence that 
started with the observation that only ~50% of ubiquitinated geminin is degraded upon 
exit from metaphase in the Xenopus early embryo (Hodgson et al., 2002), while the 
remainder becomes inactivated and unable to bind Cdt1 until geminin reactivation (Li 
and Blow, 2004). Another study in Xenopus revealed that a 3:1 geminin -Cdt1 ratio is 
active in licensing when added to interphase egg extract, while a 4:1 ratio is not active, 
suggesting the presence of a licensing switch (Lutzmann et al., 2006). The same study 
estimated that Cdt1-geminin complexes are associated with chromatin with about 5 
Cdt1 and 12 geminin molecules per origin during licensing and 20 geminin molecules 
after initiation. Consistent with those findings Ode and co-workers investigated an all-
or-none switch for origin licensing that is based on inter-origin cooperativity. They 
showed that licensing is inhibited when geminin dependent Cdt1 foci are formed on 
chromatin. In their model geminin is recruited to chromatin via its interaction to Cdt1, 
followed by an interaction of geminin-Cdt1 complexes from different origins with each 
other thus forming the inhibitory higher ordered structure visible as foci (Ode et al., 
2011).  
 In line with these findings a structural study revealed that the Cdt1:geminin 
complex can exist in two forms, a ‘permissive’ heterotrimer and an ‘inhibitory’ 
heterohexamer (De Marco et al., 2009) (Figure I. 5 A).  
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 In the heterotrimeric complex a geminin dimer binds one Cdt1 molecule via two 
interfaces such as shown by Lee et al., 2004 but only in the heterohexamer a tertiary 
interface is formed that buries Cdt1 residues required for MCM binding, which are 
exposed in the permissive heterotrimer complex. The study suggests the equilibrium 
between licensing permissive and inhibitory complex functions as conformational 
switch regulating licensing activity (Figure I. 5 B). Posttranslational modifications such 
as ubiquitination, phosphorylation or sumoylation would be potential candidates to 
change the equilibrium towards one or other of these states. The previously described 
inactivation of geminin by APC mediated ubiquitination (Hodgson et al., 2002) or the 
hyperphosphorylation of Cdt1 and geminin (Ballabeni et al., 2004; Nishitani et al., 
2004) in mitosis could inhibit the formation of the heterohexamer thus allowing 
licensing of replication origins for the next cell cycle.  
 
 A study performed by Ballabeni et al. suggests that in addition to inhibiting 
Cdt1, geminin protects Cdt1 from degradation in G2/M possibly allowing Cdt1 levels to 
build up for efficient reactivation of the licensing machinery in late mitosis. This points 
to a dual function of geminin as both a negative and positive regulator of pre-RC 
formation in human cells (Ballabeni et al., 2004). However, an alternative explanation 
for these results is that removal of geminin leads to re-replication, which causes Cdt1 
degradation by a checkpoint-mediated mechanism (Hall et al, 2008). 
 Studies also revealed that geminin can regulate neuronal differentiation by 
binding to the catalytic subunit of the switch/sucrose nonfermentable (SWI/SNF) 
chromatin-remodeling complex, Brahma-related gene 1 (Brg1) (Seo et al., 2005). 
Pefani and co-workers have recently identified Idas, another geminin interaction 
partner. Idas is a coiled-coil protein related to geminin, that binds geminin and inhibits 
its interaction with Cdt1. Idas depletion causes accumulation of cells in S-phase and 
prevents progression into mitosis (Pefani et al., 2011). 
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Figure I. 5. Structure of the human Cdt1:geminin complex and a proposed model for its 
inhibitory function. A. The 2x (Cdt1: 2x geminin) heterohexamer is shown as a cartoon repre-
sentation. Cdt1 molecules in yellow and orange and geminin dimers in green and blue shades. 
The primary, secondary and tertiary interface regons are boxed, in a magenta, pink and blue-
colored box. A schematic representation of Cdt1 and geminin proteins with the 3 interfaces 
marked in the sequence is also shown (additional functional regions are marked with black 
bars). B. Based on results from De Marco et al.,2009 a model for the mechanism of licensing 
inhibition by geminin was proposed with the heterotrimer allowing MCM chromatin loading while 
the heterohexamer blocks loading.
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 Additional regulatory roles in development, cell differentiation and cell 
proliferation have been suggested from the observations that geminin interacts with 
transcription factors of the Hox and polycomb as well as of the Six family. When 
geminin binds the Six3 transcription factor it is displaced from Cdt1 thus promoting 
proliferation of retinal precursor cells. In line with this, loss of geminin leads to 
expanded optic vesicles, while geminin over-expression causes forebrain and eye 
defects (Del Bene et al., 2004). Geminin binding to Hox transcription factors not only 
releases Cdt1, thus inducing licensing and therefore proliferation, but also inhibits 
binding of Hox to DNA thereby preventing transcription of Hox target genes (Luo et al., 
2004).  
 
 
 Figure I. 6. shows the complex regulatory network of the replication licensing 
system throughout the cell cycle. The next section describes the consequences of 
deregulation of the licensing machinery and its implications in disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   
S
G1M
G2
ORC
Cdc6
ORC
Cdc6 Cdc6
CDK mediaded
nuclear export
of Cdc6
CDK mediaded
inhibition of ORC
DNA binding
Cdt1
PCNA dependent 
Cul4/Ddb1/Cdt2 
mediated Cdt1 
degradation
geminin mediated 
inactivation of Cdt1
Cul4
Ddb1
C
dt
2 Cdt1
ge
m
in
in
Cdt1 ge
m
in
in
Cdt1
ge
m
in
in
Cdt1 geminin
Cdt1
Cul4
Ddb1
C
dt
2
Cdt1
Cul1
Sk
p2
Skp1CDK dependent 
SCF/Skp2 
mediated Cdt1 
degradation
Cdt1
Cul1
Sk
p2
Skp1
ORC
Cdt1Cdc6
Cdt1
Cdt1 geminin
ORC
Cdk1-cyclin B
(MPF)
APC/C
gem
inin
Ub
Ub
ge
m
in
in
ge
mi
nin
Cdt1
Cdt1
Figure I. 6.
I. 6. Regulation of the replication licensing system throughout the mammalian cell cycle. 
Shown are the four cell cycle phases with nuclei (light brown areas) and the relevant proteins. From 
late mitosis until late G1 the licensing machinary is active (green) and free MCMs (lila) can be loaded 
onto chromatin (blue) as double hexamer by sequential action of ORC, Cdc6 and Cdt1. Upon initia-
tion MCMs travel in front of the replication fork as replicative helicase leaving the origins unlicensed. 
In S-phase until Anaphase the licensing system is inactivated by nuclear export of Cdc6, Cdk medi-
ated inhibition of ORC and most impotantly down regulation of Cdt1 activity. Cdt1 is in an inhibitory 
complex with geminin and degraded by two ubiquitin ligases. In S-phase it is predominantly degraded 
in a PCNA dependent manner by the Cul1/Ddb1 ubiquitin ligase and from S-phase until Anaphase it 
is also degraded by the SCF/Skp2 ligase. During G2 phase Cdt1 levels start to build up and once the 
cells enter anaphase geminin is degraded by the anaphase promoting complex thus allowing licens-
ing of replication origins. 
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I. 7.  De-regulation of the Licensing Machinery 
I. 7. 1.  Insufficient licensing - the lack of dormant origins 
Section I. 4. 4. 1. described the role of excess MCM2-7 loaded onto chromatin 
during licensing to provide dormant origins that can fire during replication stress such 
as fork stalling to ensure complete genome replication (Ge et al., 2007; Ibarra et al., 
2008; Woodward et al., 2006). Minimal licensed DNA, exhibiting a ~50% reduction of 
chromatin bound ~MCM2-7 complexes, showed an essentially normal replication rate, 
average origin spacing and cell cycle checkpoint activity but a reduced long term 
viability. However cells with minimal licensed origin are hypersensitive to replication 
inhibitors such as hydroxyurea (Ge et al., 2007). This suggests that minimal licensing 
has no effect on ‘normal’ replication but reduces viability when replication stress 
occurs during normal cell cycles or is induced by the presence of replication inhibitors.  
Mice heterozygous for an MCM4 hypomorphic mutation that seems to 
destabilise MCM4 protein (MCM4Chaos3), showed an increased rate of chromosome 
breakage in response to a replication inhibitor (Blow and Gillespie, 2008b; Shima et 
al., 2007). Chaos3 mutant mice also exhibited increased levels of micronuclei and 
80% of the females died of mammary adenocarcinomas. A new paper by Kawabata 
and colleagues (2011) revealed that MCM4Chaos3/Chaos3 mice exhibit ~60% reduced 
levels of chromatin bound MCM2-7 protein and a corresponding inability to activate 
dormant origins when challenged with aphidicolin, an inhibitor of the replicative DNA 
polymerases (MCM hypomorph in Figure I. 7). Strikingly, even in the absence of 
externally supplied replication stresses, MCM4Chaos3 mutant cells had an increased 
number of stalled replication forks, a small increase in DNA damage foci containing 
Ras-related associated with diabetes 51 protein (RAD51), Replication protein A 32 
(RPA32) and RAD17, a 50% increase of Fanconi anemia group D2 (FANCD2) foci (a 
protein involved in resolving stalled replication intermediates) and >2-fold increase of 
abnormal mitoses (Kawabata et al., 2011; Klotz-Noack and Blow, 2011). This genetic 
instability very likely explains why the mice are tumour-prone. In a second study 
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homozygous transgenic MCM2 mice (MCM2Ires-CreERT2) showed a one-third reduced 
MCM2 level and exhibited severe deficiencies in the proliferative cell compartments of 
a variety of tissues. They died of T- and B- cell lymphomas at an early age (Pruitt et 
al., 2007). These findings demonstrate the critical importance of dormant replication 
origins for cells in a physiological setting, and have implications for the genetic 
instability commonly seen in cancer cells (Figure I. 7).  
 
 In primary cells a ‘licensing checkpoint’ exists in G1 phase of the cell cycle to 
ensure that a sufficient number of origins are licensed before entry into S-phase. It 
involves pathways that activate p53 and suppress retinoblastoma protein (Rb) function 
during G1 (Blow and Gillespie, 2008b; Liu et al., 2009; Nevis et al., 2009; Shreeram et 
al., 2002). In cancer these pathways are quite often disturbed and the checkpoint does 
not engage allowing insufficiently licensed cells to progress into S-phase but it remains 
unclear how sensitive the licensing checkpoint is to smaller reductions such as those 
seen in MCM4Chaos3/Chaos3 cells. Neither the MCM4 nor the MCM2 hypomorphic cells 
display gross proliferation defects. One possibility is that dormant origin defects are 
seen in MCM4Chaos3/Chaos3 and MCM2 mutant mice because the reduction is too modest 
to reproducibly engage the licensing checkpoint. The levels of MCM2-7 could just be 
enough to enter S-phase, causing replication defects that are too minor to strongly 
activate checkpoints, but in the long term substantial enough to cause genomic 
instability and cancer (Klotz-Noack and Blow, 2011)(Figure I. 7).  
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Figure I. 7.  A role for dormant origins in maintaining genomic stability.  A small segment of 
the genome is shown during the cell cycle of normal (top) and MCM hypomorphic (bottom) cells. 
In G1, efficient and normally dormant (unefficient) origins are licensed by loading MCM2-7 onto 
chromatin (green and light green dots). In S-phase, some origins fire (red dots) and replication 
forks move bidirectionally away from them, passively replicating other origins (grey dots) until 
forks stall or terminate. Fork stalling triggers the firing of some origins that usually remain dormant 
(light red dots) to ensure complete genome duplication. Lack of dormant origins can result in 
progression of cells into mitosis with unreplicated segments of the genome, leading to chromo-
some breakage and formation of micronuclei.
Figure I. 7.
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 Cyclin E/Cdk2 activity drives cell cycle progression through the restriction point 
(R) and initiates the S-phase program (Ohtsubo et al., 1995). A wealth of experimental 
data has linked deregulated expression of cyclin E to human cancer exposing a very 
powerful oncogene (reviewed in (Donnellan and Chetty, 1999). Over-expression of 
cyclin E has been shown to shorten the duration of G1 and accelerate G1/ S-phase 
transition but leads to slowing of S-phase progression (Ohtsubo and Roberts, 1993; 
Resnitzky et al., 1994; Spruck et al., 1999). Interestingly, cyclin E overexpressing S-
phase cells also exhibited a reduced number of BrdU and PCNA foci suggesting fewer 
initiation events took place possibly explaining why S-phase progression is slowed 
down (Ekholm-Reed et al., 2004). The same study showed a reduction of chromatin 
bound MCM2-7 complex components in cyclin E overexpressing cells explaining why 
fewer initiation events can be observed. The study implies that the shortened G1 
phase and the accelerated S-phase entry caused by high cyclin E levels, interfered 
with proper pre-RC formation leading to insufficient origin licensing.  Genetic instability, 
and accelerated tumourigenesis are consequences of cyclin E deregulation (Loeb et 
al., 2005; Spruck et al., 1999) and might be caused by insufficient origin licensing.  
 
 Licensing inhibitors have a high therapeutic potential and anticancer agents 
targeting ORC, Cdc6, Cdt1 or MCMs, thus preventing licensing of enough origins to 
allow complete genome duplication, would engage the licensing checkpoint of normal 
proliferating cells, whereas cancer cells would progress into S-phase trying to complete 
replication (Feng et al., 2003; Shreeram et al., 2002). Those cells would be 
hypersensitive to a range of replication inhibitors and would only partially replicate their 
genome while the G1 arrested ‘normal cells’ would be unaffected. Removal of the 
anticancer agent would enable the ‘normal cells’ to license the remaining origins and 
pass the checkpoint to progress into S-phase. The cancer cells that have progressed 
into S-phase, where further licensing is impossible are doomed to suffer the fatal 
consequences of partial replication ultimately leading to cell death. Finding licensing 
inhibitors could be an important step forward in the fight against cancer. 
Chapter I                                                                                            Introduction     
	   50 
I. 7. 2.  Uncontrolled licensing – re-replication of the genome 
I. 7. 2. 1. De-regulated expression of licensing proteins  
 Several studies have linked inappropriate expression of MCM2-7 and other pre-
RC proteins to a variety of pre-malignant dysplasias and cancer (Gonzalez et al., 2005; 
Hook et al., 2007; Lau et al., 2007; Williams and Stoeber, 2007; Xouri et al., 2004). In 
actively cycling cells, MCM2-7 are constitutively expressed and only show a cycle of 
chromatin binding and release (Figure I. 6). However most cells in metazoans exit the 
cell cycle through quiescence or differentiation and exhibit a lack of detectable MCM 
proteins (Madine et al., 2000; Musahl et al., 1998; Todorov et al., 1998).  One could 
say that MCM2-7 proteins mark proliferating cells and their expression level in human 
tissue can be indicative for early tumour formation. Therefore Ron Laskey and 
colleagues have developed a cervical smear test using MCM5 antibodies which allows 
early detection of squamous intraepithelial lesions (Williams et al., 1998). Attempts to 
recover cells from a range of body fluids to detect MCMs and screen for pre-invasive 
stages of the most common cancer types gave promising results (reviewed in 
(Tachibana et al., 2005a) and led to clinical trials for cervical, lung, colon and bladder 
cancers (Laskey, 2005). 
 It is currently not understood why malignant cells express licensing proteins 
inappropriately but one possibility would be a failure to exit the cell cycle. Frequently an 
increase in Cdk activity driving cell cycle progression can be observed during 
malignant transformation. Consequently less cells would exit the cell cycle undergoing 
differentiation but instead would proliferate and express licensing proteins (Sherr, 
1996). In this scenario MCM2-7 would be a powerful marker for ‘in-cycle’ cells but they 
would not be directly involved in malignant progression as an oncogene-induced 
stimulation of cell division is required.  
 Alternatively, a review by Blow and Gillespie (2008) discussed the deregulation 
of replication licensing as a consequence of oncogene induced cell proliferation. 
Activation of oncogenes linked to tumour formation has been shown to interfere with 
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mechanisms that typically shut down replication licensing in S-phase and G2. One of 
those oncogenes is cyclin D1, which is frequently deregulated in human cancers 
through mutations, alternative splicing and gene amplification. The accumulation of 
cyclin D1 results in an increase in cyclin D1/Cdk4 activity leading to transcriptional 
repression of CUL4 thus stabilising Cdt1 protein levels (Aggarwal et al., 2007; 
Aggarwal et al., 2010). Consequently low levels of re-replication could be detected that 
are sufficient to cause genetic instability but are compatible with cell survival mainly 
due to additional mutations in the DNA damage response. 
 Another strong oncogene is Ras and its expression causes a robust DNA 
damage response leading to oncogene induced senescence (OIS) in normal human 
cells (Di Micco et al., 2006). The senescent cells exhibit partially replicated DNA and 
segments where replication origins have fired multiple times. Interestingly the DNA 
damage response (DDR) is not activated in the absence of DNA replication suggesting 
that deregulation of the licensing machinery allowed re-firing of origins thus activating 
the DDR (Di Micco et al., 2006). Inactivation of the DNA damage response triggered 
the abrogation of OIS and promoted cell transformation in this study. It is quite likely 
that other oncogenes activating the pathways upstream of the retinoblastoma protein 
can prevent complete inactivation of the licensing machinery in S-phase and G2 thus 
promoting re-replication of DNA. 
 
I. 7. 2. 2. Loss of licensing inhibitor geminin.  
 The importance of geminin in preventing re-replication varies between different 
model systems. Geminin knockdown by siRNA is sufficient to induce re-replication in 
several human cancer cells and a few primary human cells (Klotz-Noack et al., 2012; 
Melixetian et al., 2004; Zhu et al., 2004; Zhu and DePamphilis, 2009). Kristian Helin 
and co-workers showed that geminin knockdown in normal human and cancer derived 
cell lines leads to re-replication and Chk1-dependent checkpoint activation 
accompanied by formation of γH2AX and RAD51 nuclear foci (Melixetian et al., 2004). 
They also demonstrated that abrogation of that checkpoint by caffeine or UCN01 led to 
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abortive mitosis and death of the re-replicating cell. A mitotic defect was also reported 
by Tachibana et al., whose study revealed that geminin silencing causes centrosome 
over-duplication in normal human and cancer cell lines with the consequence of 
chromosome mis-segregation in mitosis (Tachibana et al., 2005c). In contrast, several 
studies showed that geminin depletion does not cause detectable re-replication in 
several other cell types such as HeLa or MCF10A cells (Kulartz and Knippers, 2004; 
Machida and Dutta, 2007; Zhu and DePamphilis, 2009). The cell line specific response 
is perhaps due to different protein levels of Cdt1 and geminin.  
 Loss of geminin leads to extensive re-replication of DNA in D. melanogaster 
(Mihaylov et al., 2002; Quinn et al., 2001), while it does not in C. elegans (Yanagi et al., 
2005). It has been reported that in mice a lack of geminin resulted in pre-implantation 
mortality. DNA replication occurred but mitosis was not detected in the mutant 
embryos. The abnormal blastomeres contained damaged DNA and underwent 
apoptosis, likely as a consequence of the deregulation of DNA replication (Gonzalez et 
al., 2006; Hara et al., 2006). In Xenopus, depletion of geminin or inhibition of Cdt1 
degradation alone leads to little re-replication but when both mechanisms are inhibited 
directly or by Cdt1 over-expression then substantial re-replication can be detected 
(Arias and Walter, 2005; Hodgson et al., 2002; Li and Blow, 2005; Maiorano et al., 
2005; McGarry and Kirschner, 1998; Yoshida et al., 2005) 
 Knockdown of APC inhibitor early mitotic inhibitor 1 (Emi1) caused an increase 
of APC activity followed by decreased levels of geminin and cyclin A outside mitosis 
leading to re-replication even in HeLa cells (Machida and Dutta, 2007). The same 
study revealed that co-depletion of cyclin A and geminin causes re-replication, while in 
contrast the same group found that over-expression of cyclin A stimulates the re-
replication induced by Cdt1 over-expression (Vaziri et al., 2003). 
 
I. 7. 2. 3.  Stabilisation or over-expression of Cdt1  
 Cdt1 is an oncogene and its over-expression in cells injected into nude mice 
results in tumour formation (Arentson et al., 2002). Cdt1 over-expression is sufficient to 
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induce re-replication in Drosophila, Xenopus, and humans (Arias and Walter, 2005; Li 
and Blow, 2005; Maiorano et al., 2005; Thomer et al., 2004; Vaziri et al., 2003). 
Disruption of the PCNA dependent degradation pathway by siRNA targeting CUL4, 
Ddb1 or Cdt2 induces re-replication in C. elegans and several human cancer cell lines 
(Jin et al., 2006b; Lee et al., 2007a; Lovejoy et al., 2006; Sansam et al., 2006; Zhong et 
al., 2003). When both Cdt1 degradation pathways (Section I. 6. 1. 1) are inhibited by 
addition of a Nedd8 activating enzyme inhibitor called MLN4924, the activity of CUL1 
and CUL4 E3 ligases is reduced and Cdt1 is stabilised (Figure IV. 9). Several studies 
have shown that MLN4924 treatment induces re-replication within S-phase, 
senescence and apoptosis emphasising the importance of proper Cdt1 regulation 
(Klotz-Noack et al., 2012; Lin et al., 2010; Milhollen et al., 2011; Soucy et al., 2009).  
 In Xenopus egg extracts addition of recombinant Cdt1 in G2 phase of the cell 
cycle leads to re-initiation of DNA synthesis and substantial re-replication (Li et al, 
2005; Maiorano et al, 2005). High levels of Cdt1 also cause activation of the DNA 
damage response, inhibition of re-replication and appearance of small double stranded 
DNA fragments (Davidson et al., 2006). This study showed that DNA fragments only 
appear when uncontrolled re-replication takes place but not after a single round of re-
replication being explained in a fork collision model (Figure VI. 3.). Briefly, when origins 
re-fire multiple times the replication bubbles within existing bubbles are formed and the 
replication forks chase one another along the DNA. The rear forks are likely to be 
faster than the front forks as newly synthesised DNA behind replication forks is in an 
immature form (Davidson et al., 2006). When both rear forks catch up with the front 
forks causing a head-to-tail fork collision and double stranded DNA fragments would be 
released. It would be very interesting to know whether this sort of collision can occur in 
human cells as it would be tempting to assume that gene amplifications such as seen 
in many human tumours could be the attempt of a cell to resolve structures caused by 
re-replication induced DNA fragments. 
 Deregulation of MCM2-7 and Cdc6 causes re-replication on a single budding 
yeast origin leading to gene amplification. The re-replication induced gene 
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amplifications are in head-to-tail orientation and are mediated by nonallelic 
homologous recombination between repetitive elements (Green et al., 2010). Re-
replication generates slowed or stalled forks and DNA damage (Green and Li, 2005) 
and the homologous recombination most likely serves as repair mechanism to resolve 
the DNA structure cause by fork stalling and breakage within the re-replication bubble 
(Green et al., 2010). As a consequence the re-replicated segment appears in head-to-
tail orientation adjacent to the parental locus. Head-to-tail gene amplifications are a 
common feature of many tumours and suggest that re-replication could be an early 
step in malignant transformation. 
     
I.  8.  Cell Cycle Checkpoints-  
  Responding to environmental insults 
 
 The maintenance of genomic stability is the basis of cellular survival and 
environmental insults can lead to cell cycle arrest, cellular senescence, cell death and 
cancer cell transformation. The integrity of our genome is constantly challenged by 
exogenous and endogenous stress such as ionising radiation, ultraviolet radiation, 
carcinogenic agents, as well as cellular stress caused by replication errors and toxic 
by-products of cellular metabolism. DNA damage is a common event; therefore 
organisms have evolved several cell cycle checkpoint pathways, which prevent cell 
cycle progression upon detection of DNA damage or factors not favouring proliferation. 
The first cell cycle checkpoints exist between G1 and S-phase, sensing environmental 
conditions that would not favour progression into S-phase including transforming 
growth factor beta (TGF-β), differentiation factors, growth factor withdrawal, 
senescence or DNA damage. Progression into S-phase is ultimately blocked by 
inhibition of cyclin D/ Cdk4/6 and cyclin E/Cdk2 activity.  
 Another checkpoint in G1 phase of the cell cycle is the licensing checkpoint 
responding to a reduced number of licensed origins in primary cells. Consequently 
cells are delayed in G1 phase and cannot enter S-phase, thus lingering at a cell cycle 
stage where further licensing can still take place (Blow and Gillespie, 2008b). However, 
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cancer cells do not respond with activation of the licensing checkpoint and progress 
into S-phase with to few origins, leading to defects in replication and ultimately to cell 
death (Shreeram et al., 2002). 
 Once cells are in S-phase, various sensory proteins can detect DNA damage 
thus triggering the activation of the intra-S-phase checkpoint. Subsequently S-phase 
progression is blocked by inhibition of origin firing, chromatin remodelling, transcription 
of replication factors and stimulation of ribonucleotide reductase activity (Labib and De 
Piccoli, 2011). Furthermore the intra-S-phase checkpoint stabilises replication forks to 
prevent irreversible fork collapse allowing time to resolve the damage. The G2/M 
checkpoint guarantees that cells do not progress into mitosis with DNA damage or un-
replicated DNA mainly by inhibition of cyclin B/Cdk1 kinase activity via inactivation of 
Cdc25 phosphatase and activation of Wee1 kinase as well as activation of p53. The 
final checkpoint in the cell cycle is the mitotic spindle checkpoint that engages when 
the spindle is not properly attached to the kinetochores or when chromosomes are not 
correctly aligned at the metaphase plate and prevents onset of anaphase by inhibiting 
the APC. Spindle checkpoint defects can cause chromosome missegregation and 
aneuploidy and can be directly linked to cancer formation and genetic disabilities such 
as Trisomy 21. The focus of this Thesis is the process of DNA replication, therefore the 
next section will provide details about the Intra-S-phase and the DNA damage 
checkpoint response, its sensors, transducers and effectors and the consequences of 
its abrogation. 
 
I.  9.   The DNA Damage and S- phase Checkpoints 
 As described above, cells monitor the state of their DNA throughout the entire 
cell cycle to minimise the danger of passing damaged genetic material to daughter 
cells. The DNA damage pathways are linked to DNA repair and apoptotic pathways 
and can promote the resolution of damage and the subsequent re-entry into the cell 
cycle or in the event of irreversible damage can trigger apoptosis. One could say two 
main pathways; the DNA damage checkpoint and the S-phase checkpoint control the 
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maintenance of DNA. The DNA damage checkpoint recognises and responds to 
defective DNA and the S-phase checkpoint monitors the fidelity of copying DNA, 
eventually activating the DNA damage response.  
 
I. 9. 1.  The S-phase or replication checkpoint 
 The existence of a S-phase checkpoint became apparent when cells treated 
with ionizing radiation rapidly blocked DNA synthesis. The response was too quick to 
be caused by a failure in the G1/S-phase transition and could only be the result of 
immediate inhibition of origin initiation in regions where replication forks had not yet 
been established (Larner et al., 1994). This response is defective in cells lacking ATM 
kinase (Labib and De Piccoli, 2011). Interestingly, studies in yeast revealed that 
Rad53, the yeast homolog of the ATM downstream kinase Chk2, delays late origin 
firing when DNA synthesis is defective at early forks after treatment with the 
ribonucleotide reductase (RNR) inhibitor hydroxyurea (Santocanale and Diffley, 1998; 
Shirahige et al., 1998). Recent work showed that Chk2/Rad53 down regulates the 
activity of the replication promoting kinase Cdc7 by phosphorylation of its subunit Dbf4 
(Duch et al., 2011; Weinreich and Stillman, 1999b) as well as by an inhibitory 
phosphorylation of synthetic lethal mutations with dpb11–1 3 (Sld3), a replication 
regulator that recruits the essential fork protein Cdc45 (Lopez-Mosqueda et al., 2010; 
Zegerman and Diffley, 2010). In higher eukaryotes such as Xenopus or human cells 
Cdc7 exists in two complexes as Cdc7/Dbf4 and Cdc7/Drf1 and induction of replication 
stress by treatment with HU or etoposide does not inhibit Cdc7 activity in a variety of 
human cancer cell lines (Tenca et al., 2007). Consistently, in Xenopus cell free extract 
total Cdc7 activity is not altered in the presence of DNA double strand breaks or upon 
treatment with aphidicolin (Petersen et al., 2006; Yanow et al., 2003). It is currently 
unclear what function Cdc7 activity has in response to replication stress and why it is 
differentially regulated in yeast and higher eukaryotes. 
 The main function of the intra- S-phase checkpoint is to activate ATM/ ATR and 
there downstream kinases Chk2 and Chk1 to delay S-phase, activate DNA repair, 
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prevent late origins from firing, and stabilise the replisome and the stalled forks. Each 
of those functions helps to eventually overcome the replication stress and resume 
replication of the complete genome. Whereas Chk2/ Rad53 seems to be of major 
importance in the yeast S-phase response it is not clear whether the same pathways 
are active in human cells as Chk1 kinase and not Chk2 kinase has been shown to 
prevent activation of additional replication clusters but allowing activation of dormant 
origins within active clusters to complete replication of that region (Ge and Blow, 2010; 
Karnani and Dutta, 2011). Karnani and co-workers provided evidence that the intra- S-
phase checkpoint inhibits origin firing after the loading of MCM10 but before 
recruitment of Cdc45 and And-1 and suggested the loading could be inhibited by a 
local reduction of Cdk2 activity or the increased H3 lysin 4 trimethylation (Karnani and 
Dutta, 2011).  
 S-phase checkpoint activation is a consequence of slowed replication fork 
progression. This can either be a consequence of deoxyribonucleotide triphosphate 
(dNTP) depletion, inhibition of DNA polymerases, other replication fork proteins or 
aberrant DNA structures such as nicks, crosslinks, or single and double strand breaks. 
S-phase checkpoint activation results in stabilisation of replication forks to prevent 
irreversible fork collapse and in the event of encountering aberrant DNA structures 
activation of the DNA damage response. The DNA damage response can be divided 
into the double strand break (DSB) response activated by irradiation, DSB inducing 
agents, or forks encountering certain repair or recombination intermediates and into the 
single-strand DNA response. Both pathways are explained in more detail in the next 
section and are illustrated in Figure I. 8. 
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Figure I.  8. The DNA damage response. A schematic of the DNA damage pathways discussed in 
Section I. 9. is shown, focusing on the ATM mediated double strand break response and the ATR 
mediated single strand break or replication stress response. The red X’s represent DNA strand breaks 
and the blue and yellow lines DNA crosslinks. The yellow circles containing ‘P’ represent phosphate, 
while green filled circles containing ‘U’ represent ubiquitin. For detailed desciption see text.
(modified from Harper and Elledge, 2007)
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I. 9. 2.  The ATM kinase activity – Double strand break response 
 The ataxia-telangiectasia-mutated (ATM) and ataxia-telangiectasia and Rad3 
related (ATR) kinases are members of the phosphatidylinositol 3-kinase (PI-3) 
superfamily and phosphorylate their targets on serine or threonine residues. The ATM 
kinase (Tel1 in budding and fission yeast) is a 3056 amino acid protein that 
predominantly exists as an inactive dimer that auto-phosphorylates and dissociates 
turning into an active monomeric complex when recruited to DNA double strand breaks 
(Bakkenist and Kastan, 2003) (Figure I. 8). Lee and Paull demonstrated in 2005 that 
DSBs are sensed by the Mre11-Rad50-Nijmegen Breakage syndrome protein (Nbs) 
(MRN) complex, which then recruits ATM to the broken DNA molecule (Lee and Paull, 
2005). One of the first and most important targets of ATM at the site of damage is the 
phosphorylation of the adjacent histone variant H2AX (Ser139) which can also be 
phosphorylated by ATR and DNA protein kinase (PK) (Rogakou et al., 1998). The 
phosphorylated H2AX recruits mediator of DNA-damage checkpoint 1 (Mdc1), which 
acts to amplify H2AX phosphorylation possibly by inhibiting its de-phosphorylation and 
recruitment of more MRN and ATM complexes (Stucki and Jackson, 2006). Thus the 
H2AX phosphorylation spreads along chromatin resulting in DNA damage foci 
formation and the recruitment of many DNA damage response proteins facilitating an 
efficient activation of DNA repair and cell cycle checkpoints. 
  Another important target of the ATM kinase is its downstream kinase 
checkpoint kinase 2 (Chk2) (Rad53 in budding yeast). Chk2 is constitutively expressed 
throughout the cell cycle (Lukas et al., 2001) and is mainly inactive in absence of DNA 
damage. ATM phosphorylates Chk2 at Threonine 68 (Ahn et al., 2000; Melchionna et 
al., 2000) leading to homo-dimerisation via its forkhead-associated (FHA) domains and 
auto-phosphorylation of its kinase activation loop (Ahn et al., 2004). Targets thought to 
be exclusive for Chk2 kinase are breast cancer 1 (BRCA1) at Serine 988, E2F 
transcription factor 1 (E2F1), promyelocytic leukemia (Pml) and polo-like kinase 3 
(Plk3) proteins that are involved in DNA repair, damage induced transcription, 
apoptosis and cell cycle arrest (Bartek and Lukas, 2003). Other downstream targets of 
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Chk2 are tumour suppressor p53 at Serine 20 and proto-oncogenes Cdc25A/C but 
since those targets are shared with the ATR downstream kinase Chk1 more details will 
be presented in the next section. It should also be stated that p53 is directly activated 
by ATM/ATR mediated phosphorylation of Serine 15 which inhibits the binding of the 
p53 repressor transformed mouse 3T3 cell double minute 2 (Mdm2) (Figure I.8). 
 
I. 9. 3.  The ATR kinase activity – Single strand DNA response 
ATM kinase is activated in response to DSB whereas the second major DNA damage 
signalling pathway is activated by the related ATR kinase that responds to single 
stranded DNA after UV radiation or replication stress. ATR (Rad3 in fission yeast and 
Mec1 in budding yeast) is a 2644 amino acid protein whose depletion causes cessation 
of proliferation and cell death even in absence of exogenous genotoxic agents (Brown 
and Baltimore, 2003; Cortez et al., 2001). The importance of the ATR signalling 
cascade is underlined by the fact that ATR and downstream kinase Chk1 knockout 
mice are embryonic lethal (Brown and Baltimore, 2000; de Klein et al., 2000; Liu et al., 
2000; Takai et al., 2000). 
 Single stranded DNA coated by the single-strand binding protein replication 
protein A (RPA) is the primary signal or a boost for the ATR checkpoint responds. 
When replication forks encounter small lesions or nicks they stall, while the MCM 
replicative helicase continues to unwind the DNA, a process essential for downstream 
signalling as it leads to the generation of single stranded (ss) DNA (Figure I. 8) (Byun 
et al., 2005). Single stranded DNA is also generated when synthesis of lagging and 
leading strand become uncoupled (Sogo et al., 2002). When DNA-protein 
intermediates or DNA crosslinks generate DNA double strand breaks a crosstalk 
between ATM and ATR signalling can be mediated by collaboration of Mre11 with 
exonuclease 1 thus leading to generation of long ssDNA tails (Nakada et al., 2004).  
The ssDNA is recognised and bound by RPA which in turn recruits the regulatory 
subunit of ATR, the ATRIP (Zou and Elledge, 2003). The RPA-ssDNA complexes also 
facilitate the loading of clamp loader Rad17 onto chromatin, which subsequently loads 
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the PCNA like protein complex Rad9-Rad1-Hus1 (9-1-1) onto DNA (Zou et al., 2003). 
Rad17 and Rad9 are phosphorylated by ATR while the loading of Rad17 and 9-1-1 is 
largely ATR independent. Interestingly 9-1-1 has been shown to stimulate ATR activity 
in yeast (Majka et al., 2006), indicating that Rad17 and 9-1-1 loading onto DNA are 
early events in ATR signalling. Moreover phosphorylation of Rad17 and 9-1-1 by ATR 
are important for ATR stimulation and downstream signalling. 
 Another important player in the ATR signalling pathway is topoisomerase (DNA) 
II binding protein 1 (TopBP1) (Cut5 in fission yeast and Dpb11 in budding yeast) a 
protein essential for replication initiation and the DNA damage response (Garcia et al., 
2005). TopBP1 binds to the phosphorylated 9-1-1 complex (Delacroix et al., 2007; Lee 
et al., 2007b) on chromatin and interacts with ATRIP to stimulate ATR kinase activity 
(Kumagai et al., 2006). 
 The major kinase downstream of activated ATR is Chk1 whose expression in 
largely restricted to S-phase and G2 (Lukas et al., 2001). Chk1 activation is dependent 
on the presence of phosphorylated Claspin (Mrc1 in yeast)(Kumagai and Dunphy, 
2000) a replication fork protein that travels with the replication fork. In the presence of 
phosphorylated Claspin the ATR kinase activates Chk1 via phosphorylation of Serine 
317 or 345. The Chk1 signalling cascade can be inactivated via Plk1 mediated 
phosphorylation of Claspin and its subsequent ubiquitination by SCFβTRCP leading to its 
degradation (Mamely et al., 2006; Peschiaroli et al., 2006). Most Chk1 signalling 
targets are shared with the Chk2 kinase and therefore will be highlighted in the next 
section. 
 
I. 9. 4.  Chk1/ Chk2 signalling - Common targets and cellular  
  consequences  
 
 The main targets of Chk1/Chk2 kinases are p53 and Cdc25A and Cdc25C. The 
Chk1 but mainly Chk2 mediated phosphorylation of p53 (Ser20) stabilises the protein 
and activates the transcription of Cdk inhibitor p21, apoptosis promoting factor Bcl2-
associated X protein (BAX), regulatory signalling protein tyrosine 3-
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monooxygenase/tryptophan 5-monooxygenase activation protein (14-3-3) and many 
more. The p53 mediated expression of p21 has a strong inhibitory effect on cell cycle 
progression in most cell cycle phases; it inhibits progression into S-phase by blocking 
Cdk2/ cyclin E activity, prevents origin initiation in S-phase via inhibition of Cdk2/ cyclin 
A and supresses entry into mitosis by inhibition of Cdk1/ cyclin B.  
 Similar effects on cell cycle progression can be observed by the Chk1 and Chk2 
mediated inhibitory phosphorylation of the phosphatase Cdc25, which promotes cell 
cycle progression by removing the inhibitory phosphorylation on Cdk1/2 (Thr15). Chk1 
and Chk2 kinase both rapidly inhibit Cdc25C function by phosphorylation of Serine 216 
(Matsuoka et al., 1998; Peng et al., 1997; Sanchez et al., 1997) thereby creating a 
binding site for 14-3-3 which reduces Cdc25C activity and mediates it nuclear 
exclusion (Nyberg et al., 2002). The consequence of Cdc25C inactivation is a G2/M 
delay as Cdk1/ cyclin B cannot promote mitotic entry. Both kinases but mainly Chk2 
also mediate the rapid phosphorylation of Cdc25A, thereby priming it for ubiquitination 
and degradation (Mailand et al., 2000). Loss of Cdc25A prevents S-phase entry by 
inhibition of cyclin E association with phosphorylated Cdk2 (Thr15). Chk1 has also 
been shown to play a major role in the intra S-phase checkpoint responds as it inhibits 
activation of replication factories during replication stress but allows firing of dormant 
origin within active clusters to ensure completed replication after fork stalling or 
collapse (Ge and Blow, 2010). This is consistent with data from Thomson and 
colleagues (2010) revealing that lowering Cdk activity inhibits new factory activation but 
does not affect number of forks within a factory. Cdk’s could have specialized 
substrates within a factory that need to be phosphorylated to activate it and others that 
need to be phosphorylated to initiate origins. Alternatively, high Cdk activity could be 
needed to initiate the first origin within a factory, which causes a change propagating 
throughout the factory allowing the remaining origin to fire with low levels of Cdk. In the 
study of Ge and co-workers (2010) a decrease in total Cdk activity in response to 
replication stress could not be detected, therefore Chk1 most likely inhibits specific Cdk 
substrates required for factory activation or origin initiation (Ge and Blow, 2010). 
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I. 9. 5.  DNA damage response defects and cancer 
 This section serves to briefly underline the pathological consequences of a 
defective DNA damage response due to the mutation or absence of the key players. 
The absence of ATM for instance leads to the disease ataxia telangiectasia (AT) which 
is characterised at a cellular level by gross chromosomal rearrangements and 
increased sensitivity to irradiation and on an organismal level by immune deficiency, 
cerebellar degeneration and increased predisposition to cancer (Lavin and Shiloh, 
1997; Savitsky et al., 1995). Other diseases exhibiting the same symptoms as AT also 
result from defects in the double strand break response. Examples are the Nijmegan 
breakage syndrome and the “AT-like disorder” caused by mutations in the MRN 
complex genes NBS1 and MRE11 (Carney et al., 1998; Stewart et al., 1999; Varon et 
al., 1998). Further downstream in the cascade is the tumour suppressor p53 whose 
gene TP53 is mutated or deleted in about 50% of human tumours. People inheriting 
only one functional copy of TP53 exhibit a high predisposition to tumours in early 
adulthood, a disease known as Li-Fraumeni syndrome (Malkin et al., 1990). It is 
currently unclear whether the cancer predisposition is a consequence of defects in p53 
mediated cell cycle arrest or its pro-apoptotic function but it is likely to be both.  
 A serious medical condition is the hereditary breast-ovarian cancer syndrome, 
which is a result of gene mutations in the DNA repair protein BRCA1 and accounts for 
50% of all inherited cases of breast and ovarian cancer. 
 Chk1 mutations are extremely rare and have only been observed in carcinomas 
of the colon, stomach and endometrium, while Chk2 qualifies as tumour suppressor 
and mutations have been found in carcinomas of the breast, colon, lung, bladder, 
ovary, and vulva as well as in sarcomas lymphomas and patients with Li-Fraumeni 
syndrome (Bartek and Lukas, 2003).  This section described mutations in the DNA 
damage response pathways found in cancer but it should be stated that according to 
the Weinberg model six capabilities have to be acquired by a cell to cause cancer; self-
sufficiency in growth signals, insensitivity to anti-growth signals, evading apoptosis, 
limitless replicative potential, sustained angiogenesis and tissue invasion/metastasis 
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(Hanahan and Weinberg, 2000). The mutations described can only account for one or 
two of the first three points and therefore cannot solely be made responsible for the 
tumour formation.   
One central capability in tumour formation is the ability to escape apoptosis as 
irreversible genomic insults such as deregulated DNA synthesis or irreversible DNA 
damage should always result in cell death. Deregulation of the licensing machinery has 
been shown to induce DNA damage checkpoints in humans, Xenopus, Drosophila 
melanogaster and S. cerevisiae and in human cells has been associated with re-
replication induced apoptosis (Archambault et al., 2005; Green and Li, 2005; Klotz-
Noack et al., 2012; Li and Blow, 2005; Melixetian et al., 2004; Mihaylov et al., 2002; 
Vaziri et al., 2003; Zhu et al., 2004; Zhu and DePamphilis, 2009; Zhu and Dutta, 2006). 
The present work aims to investigate consequences of re-replication in human tissue 
culture cells and should therefore provide insight into the process of programmed cell 
death. 
 
I.  10. Apoptosis 
 Our understanding of the process of programmed cell death was initially 
inspired by J. F. R. Kerr and colleagues providing an electron microscopic tissue study 
illustrating the morphological changes cells undergo during the course of apoptosis. 
(Kerr et al., 1972). The initial changes start with cell shrinkage, chromatin condensation 
and loss of contact to neighbouring cells. Later in the process membrane blebbing and 
nuclear fragmentation occurs and the cell dis-aggregates into apoptotic bodies, which 
are phagocytosed by macrophages. They also suggested the term apoptosis derived 
from the Greek ‘falling off”. Investigations of the nematode C. elegans whose organism 
is composed of 1090 somatic cells of which 131 undergo apoptosis at particular and 
fixed time points during development provided further insight into the genetic regulation 
of programmed cell death and were awarded with a Nobel Prize in 2002 for Sydney 
Brenner, H. Robert Horvitz and John E. Sulston. 
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 Apoptosis is induced either via the intrinsic or mitochondrial pathway due to 
irreversible DNA damage, acute cellular stress by growth factor withdrawal or hypoxia 
or it is induced via the extrinsic or death receptor pathway where cytokines such as 
TNF-related apoptosis inducing ligand (TRAIL), tumour necrosis factor alpha (TNFα) or 
FAS ligand (FASL) are release by cytotoxic T-cells, natural killer cells or macrophages 
to kill cells (e.g. after virus infection). When the ligands bind to the appropriate receptor 
(FasL-FAS receptor (FASR) and TNFα-TNF receptor 1 ((TNFR1)) a recruitment of 
adapter proteins (FASL-FASR-Fas associated via death domain (FADD) and TNFα-
TNFR1- TNFR superfamily 1A associated via death domain (TRADD)-FADD) is 
initiated, forming the death-inducing signalling complex (DISC).  DISC triggers the 
transformation of procaspase-8 into active Caspase-8, which can activate Caspase-3 
to execute apoptosis.  
 Caspase-3 is also activated via the intrinsic pathway that is more relevant to the 
present work as it is induced by DNA damage. Increase in p53 results in the 
expression of the pro-apoptotic protein Bax, Bax activating protein p53 upregulated 
modulator of apoptosis protein (PUMA) and Noxa, a protein that interacts with anti-
apoptotic B-cell leukemia/lymphoma 2 (Bcl-2) family members resulting in Caspase-9 
activation (Oda et al., 2000). When Bax forms a homodimer in the mitochondrial 
membrane, cytochrome C is released and associates with apoptotic peptidase 
activating factor 1 (Apaf1) and procaspase-9 forming the ‘apoptosome’ that mediates 
the activation of Caspase-3. 
 Execution of apoptosis is then triggered by the Caspase-3 induced cleavage of 
the heterodimer inhibitor of caspase-activated DNase (ICAD)/CAC releasing the 
endonuclease caspase-activated DNase (CAD) (Sakahira et al., 1998), which 
facilitates the fragmentation and degradation of genomic DNA. Caspase-3 activation 
also leads to cleavage of DNA repair protein PARP possibly to prevent depletion of 
NAD and ATP from cells.  
 Apoptosis is an essential process in any organism to remove damaged cells 
and the capability to bypass cell death is one step towards oncogenic transformation. 
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I.  11. Aims of this Thesis 
 Gene amplification and chromosomal DNA rearrangements have been 
observed in a variety of cancer cells (Lengauer et al., 1998). Certain cancers have high 
frequencies of specific gene amplifications, such as human epidermal growth factor 
receptor 2 (HER2)/ v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 
(ERBB2) amplification in breast cancer, v-myc myelocytomatosis viral related 
oncogene, neuroblastoma derived gene (MYCN) amplification in neuroblastomas and 
epidermal growth factor receptor (EGFR) amplification in gliomas (Hanby, 2005; 
Pession and Tonelli, 2005; Vogt et al., 2004). It is not fully understood how these 
changes arise, but it is likely that DNA strand breaks and DNA replication defects are 
initiating events (Albertson, 2006; Myllykangas and Knuutila, 2006).  
 De-regulation of the replication licensing machinery promotes partial re-
replication of the genome (Blow and Dutta, 2005), resulting in the production of 
aberrant DNA structures (Davidson et al., 2006; Green et al., 2006; Tanny et al., 2006). 
However, the long-term genetic consequences of partial chromosome re-replication are 
unknown.  
 The aim of this thesis is to examine this in detail. We have determined the 
physiological and genomic long term consequences of human tissue culture cells that 
suffered partial DNA re-replication. We have deregulated the replication licensing 
system by geminin depletion or overexpression of Cdt1 and have investigated whether 
this leads to gene amplification or gross chromosome re-arrangement.  
 These findings have provided information about whether partial re-replication is 
a plausible initiating factor for gene amplification and rearrangement in human cancers. 
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II.  1.  Cell culture, synchronisation and Drug  
  treatment 
 
U2OS (ATCC, Cat. No. HTB-96, Lot. 7658494) and HeLa cells (kindly provided 
by Prof. Swedlow at passage 5) were grown in DMEM (Invitrogen, Cat No. 12491-023) 
and supplemented with 10% FBS (Invitrogen) and 100 U/ml Penicillin and 100 µg/ml 
Streptomycin (Invitrogen, Cat. No. 15070-063) at 37°C and 5% CO2. For the cell cycle 
synchronisation at early S-phase, a double Thymidine block was carried out. The cells 
were treated with 2.5 mM Thymidine (Sigma, Cat. No. T1895) for 14-16 h, then washed 
twice with 8 ml 1x PBS, released for 10-12 h (transfections at 10 h post release from 1st 
Thymidine block) and incubated again with 2.5 mM Thymidine for 14-16 h. 
For inhibition of ATR, ATM and DNA-PK, Caffeine (Calbiochem, Cat. No. 
205548) was freshly prepared at a 100 mM stock solution in H2O and cells were 
treated with 5 mM Caffeine for the indicated time. The ATM kinase inhibitor KU55933 
(Tocris Bioscience, Cat. No. 3544) was prepared at a 10 mM stock solution in DMSO 
and applied to cells in a final concentration of 10 µM for the indicated time. The Chk1 
inhibitor UCN-01 (Calbiochem, Cat. No. 539644) was prepared at a 0.5 mg/ml stock in 
DMSO and used at a final concentration of 300 nM. The Nedd8 activating enzyme 
inhibitor MLN4924, was provided by Dimitris Xirodimas and Philip Cohen at a 10 mM 
stock in DMSO and diluted as indicated. 
 
II.  2.  Transfection 
II. 2. 1. RNAi transfection 
Cells were transfected using Lipofectamine™ RNAiMAX (Invitrogen™, Cat.No. 
13778) at least 24 h post seeding at 25-50% confluency. Forward transfection was 
performed according to the manufacturer’s instructions with slight alterations. Briefly, 
geminin siRNA (5’ AACUUCCAGCCCUGGGGUUAU 3’, Dharmacon) and control 
siRNAi (5’ CGUACGCGGAAUACUUCGA 3’, Dharmacon) in a concentration range of 
2.5-25 nM and 10 nM sip53 (ON-TARGET plus SMART pool Human TP53, 
(Dharmacon, Cat No. L-003329-00-0005))	   was added to the corresponding volume of 
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OPTI-MEM® I + GlutaMAX™I (Invitrogen™, Cat. No. 51985-026). Lipofectamine™ 
RNAiMAX was added in a volume, specified in the manufacturer’s instructions and 
depending on the scale of the experiment, to OPTI-MEM® I. The reactions were 
combined, incubated for 15-30 min at RT and subsequently added to the cells in the 
specified volume of OPTI-MEM® I. After 4-6 h the OPTI-MEM® I was replaced by 
complete DMEM (if synchrony was required, 2.5 mM Thymidine was also added) and 
cells were grown for the indicated time. 
 
II. 2. 2. Plasmid transfection 
At 80% confluency 10 cm dishes of U2OS cells were transfected with 6 µg 
(pEGFP-N1) or 24 µg plasmid (Fl-Cdt1-GFP, Cdt1(34-546)-GFP, Cdt1(1-372)-GFP) using 
Lipofectamine™ 2000 (Invitrogen™, Cat. No. 11668) according to the manufacturer’s 
instructions. Transfections were performed in OPTI-MEM® I for 6 h then medium was 
changed to DMEM and cells were grown for the indicated time. 
 
II.  3.  Cdt1 construct design 
The IMAGE clone of human Cdt1 cDNA (Accession No. BC009410) was 
obtained in a pOBT7 vector from www.geneservice.co.uk. Initially the cDNA was re-
cloned into the EcoRI/ XhoI site of pcDNA3 (Figure IV. 1). Full-length Cdt1 (amino 
acids 1-546), Cdt134-546 (amino acids 34-546) and Cdt11-372 (amino acids 1 - 372) were 
PCR amplified from pcDNA3-Cdt1 and cloned into the EcoRI/ KpnI site of pEGFP-N1 
(Figure IV. 2). The primers are listed in Table II. 1. All restriction enzymes and T4 
ligase with their recommended buffers were obtained from New England BioLabs®. 
PCR purification and gel extraction was performed using QIAquick® PCR Purification 
Kit (QIAGEN®, Cat. No. 28104) and QIAquick Gel Extraction Kit (QIAGEN®, Cat. No. 
28704) according to the manufacturer’s instructions. One Shot® TOP10 chemically 
competent E.coli cells (Invitrogen™, Cat. No. C4040-03) were used for plasmid 
transformations (according to the manufacturer’s protocol). DNA was prepared using 
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QIAprep® Spin Miniprep Kit (QIAGEN®, Cat. No. 27106) or QIAGEN® Plasmid Maxi Kit 
(QIAGEN®, Cat. No. 12163).  
 
Table II. 1. Cdt1 primer 
Primer Name Sequence 
Full length-Cdt1_fw 5’ TCCGAATTCATGGAGCAGCGCCGCGTCACC 3’ 
Full length- Cdt1_rv 5’ CCCGGTACCGCTCCCAGCCCCTCCTCAGC 3’ 
Cdt134-546_fw: 5’ AGCGAATTCATGCCCGCACTCCGCGCCCCG 3’ 
Cdt11-372_rv: 5’ ATCGGTACCGAAATCAGGTTGCGGGCC 3’ 
 (All oligonucleotides were made by Operon) 
 
To verify correct positioning and sequence of the Cdt1 constructs the DNA was 
sequenced by the University of Dundee DNA sequencing service.  
 
II.  4.  Proliferation and Clonogenic assay 
To determine the cell growth, the control and geminin depleted cells were 
released from the double Thymidine block, trypsinised and equal numbers of cells were 
re-plated. For the proliferation assay, cells were harvested at 24, 48, 72, 96 and 120 h 
post release and counted using the automated cell counter Countess® (Invitrogen, Cat. 
No. C10227).  
 For the clonogenic assay 500 cells were plated in triplicate into 6 well dishes. 
After 10 days the colonies were washed twice with 1x PSB, fixed in ice-cold 70% 
ethanol for 20 min at -20°C and stained with crystal violet solution (0.5% crystal violet 
w/v, 25% methanol) for at least 2 h. After thorough washing and drying the colonies 
appearing as violet dots on the plate were counted by eye. 
 
II.  5.  Whole cell lysates, Chromatin fractionation, 
  Immunoblotting and Antibodies 
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II. 5. 1.  Whole cell lysates 
Cells were trypsinised, washed twice in 1x PBS, snap frozen in liquid nitrogen 
and stored at -80°C before preparing whole cell lysates. The pellets were resuspended 
in 50-200 µl radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl pH 7.4; 
150 mM NaCl; 1% NP-40 (IGEpal CA-630); 1 mM EDTA; 0.5% Na-deoxychelate) 
containing freshly added protease inhibitors (1 mM PMSF; 0.1 mM NaOVan; 0.1 mM 
NaF and 1 µg/ml leupeptin, aprotinin and pepstatin) and incubated on ice for 10 min. 
An additional lysis was carried out by sonication (Diagenode Bioruptor®, Cat. No. 
UCD-200 TM) twice for 10 min in intervals of 30 s (310 W). For clearing the lysates the 
samples were centrifuged at 14000xg for 10 min at 4°C. Protein determination was 
carried out using the Bio-Rad protein assay (Bio-Rad, Cat. No. 500-0006) and protein 
concentration quantified using a BSA standard curve ranging from 0-1 mg/ml. Equal 
protein amount and equal volume were loaded unless otherwise stated. 
 
II. 5. 2. Chromatin fractionation 
For chromatin fractionation the cells were trypsinised and washed twice with 1x 
PBS. The cell pellets were loosened and carefully resuspended in 50-150 µl freshly 
prepared, ice-cold cytoskeleton (CSK) buffer (10 mM Hepes pH 7.4; 300 mM Sucrose; 
100 mM NaCl, 3 mM MgCl2; 0.5% Triton-X-100; 1 mM PMSF, 0.1 mM NaOVan, 1 
µg/ml leupeptin, aprotinin and pepstatin). Samples were placed on ice for 15 min and 
subsequently centrifuged for 5 min at 5000xg. The supernatant containing the 
cytoplasmic fraction was collected into a new tube and snap frozen in liquid nitrogen. 
The pellets were resuspended and washed twice in 1 ml CSK buffer before snap 
freezing in liquid nitrogen. At this step chromatin pellets were either stored at -80°C or 
resuspended in 50- 150 µl RIPA buffer (depending on the volume of CSK buffer used 
for extraction) and protein concentration was measured as described for whole cell 
lysates in section II. 5. 1. 
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II. 5. 3. Immunoblotting and antibodies 
 SDS-PAGE was performed using NuPAGE® precast gels (Invitrogen™, Cat. No. 
NP0321, 2, 3 or WG1403) and PageRuler™ pre-stained Protein Ladders (Fermentas, 
Cat. No. #SM1811, #SM0671) as molecular weight standard.  Samples were mixed 
with 6x SDS loading buffer (375 mM Tris-HCl pH 6.8, 17% w/v SDS, 28% glycerol, 
0.2% bromophenol blue, 14% β-mercaptoethanol) and incubated at 95°C for 5 min 
prior to loading onto gels. Protein separation was performed at 170 V in 1x NuPAGE 
MOPS SDS running buffer (Invitrogen™, Cat. No. NP0001-02) for approximately 1¼ h. 
Proteins were transferred using either the Invitrogen XCell II Blot Module (Invitrogen™, 
Cat. No. 1301637-056) with NuPAGE Transfer Buffer (20x) (Invitrogen™, Cat. No. 
NP0006-1) containing 10% methanol for 2 h at 30 V or using a standard immunoblot 
tank with Transfer buffer 2 (200 mM glycine, 25 mM Tris-HCl, 3.5 mM SDS, 20% 
methanol) at 40 V overnight.  	  
Table II. 2. Antibodies 
Antibody Name Company Cat. No. Dilution 
Primary antibody    
Actin (ACTN05) Neomarker MS-1295 1:1000, 5% milk solution 
Cdt1 Zoi Lygerou  1:3000, 5% milk solution 
* cleaved PARP (Asp214) Cell Signalling ♯9541 1:1000, 5% milk solution 
Cyclin E (HE12) Santa Cruz Biotechnology sc-247 1:1000, 5% milk solution 
Geminin (FL-209) Santa Cruz Biotechnology sc-13015 1:500, 5% BSA solution 
MCM2 (BM28) BD Transduction Lab.  1:1000, 5% BSA solution 
PCNA (PC10) Santa Cruz Biotechnology sc-56 1:1000, 5% milk solution 
* phosphor-Chk1 Cell Signaling ♯2341 1:1000, 5% BSA solution 
phospho-Histone H2AX (S139) Upstate S139 1:500, 5% BSA solution 
* phospho-Histone H3 Cell Signalling ♯9701 1:500, 5% BSA solution 
* phospho-p53 (Ser15) Cell Signalling ♯9284 1:1000, 5% BSA solution 
Secondary antibody    
* anti-rabbit IgG HRP Cell Signalling ♯7074 1:1000, 5% milk solution 
anti-mouse HRP Sigma A5278 1:10000, 5% milk solution 
anti-rabbit IgG HRP Sigma A0545 1:50000, 5% milk solution 
* marks primary antibodies which have been used with the Cell Signalling anti-rabbit IgG HRP 	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 To check equal loading and transfer quality, the PVDF membrane (GE 
Healthcare, Cat. No. RPN303F) was stained with naphthol blue black (amido 
black) (Sigma, Cat. No. N3393). Membranes were blocked with the selected 
blocking solution for 1 h at RT and then incubated with the indicated primary 
antibodies according to the manufacturer’s instructions (Table II. 2). 
Subsequently they were washed three times for at least 5 min in 
PBS/0.2%Tween and incubated with the appropriate secondary antibody for 1 
h. The membranes were washed again and proteins of interest visualized using 
two enhanced chemiluminescent substrates depending on the signal strength 
(SuperSignal West Pico substrate (for strong signals), ThermoScientific, Cat. 
No. 34080; SuperSignal West Femto substrate (for weak signals), 
ThermoScientific, Cat. No. 34096). 
 
II.  6.  Flow cytometry  
II. 6. 1. Propidium iodide cell cycle  
For propidium iodide (PI) cell cycle analysis, cells were trypsinised, washed in 
1x PBS, resuspended in 70% ice-cold ethanol and incubated at -20°C for at least 30 
min. Afterwards cells were washed twice in Flow cytometry wash buffer (FC_WB) (1x 
PBS containing 1% BSA and 0.2% TX-100) followed by an incubation in 0.25-1.0 ml PI 
staining solution (50 µg/ml Propidium iodide, 50 µg/ml RNase, 0.1 % Triton-X-100 
made up in PBS) for 15-30 min at RT. The DNA content of each cell was measured by 
the propidium iodide staining using the Flow Cytometer FACS Calibur™ (Becton 
Dickinson) running with the CellQuest data acquisition software. Analysis was carried 
out using the FlowJo 8.8.4 software.  
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II. 6. 2. 2D BrdU/ Propidium iodide 
For 2D BrdU/PI flow cytometry, cells were cultured with freshly prepared 20 µM 
BrdU (Sigma, Cat. No. B5002) for 30 min.  
To track replicating or re-replicating cells pulse-chase experiments were carried 
out. For the chase, the 20 µM BrdU was removed, cells washed 3 times with 1x PBS 
and cultured with 100 µM Thymidine for 30 min to prevent further BrdU incubation. 
Subsequently the Thymidine was diluted to a final concentration of 10 µM.  
The cells were trypsinised, washed in 1x PBS, fixed with 70% ice-cold ethanol 
and stored at -20°C. Cells were washed twice in FC_WB and incubated in 2 M HCl 
plus 0.2% TX-100 for 30 min at RT. Afterwards the cells were washed with FC_WB 
and blocked in Flow cytometry blocking buffer (FC_BB) (1x PBS containing 5% BSA 
and 0.2% TX-100) for 1 h. The solution was replaced by FC_BB containing mouse anti-
BrdU antibody (final concentration of 0.5 µg/ml) (BD Bioscience, Cat. No. 347580) and 
incubated for 1 h at RT. Cells were washed twice in FC_WB and incubated in FC_BB 
containing rabbit anti-mouse Alexa Fluor 488 F(ab)2 fragments (final concentration 2 
µg/ml) (Invitrogen™, Cat. No. A21204) for 1 h at RT. Finally the cells were washed 
twice in FC_WB, stained for DNA content and analysed as described above.  
 
II. 6. 3. 3D GFP/ EdU/ 7AAD 
GFP transfected cells were pulsed with 10 µM Click-iT® EdU for 1 h or 2 h, 
washed and trypsinised. The cells were fixed in 4% paraformaldehyde (PFA) for 20 min 
and washed with 1x PBS containing 1% BSA. For the time course experiment, cells 
were stored in PBS containing 1% BSA until all samples were collected. The cells were 
permeabilised with 1x PBS containing 1% BSA and 0.3% TX-100 for 30 min, washed 
twice in FC_WB and blocked in FC_BB2 (PBS, 3% BSA, 0.1% TX-100) for 1 h. The 
primary mouse anti-GFP antibody (diluted 1:500, Roche, Cat. No. 11814460001) was 
incubated in FC_BB2 for 1 h. Cells were washed twice in FC_BB2 and incubated with 
Alexa Fluor 488 F (ab)2 fragment of rabbit anti-mouse (2 µg/ml) (Invitrogen™, Cat. No. 
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A21204) for 1 h. Afterwards the Click-iT EdU (Invitrogen™, Cat. No. A10202) reaction 
with the Alexa Fluor 647 azide was performed according to the manufacturer’s 
instructions and then cells were stained for their DNA content with 7AAD (20 µg/ml) 
(Sigma, Cat. No. A9400-1MG). Analysis was done as described above. 
 
II.  7.  Fluorescence activated cell sorting (FACS) 
To collect re-replicating (>4C) and control cells (2C), the cells were trypsinised, 
washed in 1x PBS and subsequently incubated in DMEM media containing 15 µg/ml 
Hoechst 33342 (Invitrogen, Cat. No. H1399) for 30 min at 37°C. Cells were filtered and 
immediately sorted according to their DNA content (performed by facility manager Dr. 
Rosemary Clarke) using the Enterprise argon ion laser at 345nm (UV) in the FACS 
Vantage (with DIVA upgrade) (Becton Dickinson). Cells were also sorted to collect 
GFP/ GFP-Cdt1 transfected cells using the Enterprise argon ion laser at 488nm. 
 
II.  8.  Microscopy 
II. 8. 1. GFP-Cdt1 localisation 
Cells were plated onto poly-L-Lysine coated coverslips (Cat. No. 354085, BD 
Biosciences) at 50% confluency and grown for at least 24 h. At 80-90% confluency 
cells were transfected with the pEGFP-N1 or pEGFP-Cdt1 plasmids as described in 
section II. 2. 2. After 24 h the coverslips were washed in 1x PBS containing 0.1% TX-
100, fixed with 4% PFA for 20 min, washed again and incubated with 1 µg/ml 4'-6-
diamidino-2-phenylindole (DAPI) (Cat. No. D9542-1MG, Sigma Aldrich) for 5 min. The 
coverslips were transferred onto microscope slides (Cat. No. 48312, VWR) with the 
cells facing down into Vectashield mounting media (Cat. No. H1000, Vector 
Laboratories). The coverslips were fixed onto the slide with nail polish. Microscopic 
analysis was performed using the Nikon TE-200 DIC microscope with a Nikon 40x/1.2, 
S fluor, CFI/60 objective and a camera (CoolSNAP HQ2, Roper Scientific). After 
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deconvolution with softWoRx (Applied Precision) the images were processed with 
OMERO 4.3.0 (Dundee University). 
 
II. 8. 2. BrdU replication timing pattern  
Cells were plated onto poly-L-Lysine coated coverslips (BD Biosciences, Cat. 
No. 354085) at 30% confluency, synchronised (section II.1) and transfected with 
geminin RNAi as described in section II. 2. 1. The geminin depleted and control cells 
were released into S-phase and 50 µM BrdU was added to the cell culture plates at 
3.5, 5.5, 7.5, 9.5, 13.5, 15.5, and 17.5 h post Thymidine release for 30 min to label S-
phase cells. At the relevant time points 4, 6, 8, 10, 14, 16, 18 h post release the 
coverslips were washed and fixed with 70% ethanol for at least 20 min or stored at 4°C 
until all time points were collected. The ethanol was removed and the cells were 
washed in 1x PBS. Subsequently the DNA was denatured in 2 M HCl containing 0.2% 
TX-100 for 30 min and washed 3 times in immunofluorescence assay wash buffer 
(IFA_WB) (1x PBS containing 1%BSA and 0.2% TX-100). Afterwards cells were 
blocked for 1 h in immunofluorescence assay blocking buffer (IFA_BB) (1x PBS 
containing 5% BSA and 0.2% TX-100) followed by incubation for 1 h at RT with mouse 
anti-BrdU antibody (0.5 µg/ml) (BD Bioscience, Cat. No. 347580). Cells were washed 
twice in IFA_WB and incubated in IFA_BB containing Alexa Fluor 488 F(ab)2 fragment 
of rabbit anti-mouse (2 µg/ ml) (Invitrogen™, Cat. No. A21204) for 1 h at RT.  Finally 
cells were washed twice in IFA_WB and stained with DAPI 1 µg/ml (Sigma, Cat. No. 
D9542-1MG) for 5 min. Cells were mounted as described above. Microscopic analysis 
was performed using the DeltaVision DV3 Deconvolution Microscope (Applied 
Precision) with a 60x NA 1.42 Plan Apochromat objective (Model 1-U2B933, Olympus) 
and a camera (CoolSNAP HQ2, Roper Scientific). After deconvolution with softWoRx 
(Applied Precision) the images were processed with OMERO 4.3.0 (Dundee 
University). Between 37 and 60 cells per time point and sample were analysed and the 
replication pattern was selected based on the work of O’Keefe et al. (1992) according 
to the following characteristics. Type I, a faintly punctate labelling throughout 
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euchromatic regions; type II, complete diffuse labelling of euchromatic regions with lack 
of nucleolar labelling; type III, intense labelling of the peripheral ring, possibly with 
some perinucleolar labelling; type IV, mainly labelling of small-speckled 
heterochromatic foci within the nuclear interior or at the periphery, with some of the 
speckled foci forming chain-like structures; type V, predominant labelling of large 
internal replication foci and at the periphery of the nucleus (Thomson et al., 2010) 
 
II.  9.  DNA isolation  
To analyse genomic alterations by microarray analysis or deep sequencing, the 
DNA from rereplicated (>4C) and control (2C) sorted cells was isolated using the 
DNeasy Blood & Tissue kit (QIAGEN®, Cat. No. 69504). The isolation was performed 
according to the manufacturer’s protocol with exceptions at the 2nd wash, which was 
performed with 80% ethanol and then DNA was eluted in H2O. The DNA quality was 
checked by agarose gel electrophoresis and DNA quantity was determined using the 
NanoDrop® Ultraviolet (UV) Spectrophotometer.  
 
II.  10. Agarose Gel electrophoresis  
The sizes of PCR and ligation products as well as the quality of microarray and 
deep sequencing DNA samples were checked using agarose gel electrophoresis.  
Depending on the size of the DNA, 0.8-1% agarose gels were prepared using standard 
melting point agarose (Cambrex Bioscience, Cat. No. 50004) in 0.5x TBE buffer (44.5 
mM Tris, 44.5 mM boric acid, 1 mM EDTA, pH 8.3). The visualisation was done using 
SYBR®-safe DNA gel stain (Invitrogen™, Cat. No. S33102) (1:10000) in molten 
agarose. The DNA samples were diluted in 6x DNA loading buffer (0.25% (w/v) 
bromophenol blue, 0.25% xylene cyanol, 40% (w/v) sucrose) and run in 0.5x TBE for 
45-60 min at 90V. A 1 kb DNA ladder (0.5 µg) (Fermentas, Cat. No ♯SM1331) was 
used as DNA size standard. Gels were visualised using the GeneFlash bio imager 
(Syngene). 
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II.  11. Human Genome Comparative Genomic   
  Hybridisation (CGH) Microarray 
 
II. 11. 1.  Details and Specifications 
Comparative genomic hybridisation was the first tool to detect potential 
genomic alterations, such as amplifications, in response to re-replication induced by 
geminin depletion. In this Thesis two Microarray formats, Sure Print G3 Human CGH 
microarray containing 8 arrays on one slide and Human Genome CGH Microarray 
containing 4 arrays on one slide, were used (Table II. 3.) to analyse the genomic DNA 
of > 4 copy (C) geminin depleted cells compared to 2C control cells. I performed the 
Sure Print G3 8x60K microarray, while Agilent Technologies performed the 4x44K 
microarray. 
 
Table II. 3. CGH microarray specifications 
 
Features Specifications 
Name 
Sure Print G3 
Human  
CGH Microarray 
Human Genome CGH  
Microarray 
Format 8x60K 4x44K 
Arrays per slides 8 4 
Amount of DNA per sample 
and per Array 250 ng 500 ng 
DNA concentration 32 ng/µl 62.5 ng/µl 
Agilent product number G4450A G4426B 
Distinct biological features 55,077 42,494 
 
Replicated biological 
features (X5) 
1,000 301 
 
Internal quality control 
features 
3,886 2,118 
Composition Content sourced from- UCSC hg18 (NCBI Build 36), March 2006 
Probe Spacing 
41 kb overall 
median probe 
spacing (33 kb in 
Refseq genes) 
43 kb overall median probe 
spacing (24 kb in Refseq 
genes) 
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II. 11. 2.  Sure Print G3 8x60K microarray - Experimental procedure 
 For the 8x60K microarray format 250 ng of >4C geminin depleted DNA and 
250 ng of 2C DNA was used for each array (setup see in Figure V. 1). The arrays were 
done in biological triplicates (A, B, C) with A and B used as experimental triplicates 
(1,2,3) and C (1,2) as duplicate to fill the 8 arrays on the slide. Each sample (A1, A2, A3, 
B1, B2, B3, C1, C2) contained 250 ng sample DNA (>4C) and 250 ng control DNA (2C). 
 
 To generate short DNA fragments that improve labelling and hybridisation 
quality, the control and sample DNA needed was heat-fragmented for 10 min at 95°C, 
kept one ice for 3 min and spun at 6000xg for 30 s to collect the sample. In the mean 
time the Agilent ULS-labelling (Cat. No. 5190-0419) master mix was prepared 
according to Table II. 4. 
 
Table II. 4. Preparation of labelling master mix 
Components Per reaction (µl) Per 8x60K slide (µl)  including excess 
Nuclease-free water 0.75 7.5 
ULS-Cy3 or ULS-Cy5 0.25 2.5 
10x labelling solution 1 10 
Final volume of labelling  
master mix 2 20 
  
 The ULS-Cy3 labelling mix was added to the sample DNA (>4C) while the ULS-
Cy5 mix was added to the control DNA (2C). The DNA-labelling mix was incubated at 
85°C for 30 min, stored on ice for 3 min and subsequently spun for 30 s at 6000xg.  
Unbound ULS-Cy3 and 5 was removed using the Agilent KREApure column 
(Cat. No. 5190-0418). The column material was mixed, the storage buffer removed by 
centrifugation (1 min, 16,000xg) and the column washed with 300 µl nuclease free 
water. Residual water was removed by filter paper and then the column was 
transferred into a clean 1.5 ml tube, the labelled DNA added and spun at 16,000xg for 
1 min to collect the purified labelled DNA. The labelling efficiency was determined 
using 1.5 µl sample on the NanoDrop ND-1000 UV Spectrophotometer. The 
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experiment was discarded when the labelling efficiency differed from the recommended 
0.75-2.5% for Cy5 and 1.75- 3.0% for Cy3. The appropriate ULS-Cy3 sample DNA and 
ULS-Cy5 control DNA (total volume 17 µl) were combined. Labelled DNA was stored in 
the dark at 4°C overnight. 
 
 To obtain a 100x solution the lyophilised CGH blocking agent (supplied with 
Agilent Oligo CGH hybridisation kit, Cat. No. 5188-5220) was resuspended in 135 µl 
nuclease-free water and left at RT for 60 min. In the mean time the labelled DNA was 
concentrated to 9 µl. The hybridisation master mix was prepared as listed in Table II. 5.  
 
Table II. 5. Preparation of hybridisation master mix 
Components Per reaction (µl) Per 8x60K slide (µl)  including excess 
Human Cot-1 DNA (1.0mg/ml) 2.0 20 
100x CGH blocking agent 0.5 5 
2x CGH hybridisation buffer 22.5 230 
Final volume of hybridisation 
master mix 25 255 
 
 The hybridisation mix was added to the labelled DNA, the sample mixed by 
pipetting up and down and spun to collect the sample. The sample was incubated at 
95°C for 3 min, then immediately transferred to 37°C for 30 min and spun to remove 
residual liquid from the wall. The hybridisation sample mixture was supplemented with 
11 µl of Agilent-CGH Block (supplied with the ULS-labelling kit), mixed and spun down.  
 The hybridisation chamber and gasket slides were assembled as described and 
illustrated in the Microarray Hybridisation Chamber User Guide (Cat. No. G2534-
90001). The gasket slide was placed on the chamber base and 42 µl sample were 
dispensed on the gasket. The microarray was placed “active side” down onto the 
gasket and the chamber cover was placed onto the sandwiched slides. Chamber base 
and cover with the sandwiched slides were clamped and the mobility of bubbles was 
assessed before the slide was placed into the hybridisation oven (Cat. No. G2545A) at 
65°C. The hybridisation rotor was set at 20 rpm for 40 h. 
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 The hybridisation chamber was disassembled in Oligo aCGH Wash Buffer 1 
(Cat. No. 5188- 5221) at RT. The array was carefully placed in a slide rack and 
immediately transferred into fresh stirring Oligo array CGH (aCGH) Wash Buffer 1 for 5 
min. Subsequently the array was incubated in stirring Oligo aCGH Wash Buffer 2 (Cat. 
No. 5188- 5222) at 37°C for 1 min. The array was slowly removed from Oligo aCGH 
Wash Buffer 2 and scanned immediately using the InnoScan900AL scanner. 
 
II. 11. 3.  Sure Print G3 8x60K Microarray - Analysis  
 The scanned 8x60K array was further analysed using the Mapix® (4.1.0) 
software to save the acquired images in TIFF format thereby saving all scan and 
analysis parameters. Furthermore Mapix® was used to analyse the image by 
determining the position of each spot automatically using a grid (GAL file for 8x60K 
array, provided by Norman Pratt, Department of Human Genetics, Ninewells Hospital, 
Dundee). This GAL file contains all the information for each spot on the array eg. spot 
position, spacing, diameter and identification (chromosomal location, gene name if 
applicable, control type etc.). Mapix used the photometric results from the grid to 
extract the data and display the results in table format (txt.). The table contains the 
information from the GAL file and the photometric information such as the Cy5 and Cy3 
median of a spot, the Cy5 and Cy3 median of background, the median of a spot minus 
background, the Cy5/Cy3 ratio etc.  
In case of the 8x60K array performed first, whole genome plots of the Cy3/Cy5 
ratios performed by Nexus 4 software showed very poor reproducibility between 
biological (A, B, C) and even technical (1, 2, 3) replicates. Therefore the Cy5 and Cy3 
median minus background values were used to generate quality control plots of two 
technical replicates for each wavelength and their Cy3/Cy5 ratios (Figure V. 2, 3, 4). 
Discussion with Nick Schurch from the Data Analysis Group, University Dundee led to 
the idea of excluding invalid data points based on their poor Cy5/Cy5 correlation. 
Reproducibility between technical replicates is a basic necessity in microarray 
experiments, and Cy5/Cy5 ratios between technical replicates should be around one. 
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Values smaller 0.7 or greater 1.3 were excluded from the analysis using the IF 
command in Excel.  
=IF(logical_test,[value_if true],[value_if_false]) 
=IF(AND(cy5replicate 1/cy5replicate 2 <1.3, cy5replicate 1/cy5replicate 2 >0.7), cy5replicate 
1/cy5replicate 2, 0) 
Using this command all invalid data points were labelled with a zero and the filter tool 
“Does Not Equal” zero could be used to hide all invalid data points. 
The remaining valid data points of the 8x60K array were sorted according to 
chromosome number and chromosomal location using the information provided by the 
GAL file.  
The 8x60K microarray was normalised using the designated normalisation 
probes provided on the array. The probes were filtered for invalid data points as 
described above and the median Cy3/Cy5 ratio for normalisation probes for each array 
was calculated. Subsequently all valid Cy3/Cy5 data points for each array were divided 
by the median Cy3/Cy5 ratio of their normalisation probes.  
The >4C/2C ratio of every experiment was used to generate whole genome 
plots with KaleidaGraph 4.0 which provided information about possible amplified 
regions in the genome of geminin depleted and re-replicated cells (Figure V. 6, 7, 8). 
 
II. 11. 4. 4x44K human genome microarray 
Agilent Technologies, Germany, performed the heat fragmentation, the labelling 
and hybridisation for the 4x44K microarray slide as described above according to their 
manual. For each array 500 ng geminin depleted (>4C) and 500 ng control (2C) input 
DNA was used. The 4x44k slide setup is illustrated in Figure V. 9. All DNA samples are 
from one biological experiment but used as technical quadruple. The >4C DNA was 
Cy3 labelled in array 1 and 2 and Cy5 labelled in array 3 and 4, while control 2C DNA 
was Cy5 labelled in array 1 and 2 and Cy3 labelled in array 3 and 4. This dye change 
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was done to obtain a better control for the labelling quality and increase the chance to 
receive valid data even if one colour gives bad signal.  
The array was scanned using the Agilent C Scanner and the output text file 
generated using the Agilent Feature Extraction Software 10.7.3 providing normalised 
signal intensities for each wavelength. In contrast to the 8x60K microarray the 
reproducibility between technical replicates was very good and filtering of data points 
was not necessary (Figure V. 10). Therefore all data points of the 4x44K were sorted 
according to chromosome number and chromosomal location using the information 
provided by the GAL file and whole genome plots were generated with KaleidaGraph 
4.0 providing information about possible amplified regions in the genome of geminin 
depleted and re-replicated cells (Figure V. 11, 12). 
 
II.  12. Solexa Sequencing, data reduction and  
  processing  
 
The >4C and 2C DNA from geminin depleted and control cells was sequenced at 
the GenePool Next-Generation Sequencing facility in Edinburgh 
(http://genepool.bio.ed.ac.uk/). The six samples (3 biological replicates for each 
treatment) produced more than 82×106, 50 bp long, single-end, sequenced reads. 
Quality scores were >38/40 along the entire length of the sequences across all 
samples, and reads needed no clipping prior to alignment. The reads were aligned to 
the reference human genome (GRCh37/hg19) with the Bowtie short read aligner 
(v0.12.3). The resulting alignment was filtered for reads that were unique matches to a 
position in the genome, allowing for up to two mismatches in the sequence alignment. 
~80% of the reads fulfilled these criteria. A further 42x105 reads were excluded 
because they were mapped to the human mitochondrial chromosome (37x105 reads) 
or to the Y chromosome (5x105 reads; as the U2OS is a female cell line). Therefore a 
total of ~70×106 usable mapped reads remained covering 3.04×109 bases (average 
depth=0.02). Data from the biological replicates were combined and then initially 
binned into 10 kb bins, resulting typically in 10s of reads per bin.  
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Data binning was also increased to 100 kb bins to ensure that the random 
counting errors for each bin were normally distributed, before the ratio of each of the 
bins was taken. There were large regions of several chromosomes composed of bins 
with read counts per bin that were more than an order of magnitude less than the 
average across the genome (~102 reads/100kb c.f. ~104 reads/100kb across most of 
the genome). The low numbers of counts in these bins produced a significant increase 
in the variance of the ratios in these regions and produced values for the ratios strongly 
depending on the binning factor chosen. The origins of the low read counts in these 
bins were not clear from this data. There was no correlation for any of the classes of 
repeat annotated by RepeatMasker with the low count bins. Instead we hypothesised 
that they may be associated with mutations in the U2OS genome relative to the 
reference sequence.  
Of the high-quality reads that mapped to the female core genome (ignoring reads 
mapping to the Y chromosome or mitochondria), 89.9% (+-0.2%) mapped uniquely to a 
single location in both the control and geminin-depleted samples. To investigate the re-
replication of repetitive DNA, ratios of geminin-depleted/control ratios were examined 
for the non-unique mapping data. These ratios were almost identical to the ratios 
observed in the unique mapping data. The average difference between the ratio for 
non-unique reads minus the ratio for unique reads was consistent with zero (-0.0001 ± 
0.0007) for the 10 kb binned-data, which corresponds to 0.13% ± 0.06% as a fraction 
of the ratio. 
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III.  1. Introduction 
 It has already been described in Chapter I. of this Thesis that the correct 
regulation of the licensing machinery is crucial to prevent re-replication of genomic 
DNA. In metazoans the loading of mini-chromosome maintenance 2-7 (MCM2-7) 
complex onto chromatin is restricted to late mitosis and G1 phase of the cell cycle. The 
key regulator is the Cdc10 dependent transcript 1 (Cdt1) protein and its activity is 
restricted to G1 and mitosis by proteolysis via at least three distinct pathways and by 
formation of a heterohexameric (2x (2xgeminin+1xCdt1)) inhibitory complex with a 
protein called geminin. Geminin is expressed from late G1 until anaphase where it is 
degraded or inactivated by the anaphase-promoting complex. Geminin depletion leads 
to premature endoreduplication and failure to form pluripotent cells during mammalian 
development (Gonzalez et al., 2006), centrosome over-duplication (Tachibana et al., 
2005b) and re-replication of DNA in various human cell lines (Klotz-Noack et al., 2012; 
Melixetian et al., 2004; Zhu et al., 2004).  
 Interestingly, a study by Ballabeni and colleagues demonstrated that geminin is 
a negative and a positive regulator of pre-replication complex (pre-RC) formation in 
human cells. They revealed that during G2/M when Cdt1 levels have to increase for 
MCM2-7 complex loading geminin-bound Cdt1 is protected from degradation. Geminin 
depletion during mitosis leads to reduced loading of MCM2-7 proteins and defects in 
DNA replication (Ballabeni et al., 2004). 
  
 In this Chapter the physiological consequences of re-replication induced by 
geminin depletion in synchronised U2OS cancer cells were elucidated. Synchronisation 
was required to avoid defects in pre-RC formation and replication when geminin is 
depleted during mitosis. Initially the long term consequences of an acute loss of 
geminin were investigated in detail. Furthermore the work reveals precise information 
about a restricted cell cycle phase that allows re-firing of replication origins and 
provides insight into the role of checkpoint kinases in enhancing re-replication.  
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III.  2. How to deplete geminin in synchronised U2OS 
  cancer cells? 
 
 Taking into account the data of Ballabeni and colleagues a synchronisation 
protocol was designed to deplete geminin in G1/ S-phase of the cell cycle. As shown in 
Figure III. 1, cell cycle profiles of asynchronous U2OS human osteosarcoma cells 
treated with 2.5 mM Thymidine for 16 h showed an enrichment of cells in early S-
phase. The cells were released and profiles monitored after 10 and 12 h (data not 
shown). At 12 h post Thymidine release the cells were synchronised again in early S-
phase with Thymidine. After releasing the cells from the second Thymidine block, this 
time point was designated as ‘T0’. More time points were taken while cells progressed 
synchronously through S phase (T4, T6, T8), G2/M phase (T12, T14) into G1 phase of 
the subsequent cell cycle (T18).  
 On the basis of these cell cycle profiles the geminin RNAi transfection protocol 
was designed (Figure III. 2). Transfections were performed 10 h post release from first 
Thymidine block as most cells have finished S-phase. At this time point the geminin 
levels were very high and Cdt1 levels started to increase again. At 6 h post 
transfection, a second Thymidine block was carried out for 16 h. At this time point, 
geminin siRNA treated cells already showed a decrease in geminin and Cdt1 levels by 
immunoblotting (Figure III. 2). However, an impairment of DNA replication in the 
subsequent S-phase was never detected by flow cytometry. In accordance with its 
known cell cycle regulation Cdt1 levels were low at the time of the second Thymidine 
release (T0) in geminin RNAi treated cells and control cells. Geminin levels were high 
in cells treated with non-targeting siRNA and efficiently decreased in geminin siRNA 
treated cells. This protocol was established to guarantee experimental conditions in 
which the cells undergo S-phase and G2/M without geminin as inhibitor of origin 
licensing. 
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Figure III. 2.
* The synchronisation protocol was established by me during the course of my PhD but this 
Cdt1, geminin blot was kindly provided by Debbie McIntosh as part of the JCS paper revision.
Figure III. 2. Schematic for double thymidine synchronisation and RNAi transfection and 
the corresponding Cdt1 and geminin levels. At the indicated time points during the synchroni-
sation protocol, whole cell extracts were prepared and immunoblotted for geminin, Cdt1 and tubu-
lin. Cells treated with 15 nM control siRNA (-) and cells treated with 15 nM geminin siRNA (+).
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III.  3. Transient geminin depletion is lethal 
III. 3. 1. Geminin depletion blocks cell proliferation 
 To study the long-term consequences of geminin depletion, U2OS human 
osteosarcoma cells were synchronized and transfected (as in Figure III. 2) with 
increasing amounts of geminin siRNA. The cell proliferation was severely inhibited for 
up to 120 h even at very low concentrations (2.5 nM) of geminin siRNA (Figure III. 3 A). 
This observation was strengthened by the results of clonogenic assays showing that 
siRNA concentrations as low as 2.5 nM geminin siRNA decreased colony numbers 
nearly to background levels (Figure III. 3 B, C). 
 
III. 3. 2. Geminin depletion results in re-replication and cell death 
 In agreement with previous studies (Melixetian et al., 2004; Zhu et al., 2004) we 
observed by flow cytometry that geminin RNAi induced substantial levels of re-
replication, with typically 15 - 35% of cells exhibiting a >4C DNA content 48 h after 
Thymidine release (Figure III. 4 A). At longer times, the number of re-replicated cells 
(>4C DNA content) decreased with an associated increase in cell death (<2C DNA 
content) (Figure III. 4 B). These results suggest that re-replication induced by a lack of 
geminin ultimately results in apoptosis in U2OS cells, as it has been reported in other 
cancer cell lines (Zhu et al., 2004; Zhu and DePamphilis, 2009).  
 To investigate possible molecular mechanisms leading to cell death, low 
concentrations of geminin RNAi (2.5 nM) were applied to the cells and re-replication as 
well as cell death were monitored over several days. In parallel immunoblotting of 
whole cell extracts was performed and revealed a significant increase of apoptosis 
marker cleaved Poly (ADP-ribose) polymerase (PARP) and phosphorylated p53 at 
Serine 15 in geminin depleted cells as early as 48 h post Thymidine release (Figure III. 
5 A). The levels of re-replication increased to 12% at 96 h, but dropped again at 120 h 
accompanied by a substantial increase in cell death (Figure III. 5 B).  
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Figure III. 3. Geminin depletion causes inhibition of proliferation. Cells were released from
a double thymidine block after prior treatment with either control or geminin RNAi, as in 
Figure III. 2. A. Graph shows the cell number at various times after transfection with different 
concentrations of control or geminin RNAi. B. Example well of clonogenic assays for 500 cells 
plated at release from double Thymidine block after treated with 2.5 nM control or geminin siRNA.
C. Clonogenic assay of cells treated with increasing amounts of geminin or control RNAi. The 
graph shows the results of two biological experiments in triplicates, with standard error.
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Figure III. 4. Geminin depletion causes dose dependent levels of re-replication and cell 
death. A. DNA content of cells treated with 20 nM geminin or control RNAi is shown at 48 h 
after release from double Thymidine block. B. Titration of geminin siRNA at different time points 
after release from 2nd Thymidine block; cultures were analysed by flow cytometry, and the 
percentage of cells with <G1 or >G2 DNA content is illustrated.
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In parallel, phosphorylated H2A histone family member X (H2AX) was detected by 
immunoblotting (Figure III. 5. A), which is most likely due to fragmentation of the 
genome during apoptosis. The presented data suggests that under these experimental 
conditions, cell death is an inevitable consequence of re-replication in U2OS cells.  
 
III. 3. 3. Cells with a >4C DNA content form no colonies 
 One of the main objectives of this project was to study the long-term 
consequences of re-replication and potential underlying genomic alterations. Therefore 
experiments were designed to obtain cells with >4C DNA content. Geminin depleted 
>4C and control 4C cells were isolated by FACS 120 h post Thymidine release. This 
time point was chosen as previous results (Figure III. 5 B) showed that maximum cell 
death had taken place by that time. The sorted cells (Figure III. 6 B) were re-plated as 
populations of 50,000 cells in 24 well dishes. In Figure III. 6 B, the sorted population of 
control 4C cells attached and grew normally on the plate over a period of 168 h, while 
the geminin depleted >4C cells attached to a lesser extent and did not proliferate but 
died instead. Moreover, it should be stated that a geminin depleted single >4C cells 
plated individually into 96 well plates were unable to form colonies while a single 4C 
control cell did (data not shown). This suggests that re-replication to an extent 
detectable by flow cytometry, causes cell damage that ultimately leads to cell death. 
Therefore it was not possible to study long term consequences or genomic alterations 
of clones derived from cells with >4C DNA content. 
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Figure III. 5. DNA damage and apoptosis in geminin depleted cells. U2OS cells were released
from a  double Thymidine block after prior treatment with either control or geminin RNAi, as in
Figure III. 2. A. At different times after 2nd Thymidine release whole cell extracts were prepared, 
seperated by SDS-PAGE and immunblotted for the indicated protein. B. At different times after 
release, cells were analysed by flow cytometry and percentage of cells with either <G1 DNA 
content or >G2 DNA content was measured.
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Figure III. 6. Cells fail to survive re-replication. During Thymidine synchronisation, U2OS cells 
were treated with 2.5 nM geminin or control RNAi, and grown for 120 h after thymidine release (so 
the bulk of apoptosis in the geminin-depleted culture was over). Cultures were washed to remove 
apoptotic cells and stained with Hoechst 33342 for FACS. For Geminin RNAi treated cultures, 
cells with >4c DNA were collected, whereas for control cultures cells with a 4c DNA content were 
collected. 50,000 cells were re-plated into 24 well dishes and cultures monitored microscopically 
over the next 168 h (48 h, 120 h, 144 h and 168h are shown). After 96 h control cells were conflu-
ent and had to be diluted 1:6 explaining the difference between 48 and 120 h.Over time no cells 
with an altered DNA content could be recovered. A. FACS profiles plus sort windows. B. 
Examples of cultures 48, 120, 144 and 168 h after FACS.   
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III.  4. Geminin depletion does not significantly alter 
  S-phase progression 
 
 Given the dramatic consequences of re-replication, the objective of the next 
part of the project was to investigate the initiation of re-replication and how cellular 
processes such as DNA replication, mitosis and checkpoint activation are affected by 
geminin depletion. To study whether geminin depletion alters cell cycle progression, 
U2OS cells were synchronised and transfected with 15 nM geminin RNAi as described 
in Figure III. 2. The cells were released from the 2nd Thymidine block and then cultured 
for different times, subsequently whole cell lysate were analysed by Western Blot 
(Figure III. 7 A). In parallel cells were incubated for different time periods and then 
pulsed with 20 µM BrdU for 30 min just prior to cell cycle analysis by flow cytometry 
(Figure III. 7 B). As shown in panel B, cells progress through S-phase (T4 and T10), 
G2/M (T14 and T16) and then into the following cell cycles (T29, T38 and T48). During 
the first 10 h of S-phase there was no significant difference in BrdU intensity or DNA 
content between control and geminin depleted cells. After 14-16 h about 50-60% of 
control cells were BrdU negative and had a G2/M DNA content. Many of these cells 
were passing through mitosis as indicated by increased phosphorylated histone H3 
levels (Figure III. 7 A). Whilst the majority of geminin depleted cells also exhibited a 
near-G2/M DNA content after 14-16 h of Thymidine release (Figure III. 7 B), a 
significant proportion remained BrdU positive. This was associated with a reduced 
staining for phosphorylated H3 and an increase in phosphorylated p53 and cleaved 
PARP (Figure III. 7 A). At later times, control cells entered again G1 and S phase, 
while geminin depleted cells were either enriched at G2/M or exhibited a >4C DNA 
content. 
The flow cytometry results indicate that at least until late S-phase, geminin 
depletion seems not to significantly alter S-phase progression.  
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Figure III. 7. Geminin depletion does not alter S-phase progession and induces re-replication 
earliest in late S-phase or G2. Cells were released from a double Thymidine block after prior 
treatment with either control or geminin RNAi, as in Figure III. 2. A. Western blot analysis of whole 
cell extracts at different times after Thymidine release. Geminin RNAi: +; control RNAi: -. As DNA 
damage positive control, cells were treated with 120 mJ UV. The membrane was stained with 
amido black to show equal loading of histones. B. At different times after release from double 
Thymidine block, cells were pulsed with BrdU and analysed by flow cytometry to determine the 
cell cycle progression based on the BrdU staining intensity and the propidium iodide intensity.
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 To strengthen this observation the chromatin association of replication proteins 
such as MCM2, Proliferating Cell Nuclear Antigen (PCNA) and Cdt1 during S-phase 
was elucidated after geminin depletion. Therefore geminin was depleted again in 
synchronised U2OS cells and supernatant and chromatin fractions from time points T0, 
T4, T8, T10, T14 and T18 were collected (Figure III. 8). In agreement with the flow 
cytometry results no increase of MCM2, PCNA or Cdt1 was detected on S-phase 
chromatin in geminin depleted cells in comparison to control cells, which would be 
expected if re-replication would occur already in the first S-phase in geminin depleted 
cells. Instead it is possible that the low levels of Cdt1 during the first S phase (Figure 
III. 7 A; Figure III. 8) limit the amount of re-licensing that occurs in the absence of 
geminin. However, geminin depleted cells showed a defect in progression into mitosis, 
associated with continued BrdU incorporation and checkpoint activation, which is 
potentially the result of a small number of origins re-firing.  
During G2 phase and mitosis, Cdt1 levels start to rise again. It should be noted 
that the Cdt1 accumulation in the whole cell extracts (Figure III. 7 A) and the 
supernatant fractions (Figure III. 8) was lower in the geminin depleted cells than in 
control cells. The lower Cdt1 levels in the geminin depleted cells are likely a 
consequence of increased Cdt1 proteolysis (Ballabeni et al., 2004), which could be a 
result of re-replication induced activation of the DNA damage response (Hall et al., 
2008). In contrast, on late S-phase and G2 phase chromatin the increase in Cdt1 
binding was equal in geminin depleted and control cells (Figure III. 8). Consequently, 
cells lacking geminin failed to restrain Cdt1 activity at the G2/M border and could 
therefore load MCM2-7 complexes onto DNA inducing massive re-replication.  
Consistent with this interpretation, at 18 h after Thymidine release, MCM2 
chromatin association was approximately equal in geminin depleted and control cells, 
although many of the geminin depleted cells were still in G2 as indicated by the 
reduced phosphorylated histone H3 level (Figure III. 8).   
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Figure III. 8. Chromatin proteins during S-phase in geminin depleted cells. Cells were 
released from a double Thymidine block after prior treatment with either control (-) orgeminin (+) 
RNAi, as in Figure III. 2. At different times after release, cells were treated with CSK buffer for 
chromatin fractionation and seperated into supernatant and pellet fractions. Samples were then 
run on SDS-PAGE and immunoblotted for the indicated proteins. The lower part of the membrane 
was stained with amido black to show equal loading.
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III.  5. Geminin depletion does not significantly alter 
  replication timing 
 
 Another way to study and compare S-phase progression of control and geminin 
depleted cells is to monitor the replication timing pattern. Therefore the cells were 
released from a double Thymidine block after prior treatment with either non-targeting 
or geminin RNAi. At indicated times cells were pulsed with BrdU and subsequently 
fixed (Figure III. 9 A). For each time point at least 37 cells were analysed and grouped 
into the five different timing patterns in accordance with previous nomenclature 
(O'Keefe et al., 1992). In the first pattern replication occurs throughout the nucleus, 
specifically in regions of euchromatin with a distinct lack of peripheral heterochromatin 
and nucleolar labelling. In the second pattern the sites of replication are larger and 
more discrete, they are localised more towards the periphery of the nucleus with fewer 
interior sites. In the third pattern the sites are predominantly at the nuclear periphery 
and the perinucleolar regions. In the fourth pattern the sites become larger in size and 
fewer in number they are located throughout the interior and at few discrete sites at the 
periphery (O'Keefe et al., 1992). Pattern five is characterised by labelling of large 
internal replication foci and at the periphery of the nucleus (Thomson et al., 2010). 
Figure III. 9 B shows the percentage of control or geminin depleted cells within the 
different replication patterns at times across S-phase (T4, T6, T8, T10), G2/M (T14, 
T16) and G1 (T18) of the cell cycle. A microscopic example of how the BrdU staining is 
categorised into the five patterns is given in Figure III. 9. C. There was no significant 
difference in the temporal progression through those patterns between control and 
geminin depleted cells. This suggests that extensive re-firing of replication origins does 
not occur in this phase of the cell cycle. Only during late S or G2, in the time points 
T14, T16 and T18, was a difference observed, with slightly fewer unlabelled cells in the 
geminin-depleted samples, which could mean that cells either finish S-phase slower or 
especially in T18 start to replicate again. 
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Figure III. 9. Replication timing pattern in synchronised geminin depleted cells. Cells were 
released from a double Thymidine block after prior treatment with either control or geminin RNAi, 
as in Figure III. 2. and pulsed with BrdU for 30min at indicated times to monitor replication timing 
pattern. A. Schematic of the experiment. B. At each time point at least 37 cells were analysed for
their replication timing pattern according to O’ Keefe et al.,1992. The percentage of cells falling 
into each of the 5 patterns is illustrated. C. For each time point representive images of U2OS cells 
with their timing pattern are shown, see Materials and Methods Section II. 9. 2. for description of 
the different replication timing patterns.   
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III.  6. Progression through mitosis is inhibited in 
  geminin depleted cells that undergo   
  re-replication.  
 
 The results so far showed that geminin depletion neither alters S-phase 
progression and chromatin association of replication proteins within the first S-phase, 
nor changed the replication timing pattern. However, geminin-depleted cells remain 
longer in G2 and after some time a large proportion of these cells acquired a >4C DNA 
content. Therefore it was interesting to ask, whether geminin depleted cells that fail to 
enter mitosis are doomed to undergo re-replication from the late S-phase or G2 stage. 
To address this, control and geminin depleted cells were released from the 2nd 
Thymidine block for 14 h. At this time point cells were mainly in G2/M with 12% 
(control) and 17% (geminin depleted) still in late S-phase. Thymidine was then added 
again for 10 h, allowing those cells that had completed S-phase to progress through 
mitosis and G1 but preventing any further DNA replication or re-replication (Figure III. 
10). Moreover we analysed the cell cycle profile after the 3rd Thymidine release (T24). 
About 83% of the control cells progressed through mitosis and G1 and then 
accumulated in early S-phase, while the 12% that were in late S-phase at the time of 
3rd Thymidine addition, arrested in late S-phase. In the population of geminin depleted 
cells only 62% progressed through mitosis and G1, while 33% remained with a ~4C 
DNA content. Since only 17% of 33% were incorporating detectable amounts of BrdU 
at the time of the 3rd Thymidine addition, this suggests that a significant proportion of 
the geminin depleted cells were prevented from entering mitosis even though they had 
essentially finished synthesising DNA. When the cells that had passed through mitosis 
and had been arrested in early S-phase (79% control cells, 58% geminin depleted 
cells) were released from the 3rd Thymidine block for 5h, almost all of them progressed 
into S-phase and incorporated BrdU. At the same time, almost two thirds of the 
geminin depleted cells that had arrested in G2/M (19% of the total) started to re-
replicate. 
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Figure III. 10. Geminin depletion prevents passage through mitosis followed by 
rereplication. Cells were released from a double Thymidine block after prior treatment with 
either control or geminin RNAi, as in Figure III. 2. 14 h later cells were optionally given a 3rd 
thymidine block for 10 h, and then released for a further 5 h. A. Schematic of experiment. 
B. At different times during the procedure, batches of cells were given a BrdU pulse and then
analysed by flow cytometry. Arrows show the movement of cells suggested by the data.
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 In comparison, geminin depleted and non-arrested cells that were not given a 
3rd Thymidine treatment (Figure III. 10 B ‘T24 – no 3rd thymidine’) showed a very 
similar final cell cycle profile and underwent similar levels of re-replication.  
 Taken together, these results suggest that geminin depletion causes a subset 
of cells to arrest in the late S/G2 phase state without progressing into mitosis, and that 
these cells subsequently start to re-fire replication origins leading to re-replication of 
their DNA. 
 
III.  7. Re-replication occurs from G2 Phase 
 Observations from numerous experiments including the time course (Figure III. 
7 and 10) suggested that geminin depletion causes re-replication in cells arrested in a 
G2-like state. The cells appeared to stop the incorporation of BrdU and later on start to 
incorporate again, moving into a state that could be mistaken as late S-phase by flow 
cytometry as substantial re-replication has to occur before cells clearly acquire a >4C 
DNA content. In order to confirm that re-replication can occur in cells in G2 phase that 
have effectively ceased DNA synthesis, we carried out a pulse chase experiment, 
where control and geminin depleted cells were pulse labelled with BrdU 12 h after the 
2nd Thymidine release (T12) (Figure III. 11 A). At this time the majority of cells had 
progressed through S-phase and were BrdU negative, with only 30 – 35% of cells still 
incorporating significant quantities of BrdU (Figure III. 11 B). The BrdU was then 
removed and the cells chased for 36 h to allow sufficient time for a measurable degree 
of re-replication to occur. The results showed that after the chase, more than half 
(22%) of the cells with a >4C DNA content (39%) were BrdU negative. This shows that 
cells in G2 can subsequently start to re-replicate. It can not be completely excluded 
that a small proportion of cells start to re-replicate from late S-phase, but it is more 
likely that there is a common mechanism in which cells stop incorporating BrdU and 
enter G2 before re-replication occurs. 
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Figure III. 11. Assessment of cells spontaneously re-replicating from G2. Cells were 
released from a double Thymidine block after prior treatment with either control or geminin RNAi, 
as in Figure III. 2. Twelwe hours later cells were pulsed with BrdU for 30 mins. BrdU was then 
removed and cultures continued for a further 35.5 h. A. Schematic of experiment. B. At different 
times during the procedure, batches of cells were analysed by flow cytometry. Red labelled cells 
are BrdU positive and black labelled cells are BrdU negative.
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III.  8. The G2/M checkpoint promotes re-replication 
  of geminin depleted cells 
 
 Several studies have investigated the role of the G2/M checkpoint in re-
replication induced by geminin depletion. Melixetian et al., 2004 have shown that re-
replicated HCT116 cells can re-enter mitosis if the ATR checkpoint pathway is 
abolished but subsequently undergo mitotic catastrophe and cell death. Consistent with 
this study, Zhu et al. (2004) demonstrated that the level of re-replication decreased 
upon checkpoint abrogation accompanied by a significant increase in mitotic cells 
(Melixetian et al., 2004; Zhu et al., 2004). However, the increase of Cdt1 protein that 
occurs during G2 may make cells particularly dependent on geminin to restrain re-
licensing of replicated DNA during G2.  
 The results so far suggest that geminin depletion causes cells to arrest in G2, 
precisely the cell cycle phase where they are most reliant on geminin to prevent re-
replication. Therefore we investigated whether the G2/M checkpoint activity actually 
enhances re-replication in geminin depleted cells. The synchronised re-replication 
assay was used to address this question by treating cells with checkpoint inhibitors 12 
– 18 h after release from the 2nd Thymidine block, during the time when geminin 
depleted cells accumulate in G2 (Figure III. 12 A). This allows geminin depleted cells to 
pass through mitosis and re-enter G1. The checkpoint inhibitors were withdrawn after 
18 h and the incubation continued for a further 9 h to allow cells to progress into the 
subsequent S-phase. After this time (27 h) cells were labelled with BrdU and analysed 
by flow cytometry. Treatment of geminin depleted cells with the ATM/ATR and DNA PK 
inhibitor caffeine significantly reduced both the number of cells arrested in G2 and the 
number of re-replicating cells with >4C DNA content. Consequently the percentage of 
geminin depleted cells in G1 and S-phase was dramatically increased, though they 
showed a slight delay in S-phase progression compared to control cells (Figure III. 12 
B, F).  
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Figure III. 12. The G2/M checkpoint promotes re-replication. Cells were released from a 
double Thymidine block after prior treatment with either control or geminin RNAi, and optionally 
p53 RNAi, as in Figure III.2. Twelve hours after release, cells were optionally treated with 
caffeine, UCN-01 or KU55933 for 6 h. 27 h after Thymidine release, cells were pulsed with BrdU 
and analysed by flow cytometry. A. Schematic of experiment. B. Flow cytometry profiles of 
geminin RNAi and control RNAi cells plus and minus caffeine treatment. C. Flow cytometry 
profiles of geminin RNAi and control RNAi cells plus and minus UCN-01 treatment. D. Flow 
cytometry profiles of geminin RNAi and control RNAi cells plus and minus KU55933 treatment. 
E. Flow cytometry profiles of geminin RNAi and control RNAi cells plus and minus p53 RNAi and
demonstration of geminin and p53 knock-down by immunoblotting. F. The suppression of re-
replication observed in geminin RNAi seen with different inhibitor treatments or with additional p53 
knockdown, expressed as a percentage of the amount of re-replication in geminin RNAi cells 
without inhibitor treatment (average of 3 independent experiments is shown).
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 Similar results were observed when checkpoint kinase 1 (Chk1) was inhibited 
by UCN-01 treatment (Figure III. 12 C, F). In contrast, addition of ATM inhibitor 
KU55933 or co-depletion of p53 showed no or very little impact on the levels of re-
replication (Figure III. 12 D, E, F).  
 
I II.  9. Summary 
Geminin depletion caused severe levels of DNA re-replication and inhibition of 
proliferation in U2OS cancer cells. However, S-phase progression and the replication 
timing pattern were not significantly altered in geminin depleted cells but due to the 
G2/M checkpoint activity some cells arrest in G2 and are unable to enter mitosis. ATR 
and Chk1, but not ATM, are the major checkpoint kinases responsible for the G2/M 
arrest of geminin depleted cells. It is currently unclear what is responsible for the 
activation of these kinases, but low levels of re-replication is a likely cause. In the 
absence of geminin, many of these G2-arrested cells then undergo further re-
replication to gain a >4C DNA content. ATR and Chk1 therefore promote DNA re-
replication in geminin depleted cells by preventing mitotic entry and delaying them in 
G2. At this cell cycle stage cells are particularly dependent on geminin to prevent re-
licensing of replicated DNA. The checkpoint mediated cell cycle arrest thereby 
amplifies the effect of a small amount of re-replication, creating an ‘all or nothing’ effect 
(see Discussion). Once re-replication has taken place the >4C cells are not able to 
form colonies and are doomed to undergo apoptosis as a consequence of the genomic 
damage they suffered. 
 
III.  10. Future Directions 
This is the first study to show that geminin depletion in synchronised cells causes 
re-replication from G2. The data provided is based exclusively on the U2OS cell line. 
Given that tumour-derived cell lines vary greatly in their ability to re-replicate and the 
general resistance of ‘normal’ cells to re-replication, the findings would be strengthened 
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be re-capitulating some of the key cell cycle or and checkpoint results in other cell 
lines. During the course of this project, the re-replication assay has been done on HeLa 
cervical cancer cells and HCT116 colon cancer cells. HeLa cells showed no re-
replication detectable by flow cytometry in response to geminin depletion whereas 
HCT116 re-replicated massively consistent with previous reports (Zhu et al., 2004). 
However, HCT116 cells do not respond to double Thymidine synchronisation, which  
complicated the investigation of re-replication from G2 phase. A possible approach 
would be to subject HCT116 cells to counterflow centrifugation elutriation and collect a 
pure G1 population to transfect them with geminin RNAi once they reached G2/M. This 
way the progression to subsequent S-phase could be studied in a more or less 
synchronised population to identify the origin of re-replication. Another promising 
candidate for reproducing the U2OS results are Saos2 cells, as they are from similar 
tumour type as U2OS and synchronise well with Thymidine. 
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IV. 1.  Introduction 
 Deregulation of the licensing machinery can be achieved by other ways in 
addition to geminin depletion. Geminin’s main function is to inhibit origin re-licensing in 
S-phase and G2 phase by formation of a heterohexameric inhibitory complex with 
licensing factor Cdt1 (Section I. 6. 1. 2). Cdt1 is expressed throughout the cell cycle but 
its activity is limited to late mitosis and G1 by geminin inhibition and by proteolysis via 
two Cullin-Ring and the APC ubiquitin ligases (Section I. 6. 1. 1). Overexpression of 
Cdt1 can therefore neutralise the inhibitory effect of geminin simply by overwhelming 
the system and titrating out the geminin. Similarly the degradation machinery can only 
remove a limited amount of Cdt1 protein and its over-expression has been shown to 
induce re-replication of genomic DNA in several model organisms (Arias and Walter, 
2005; Li and Blow, 2005; Maiorano et al., 2005; Thomer et al., 2004; Vaziri et al., 
2003). Alternatively to Cdt1 over-expression, the protein can also be stabilised by 
inhibition of its degradation machinery. Recent studies revealed that treatment of cells 
with the Nedd8 activating enzyme inhibitor MLN4924 stabilises Cdt1 in S-phase and 
causes re-replication, apoptosis and senescence (Lin et al., 2010; Milhollen et al., 
2011; Soucy et al., 2009). 
 
 In this Chapter the physiological consequences of Cdt1 overexpression or 
stabilisation were investigated to further characterise the mechanism of re-replication in 
human cells. The previous Chapter showed that geminin depletion did not alter the 
initial S-phase progression but induced re-replication from G2 phase of the cell cycle. 
The hypothesis is that this is due to low levels of Cdt1 during ‘normal’ S-phase, and 
that over-expression or stabilisation of Cdt1 could lead to a different phenotype being 
most likely visible directly during S-phase progression. Consequently, Cdt1 was over-
expressed as GFP-fusion protein or stabilised by MLN4924 treatment to study changes 
in the DNA content during cell cycle progression. It is important to gain further insight 
into the deregulation of the licensing machinery especially if it leads to re-replication via  
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several pathways in distinct cell cycle phases, which may result in different genomic 
alterations.   
 
IV. 2. Cdt1 overexpression inhibits DNA replication 
 
 Previous studies have shown that besides deregulation of the licensing 
machinery by geminin depletion, over-expression or stabilisation of licensing factor 
Cdt1 can also cause re-replication (Arias and Walter, 2005; Li and Blow, 2005; 
Maiorano et al., 2005; Nishitani et al., 2004; Thomer et al., 2004; Vaziri et al., 2003). 
We were interested whether re-replication in U2OS cells caused by Cdt1 stabilisation is 
initiated via the same mechanism that is seen following loss of geminin (Section III. 9). 
Initially, human Cdt1 was overexpressed using GFP-Cdt1 fusion proteins to study how 
Cdt1 stabilisation causes re-replication. 
 
IV. 2. 1.  Cloning of human Cdt1 and GFP-Cdt1 construct design 
 Human CDT1 (Accession BC009411) was obtained in a pOBT7 backbone from 
www.geneservice.co.uk. and transferred into pcDNA3 (Figure IV. 1). GFP-Cdt1 fusion 
constructs were designed according to the previous results of Ferenbach and 
colleagues (Figure IV. 2 A) (Ferenbach et al., 2005). Beside full-length Cdt1, truncated 
constructs were generated to gain insight in possible functions during re-replication. In 
detail, Cdt134-546 lacks the N-terminal region required for its proteolysis and therefore 
should stabilise the protein and induce higher levels of re-replication than the full-length 
protein. Cdt11-372 lacks the C-terminal region essential for MCM2-7 binding and loading 
onto chromatin and therefore could only promote re-replication indirectly by titrating out 
geminin and overwhelming the Cdt1 degradation machinery (Figure IV. 2 A). All 
constructs can still bind and titrate out geminin but only full-length -Cdt1 and Cdt134-546 
can actively load MCM2-7 complex onto chromatin. The nuclear localisation of the 
Cdt1-GFP fusion proteins was verified microscopically (Figure IV. 3) and the 
sequences were confirmed using the College of Life Sciences sequencing service. 
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Figure IV. 1. Cloning of human Cdt1 into pcDNA3. Cdt1 was obtained in a pOBT7 vector
and cloned into the EcoRI/ XhoI site of pcDNA3. A. pOBT7 map with relevant restriction sites
and the Cdt1 construct. B. Agarose gel with the Cdt1 and linearised pcDNA3 restriction 
fragments (red box). C. pcDNA3 vector map. D. Agarose gel with EcoR I linearised plasmid
DNA of eight colonies. Lane 1,4,6,7,8 shows pcDNA3 containing Cdt1 cDNA.
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Figure IV. 2. PCR amplification of Cdt1 constructs and cloning into pEGFP-N1. Three Cdt1
constructs were PCR amplified from pcDNA3-Cdt1. PCR products were purified, cut with EcoRI/
KnpI and run on an Agarose gel with EcoRI/KnpI restricted pEGFP-N1. All fragments were gel 
purified and the Cdt1 constructs transferred into pEGFP-N1 via T4 ligase reaction. A. Functional 
domains of human Cdt1 and constructs used in this study. B. PCR reaction products with and 
without addition of DMSO. C. Vector map of pEGFP-N1 with MCS and PCR fragments before 
ligation. D. Transformants after ligation. Plasmid DNA was cut with EcoRI/NotI to check Cdt1-
GFP presence. * Fl-Cdt1-GFP, Cdt1(34-546)-GFP and Cdt1(1-372)-GFP fragments.
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Figure IV. 3. Localisation of Cdt1 constructs. U2OS cells were transfected with Cdt1-GFP
constructs or pEGFP-N1 for 24 h and then monitored by microscopy. The left panel shows the DAPI 
(nuclear) staining for all samples while the middle panel shows the GFP signal. On the right site the
merge of both signals is shown.
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IV. 2. 2. Cdt1 overexpression blocks replication in asynchronous 
  U2OS and HeLa cancer cells 
 
 HeLa (cervical cancer cells) and U2OS (human osteosarcoma cells) cancer 
cells were transfected with empty pEGFP-N1 vector or one of the Cdt1-GFP fusion 
constructs and grown for 48 h. Two hours prior harvesting the cells were pulsed with 
the Thymidine analogue EdU (5-Ethynyl-2’-deoxyuridine) to monitor DNA replication. 
To investigate the impact of Cdt1 over-expression on DNA replication a flow cytometry 
assay was performed to determine the DNA content and EdU incorporation (Section II. 
7. 3) (Figure IV. 4 A, Figure IV. 5 A). However due to a very low transfection efficiency 
no clear effect could be detected by analysing the entire cell population. Therefore 
green fluorescent protein (GFP) positive and GFP negative cells were considered 
separately (Figures IV. 4 and 5). When cells were transfected with control plasmids 
expressing GFP alone, the DNA content and EdU intensity was similar in GFP negative 
(black frame) and GFP positive (green frame) cells, suggesting that the levels of DNA 
replication are not significantly altered by GFP over-expression. In contrast the cells 
transfected with any of the Cdt1-GFP constructs exhibited significantly less EdU 
staining, and accumulated in G1 and early S-phase of the cell cycle (Figure IV. 4 and 
IV. 5).  The GFP-negative cells in these populations provide an internal control for 
these experiments. Similar results were obtained in U2OS (Figure IV. 4 and IV. 5) and 
HeLa cell lines (Figure IV. 4. and IV. 5). 
 To investigate the inhibition of replication in more detail, cells were transfected 
as described above but 24 h post transfection EdU was added for 24 h to monitor DNA 
replication over a full cell cycle (Figure IV. 6). As expected around 90% of control cells 
(GFP negative and empty vector) incorporated significant amounts of EdU. In contrast 
only 25-30% of cells transfected with full-length Cdt1-GFP and (Cdt11-372)-GFP and 
49% of cells transfected with (Cdt134-546)-GFP showed incorporation of EdU. Re-
replication of DNA was never observed under these experimental conditions.
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Figure IV. 4.
Figure IV. 4. Cdt1 over-expression blocks S-phase progression in U20S cells. U2OS 
cellswere transfected with empty expression vector or constructs containing GFP, full-length 
GFP-Cdt1, GFP-Cdt1(34-546) or GFP-Cdt1(1-372). 48 h later, cells were pulsed with EdU for 20 
min and were then stained with anti-GFP antibodies, DNA content, and for incorporated EdU.
A. Schematic of the experiment. B. Cells were then analysed by flow cytometry. Cells were 
separated by the GFP intensity (left columns) into GFP-ve (non-transfected or non-expressers,
black frame) and GFP+ve categories (green frame). DNA content frequency graphs and EdU 
versus DNA content is shown for each category.
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Figure IV. 5. Cdt1 over-expression blocks S-phase progression in HeLa cells. HeLa
cellswere transfected with empty expression vector or constructs containing GFP, full-length 
GFP-Cdt1, GFP-Cdt1(34-546) or GFP-Cdt1(1-372). 48 h later, cells were pulsed with EdU for 20 
min and were then stained with anti-GFP antibodies, DNA content, and for incorporated EdU.
A. Schematic of the experiment. B. Cells were then analysed by flow cytometry. Cells were 
separated by the GFP intensity (left columns) into GFP-ve (non-transfected or non-expressers,
black frame) and GFP+ve categories (green frame). DNA content frequency graphs and EdU 
versus DNA content is shown for each category.
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Figure IV. 6. Cdt1 over-expression inhibits DNA replication in a full U20S cell cycle. 
U2OS cells were transfected with pEGFP-N1 or full-length GFP-Cdt1, GFP-Cdt1(34-546) 
or GFP-Cdt1(1-372). 24 h later, cells were pulsed with EdU for 24 h and were then stained  
with anti-GFP antibodies, DNA content, and for incorporated EdU. A. Schematic of 
the experiment. B. Cells were then analysed by flow cytometry to monitor replication 
efficiency in a full cell cycle. Cells were separated by the GFP intensity into 
GFP-ve (non-transfected orrnon-expressers, grey bars) and GFP+ve (green bars).
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IV. 2. 3. S- phase progression is blocked by Cdt1 over-expression 
 To further investigate the block in DNA replication seen in Cdt1 over-expressing 
cells, an experiment was designed to analyse S-phase progression in synchronised 
U2OS cells. The (Cdt134-546)-GFP construct, showing the weakest phenotype (Figure 
IV. 6) was selected and transfected into synchronised U2OS cells 10 h after Thymidine 
release (Figure IV. 7 A). Six hours post transfection the cells were treated again with 
Thymidine for 14 h and subsequently released into S-phase to monitor cell cycle 
progression via EdU incorporation at the indicated time points (Figure IV. 7 B). 
Whereas 50-80% of control cells advanced into S-phase, less than 5% of the (Cdt134-
546)-GFP positive cells showed EdU incorporation after 6 h.  
 
IV. 2. 4. Checkpoint activation is induced by Cdt1 over-expression 
 The eukaryotic cell cycle is tightly regulated by cell cycle checkpoints. These 
checkpoints control whether the processes in one cell cycle phase are accurately 
completed before entering the next phase. Many proteins such as cyclin E, H2AX, Chk1 
or p53 are regulated by these checkpoints and become inhibited or activated to stop 
cell cycle progression or induce apoptosis. To test for activation of cell cycle 
checkpoints, cells from the previously described experiments were analysed (Figure IV. 
4 and IV. 7). Therefore cells were handled as described before and GFP positive and 
negative cells were separated by FACS (Figure IV. 8 and IV. 7 C). Whole cell lysates 
were prepared and analysed for the expression of indicated proteins. As shown in 
Figures IV. 8 and IV. 13, the Cdt1-GFP fusion protein levels were roughly 100 times 
higher than endogenous Cdt1 protein levels. Cyclin E levels fluctuate periodically 
through the mammalian cell cycle peaking in late G1 and early S-phase (Dulic et al., 
1992). Therefore the high cyclin E protein levels (Figure IV. 8) correlate well with the 
increased percentage of Cdt1-GFP positive cells in G1/ early S-phase of the cell cycle 
observed by flow cytometry (Figure IV. 4 and 5).  
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Figure IV. 7. Cdt1 over-expression blocks S-phase progression in synchronised U20S cells. 
U2OS cells were synchronised with 2.5 mM Thymidine for 16 h, released into S-phase and trans-
fected with pEGFP-N1 or GFP-Cdt1(34-546). 6 h later, cells were treated again with Thymidine for 14 
h and subsequently S-phase progression was monitored at different times by 20 min pulses with 
EdU. Cells were stained with anti-GFP antibodies, DNA content, and for incorporated EdU. A. Sche-
matic of the experiment. B. Cells were then analysed by flow cytometry and gated for the GFP inten-
sity into GFP-ve (non-transfected or non-expressers, black line) and GFP+ve categories (green 
line).C. The 6 h time point (red frame) of Cdt1(34-546)-GFP was also subjected to FACS and sorted 
for GFP-ve and +ve cells which were then used to prepare whole cell lysates and run on SDS-PAGE 
to immunoblot for the indicated proteins. As controls, extracts were prepared from U2OS 
cells 3 h after treatment with UV (120 mJ/cm  ) or 18 h after treatmentwith 20 mM hydroxyurea.
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Figure IV. 8. Checkpoint activation following Cdt1 over-expression. U2OS cells were 
transfected with empty pEGFP-N1 or full-lenght Cdt1-GFP, Cdt1(1-372)-GFP or Cdt1(34-546)-GFP.
48 h later, cells were sorted according to GFP expression into GFP-ve (non-transfected or non-
expressers) and GFP+ve categories (green frame). Whole cell extracts were then prepared 
and subjected to SDS-PAGE and immunoblotted for the indicated proteins. As controls, 
extracts were prepared from U2OS cells 5 h after treatment with UV (120 mJ/cm  ), 18 h 
after treatment with 20 mM hydroxyurea, or 5 h after treatment with 1 !M staurosporine.
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 The Cdt1 over-expressing cells also showed a rapid activation of Chk1 and p53 
(Figure IV. 8 and IV. 7 C). Moreover 48 h post transfection (not 26 h post transfection 
Figure IV. 7 C) high levels of the DNA damage marker γ- H2AX were observed (Figure 
IV. 8). The high H2AX levels could also indicate fragmentation of the genome during 
apoptosis as the apoptosis marker cleaved PARP rapidly increased in Cdt1 over-
expressing cells (Figure IV. 7 C) 
 In summary, these experiments revealed that Cdt1 over-expression led to 
checkpoint activation, inhibition of DNA replication and G1/ early S-phase arrest rather 
then re-replication of DNA. 
 
IV. 3. Nedd8 activating enzyme inhibitor MLN4924 
  causes re-replication 
 
 Stabilisation of Cdt1 by interference with its degradation might be a less severe 
approach then over-expression of Cdt1 and thus might be a better tool to study Cdt1 
induced re-replication. As described in detail in Section I. 6. 1. 1 mammalian Cdt1 
degradation in S-phase is mediated by two ubiquitin ligases: a PCNA dependent one in 
a complex with Cullin 4 (CUL4) (Arias and Walter, 2006; Nishitani et al., 2006; Senga 
et al., 2006; Zhong et al., 2003) and a second dependent on SCF-Skp2 in complex with 
CUL1 (Li et al., 2003; Nishitani et al., 2006; Sugimoto et al., 2004). Cullin activity itself 
is dependent on its modification by Nedd8, which can be blocked by the small molecule 
inhibitor MLN4924 (Soucy et al., 2009) (Figure IV. 9 A).  
 
IV. 3. 1. Overview of MLN4924 action on U2OS cells 
 MLN4924 is a small molecule inhibitor of Nedd8 activating enzyme (NAE) with a 
potential antineoplastic activity. The drug acts as an inhibitor of Cullin-RING ubiquitin 
ligase (CRL) activity by interfering with the neddylation of the Cullins (Figure IV. 9 A). 
For CRL activation Nedd8 reacts initially with ATP to bind to NAE, which in turn 
transfers Nedd8 to the Nedd8-conjugating enzyme E2 (N8E2).  
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Figure IV. 9. Nedd8 activating enyme inhibitor MLN4924 on U2OS cells. A. MLN4924 
inhibits Cullin-RING ubiquitin ligase (CRL) activity by interfering with the neddylation of the 
Cullins. Nedd8 activation of Cullins starts when Nedd8 reacts with ATP followed by 
binding to the Nedd8 activating enzyme (NAE). Without MLN4924 Nedd8 gets transfereed to the 
Nedd8-conjugating enzyme E2 (N8 E2) which transfers Nedd8 to the CRLs. CRL enzymes are 
important for the ubiquitination of protein substrates such as Cdt1 which subsequently becomes 
degraded. Without Nedd8 CRL activity is low but once Nedd8 is attached to the Cullins the 
conformation of the RING subunit changes and allows the ubiquitin to be transfered to 
the target protein. B. U2OS cells were treated with 1 !M MLN4924 for 24 h and pulsed with 
BrdU the resulting changes in the cell cycle profile were monitored by flow cytometry.   
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N8E2 transfers Nedd8 to the non-activated CRL, thus mediating a change in 
conformation of the RING subunit allowing the transfer of ubiquitin to CRL target 
proteins such as Cdt1. MLN4924 addition causes an immediate inhibition of Nedd8 
binding to NEA and consequently low activity of CRLs (Soucy et al., 2009). 
 In agreement with previous studies (Lin et al., 2010; Milhollen et al., 2011; 
Soucy et al., 2009) addition of 1 µM MLN4924 to asynchronous U2OS cells for 24 h led 
to a significant increase in cells exhibiting a >4C DNA content (Figure IV. 9 B). In 
contrast with geminin induced re-replication, the BrdU profiles revealed a loss of a 
distinct G1 and G2/M cell populations. 
 
IV. 3. 2. Time and dose dependency of MLN4924 induced  
  re-replication 
 To analyse the mechanism by which MLN4924 induces re-replication, U2OS 
cells were treated with increasing levels of MLN4924 for 24 h and analysed by 
immunoblot or flow cytometry after pulsing cells with BrdU. Substantial re-replication of 
DNA was seen at concentrations of 0.5 - 2 µM MLN4924 causing Cdt1 levels to rise 2 - 
5 fold (Figure IV. 10). This was associated with an enrichment of cells in S-phase, and 
a loss of G1 or G2/M cells. The lack of G2 cells is in marked contrast with previous 
results in geminin-depleted cells suggesting that unlike geminin depletion, Cdt1 
stabilisation induces re-replication directly from S-phase without entering G2/M or a 
subsequent G1 phase. An increase in phospho-p53 and weak up-regulation of cleaved 
PARP was also detected at concentrations of 0.5 – 2 µM MLN4924 (Figure IV. 10 A) 
indicating a DNA damage response and an increase in apoptosis. Interestingly, 
concentrations higher than 1 µM led to an accumulation of cells in early S-phase with 
reduced BrdU intensity, similar to the results we obtained with massive Cdt1 over-
expression (Section IV. 2).  
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 In order to provide further evidence that cells re-replicating in response to 
MLN4924 do not enter G2 phase, cells were treated with 1 µM MLN4924 for different 
times and pulsed with BrdU for 30 min prior harvesting (Figure IV. 11 B). Re-replication 
was detectable in cells treated with MLN4924 for 14 h and 24 h where they appear to 
continuously incorporate BrdU as they acquired >4C DNA content without passing 
through a G2 phase where no BrdU incorporation occurs. A strong increase of Cdt1 
and phospho-p53 protein level was detected 14 h and 24 h post drug addition (Figure 
IV. 11 A).  
 
IV. 3. 3. MLN4924 treatment results in loading of licensing and  
  replication proteins onto chromatin  
   
  MLN4924 mediated stabilisation of Cdt1 causes re-replication most likely 
starting in S-phase. To investigate the mechanism behind this re-replication event, 
U2OS cells were synchronised with a double Thymidine block and then released into 
S-phase in the presence or absence of the drug. Prior to harvesting, cells were pulsed 
with BrdU for flow cytometry or trypsinised and subjected to CSK extraction based 
chromatin fractionation. Cells were collected after 3, 6 and 9 h where no measurable 
degree of re-replication was detectable by flow cytometry (Figure IV. 12 A). A DNA 
content of >4C within the cells was not seen before 14 h in previous experiments 
(Figure IV. 11). Cells re-firing origins within the first 9 h of S-phase would need more 
time to re-replicate to an extent detectable as a >4C DNA content providing the 
possibility to analyse chromatin composition at “the start” of re-replication. Immunoblots 
of whole cell lysate, supernatant and chromatin fraction showed a significant increase 
in Cdt1 levels throughout S-phase when MLN4924 was added (Figure IV. 12 B). The 
presence of Cdt1 on chromatin was accompanied by increased loading of MCM2 and 
PCNA. The increase of replication proteins on chromatin during S-phase upon drug 
treatment strongly suggests that re-replication already starts in S-phase. 
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   In contrast the recruitment of replication factors onto chromatin in S-phase was 
never observed in geminin depleted cells (Chapter III) indicating that re-replication 
cannot start efficiently before G2 due to a lack of Cdt1.   
 
IV. 4. Comparison of Cdt1 over-expression and  
  MLN4924 treatment 
 
 Cdt1 over-expression caused a strong inhibition of DNA replication, while 
MLN4924 led to substantial levels of re-replication. How can these two very different 
phenotypes caused by stabilisation of the same protein be explained? In order to 
address this question, U2OS cells were treated with 0, 0.5, 1 and 2 μM MLN4924 or 
transfected with full-length Cdt1-GFP (Figure IV. 13). To compare Cdt1 expression 
levels whole cell lysates were prepared, normalised as shown by the equal tubulin 
signals and blotted for Cdt1. Consistent with previous results, MLN4924 caused a 2-10 
fold increase in Cdt1 levels. In contrast, even a 100 times diluted full-length Cdt1-GFP 
extract exhibited higher levels of Cdt1 than lysates from cells treated with 2 µM 
MLN4924. It can be concluded that the very high levels of Cdt1 expression driven by 
the GFP expression vector causes very strong checkpoint activation and inhibition of 
DNA synthesis, whilst the lower levels of Cdt1 expression caused by MLN4924 allows 
significant re-replication to occur. 
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Figure IV. 13. Comparison of Cdt1 levels after MLN4924 treatment with Cdt1 over-
expression. Cells were treated with either 0, 0.5, 1 or 2 !M MLN4924 and harvested 24 hr later 
(lanes 1-4). In parallel, cultures were transfected with constructs to express either GFP (lane 5) or 
full-length Cdt1-GFP (lanes 6-9), and after 24 h, GFP-expressing cells were isolated by FACS. 
Whole cell extracts were prepared and immunoblotted for Cdt1 and tubulin. To compare Cdt1 
expression in MLN49234-treated cells and GFP-expressing cells, extract volumes were norma-
lised to give equal tubulin signals (lanes 1-6). In order to assess the degree of GFP-Cdt1 overex-
pression, extracts of Cdt1-GFP expressing cells were diluted 10-, 100- and 1000-fold (lanes 7-9). 
* this experiment was designed by me and Julian Blow for revision of Klotz-Noack 
et al.,2012 and performed by Debbie McIntosh due to my maternity break.
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IV. 5. Summary 
 In mammalian cells Cdt1 functions as a key regulator of the licensing 
machinery. Cdt1 levels increase in G2/M to mediate efficient loading of MCM2-7 
complex onto chromatin after progression into anaphase. It is crucial that Cdt1 levels 
decline in late G1 and S-phase, as cells should not be able to load MCM2-7 complex 
once replication has started. In this Chapter of the thesis a number of different GFP-
tagged Cdt1 constructs binding all to geminin but maintain different degrees of cell 
cycle regulation and licensing activity were massively over-expressed (>100 fold) in 
U2OS cells. Expression of all GFP-fusion proteins led to activation of the DNA damage 
checkpoint response and inhibition of EdU incorporation and S-phase progression. In 
contrast, when Cdt1 was stabilised with the ‘neddylation’ inhibitor MLN4924 the cells 
started to re-replicate their DNA directly from S-phase without entering G2/M or a 
subsequent G1 phase. This difference in response is likely due to the very different 
levels of Cdt1 over-expression in these treatments. 
 
IV. 6. Future Directions 
 In order to investigate the relationship between the Cdt1 expression level and 
the resulting phenotype, the protein could be expressed with an inducible expression 
system like the Tet-ON or Tet-OFF system from Clontech or RheoSwitch from NEB. 
These would allow the induction of Cdt1 expression to different levels at specific times.  
Previous studies in the Blow lab showed that in Xenopus egg extracts addition of 
recombinant Cdt1 initially induced re-licensing and re-replication but at high levels 
inhibit DNA synthesis. The inhibition was accompanied by activation of the DNA 
damage response and appearance of DNA fragments caused by head-to-tail 
replication fork collision (Davidson et al., 2006). This could explain the rapid inhibition 
of DNA replication that occurred when Cdt1 is overexpressed to very high levels in 
mammalian cells.  
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Experiments showing the existence of re-replication induced DNA fragments in Cdt1  
over-expressing cells could therefore provide evidence for head-to-tail fork collision as 
trigger for replication inhibition. Personal communication from Dimitris Xirodimas 
(Macromolecular Biochemistry Research Center, Montpellier) revealed that MLN4924 
treatment of MCF7 cancer cells caused G1/ S-phase arrest such as seen when Cdt1 is 
over-expressed. Treatment of different cell lines with MLN4924 could therefore provide 
a good way to study the head-to-tail fork collision model. 
 In contrast to geminin induced re-replication within G2 phase (Section III. 9), 
MLN4924 treatment induces re-replication in S-phase. It is impossible to show low 
levels of re-replication in S-phase by flow cytometry as it is indistinguishable from 
‘normal’ replication. However, BrdU labelling of synchronised MLN4924 treated S-
phase cells followed by DNA isolation and Cesium Chloride centrifugation could yield 
fractions with heavy-heavy DNA thus providing evidence for re-replication in S-phase. 
Alternatively an elegant approach established by Dorn and colleagues using dual 
colour DNA fibre analysis could be used on MLN4924 treated S-phase cells. They 
pulsed cells with CldU (green) for 30 min and subsequently incubated them in fresh 
medium for 10 min before treatment with a second colour (IdU-red) for 10 min. Re-
replication in response to Cdt1 over-expression caused 3-4 fold increase in yellow fibre 
tracks, which only appear if DNA is replicated in presence of CldU and IdU (Dorn et al., 
2009). 
 The next Chapter reveals how re-replication induced by geminin depletion 
alters the genome. Solexa deep sequencing of >4C DNA from geminin depleted cells 
generated information about the sites of re-replication. It would be interesting to 
compare the genetic alterations of MLN4924 treated S-phase cells with geminin 
depleted >4C cells. It is likely that re-replication induced in G2 will give different sites of 
amplification than re-replication induced upon S-phase entry.  
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V. 1.  Introduction 
 Over the past few years great breakthroughs have been made in the field of 
cancer biology due to the availability of high-resolution detection of copy number 
changes. Platforms like deep sequencing or comparative genomic hybridisation enable 
researchers to compare the genetic composition of ‘normal’ cells versus cancer cells 
and provide knowledge about genetic alterations acquired by tumour cells during or 
before malignant transformation. Plenty of data for numerous cancers is available 
indicating that the genomic variations range from point mutations and single base 
deletion over deletions, translocations or amplifications of chromosomal regions up to 
loss or gain of whole chromosomes.  
 Re-replication as studied in Chapter III and IV of this thesis leads to 
amplification of genomic DNA and could therefore be an early or initial step in tumour 
formation. Consistent with this, recent data from S. cerevisiae shows that re-replication 
of a single origin induced by deregulation of MCM2-7 and Cdc6 leads to an increase in 
gene copy number of one or more (Green et al., 2010). Interestingly, the amplicons are 
bound by repetitive elements, which may be required for the homologous 
recombination of the amplicon in a head-to-tail orientation into the endogenous locus. 
 An important remaining question is where does re-replication start and whether 
it occurs at preferential sites within the genome or whether it is a stochastic event that 
takes place randomly across the genome. CGH analysis of geminin depleted 
Drosophila S2 cells revealed that re-replication occurs preferentially on 
heterochromatic regions (Ding and MacAlpine, 2010), while a study in mammalian cells 
showed re-replication on early replication origins such as Lamin B rather than in 
centromeric (often heterochromatin) or telomeric regions (Zhu et al., 2004). A third 
study revealed that re-replication from G2 phase occurs randomly without preference 
for early or late firing origins (Lu et al., 2010). 
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 Given the controversial results in the field, this Chapter investigated the genetic 
composition of geminin depleted cells after substantial re-replication. Comparative 
genomic hybridisation and deep sequencing were applied to identify the sites of re-
replication in cells with a >4C DNA content. 
 
V. 2.  Comparative Genomic Hybridisation of geminin 
  Depleted vs. control cells 
 
 The results described in Chapter III of this Thesis showed that depletion of 
geminin leads to re-replication in human U2OS cells. To test if the re-replication occurs 
at preferential sites within the genome, we initially performed a CGH approach. Two 
different Agilent CGH microarray formats named (8x60K and 4x44K) were used during 
the course of this study. Both arrays use 60mer oligonucleotides, which are deposited 
uniformly onto specially prepared glass slides. The probes cover the entire human 
genome but probe spacing and therefore data resolution is different between the two 
arrays. The 8x60K microarray slide consists of 8 arrays providing 5.5 x 104 data points 
covering the entire human genome (3.04 x 109 bases) with 41 kb overall median probe 
spacing. The 4x44K microarray was performed by Agilent in Germany and consists of 
4.2 x 104 data points with 43 kb overall median probe spacing (see Section II. 12 for 
specifications). To induce re-replication U2OS cells were released from a double 
Thymidine block after prior treatment with either control or geminin RNAi and grown for 
48 h (see Chapter III). Subsequently cells were stained with Hoechst 33342 and 
subjected to FACS to isolate cells with a >4C DNA content in the geminin depleted and 
cells with a 2C DNA content in the control.  
 
V. 2. 1. 8x 60K Sure Print G3 Human CGH Microarray 
  
V. 2. 1. 1. Array setup and Quality Control 
 The DNA was isolated and quality as well as quantity were validated by 
agarose gel electrophoresis and NanoDrop® UV Spectrophotometer.  
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DNA from three biological replicates (A, B, C) was labelled with Cy3 for DNA 
from geminin depleted cells and Cy5 for DNA from control cells in three (A and B) or 
two (C) technical replicates. The Cy3 and Cy5 labelled DNA from each replicate was 
mixed and transferred onto the microarrays (for overview see Figure V. 1). Details 
about the data processing can be found in Methods Section II. 12. 3. To test the 
variability between technical replicates within these microarrays the Cy3/Cy5 ratio of all 
technical replicates was plotted against each other. The graphs in Figure V. 2 show 
that many data points did not correlate in the technical replicates. To further investigate 
why the data quality was so poor, plots for each wavelength were generated (Figure V. 
2). The Cy3 median minus background values showed a good correlation between 
technical replicates except the data from array A1 where a loss of sample during the 
array assembly was observed (Figure V. 3). In contrast the Cy5 median minus 
background values showed poor correlation between the replicates especially among 
the low intensity values (Figure V. 4). This clearly shows that the low reproducibility 
between technical replicates is due to poor Cy5 signal quality. 
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Figure V. 1. Array setup for preparation of 8x60K microarray. U2OS cells were released 
from a double thymidine block after prior treatment with either control or geminin RNAi, as in
Figure III. 2. 2. 48 h later, cells were labeled with Hoechst 33342 for 30 min and indicated 
populations (2c, >4c) were seperated by FACS. Subsequently the DNA from each population
of cells was isolated, quantified by agarose gel electrophorese and Nano Drop UV spectro- 
photometer and cy5 (2c) or cy3 (>4c) labeled according to Agilent instructions. 250ng input DNA 
was used per sample and per array.
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Figure V. 2. Quality control plots for the 
cy3/cy5 ratios of the 8x60K microarray. 
The panels shows the cy3/cy5 (>4c/2c) 
ratios of each of the three biological repli-
cates A, B, Cversus their technical repli-
cates 1,2,3. cy3/cy5 A1 vs A2, A1 vs A3, A2 
vs A3 as well as B1 vs B2, B1 vs B3, B2 vs 
B3 and C1 vs C2
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Figure V. 3. Quality control plots for the 
cy3 labeling of the 8x60K microarray. The 
panels shows the cy3 median signal intensitys
of each of the three biological replicates A, B, C
versus their technical replicates 1,2,3. A1cy3 vs
A2cy3, A1cy3 vs A3cy3, A2cy3 vs A3cy3 as well 
as B1cy3 vs B2cy3, B1cy3 vs B3cy3, B2cy3 vs 
B3cy3 and C1cy3 vs C2cy3.
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Figure V. 4. Quality control plots for the 
cy5 labeling of the 8x60K microarray. The 
panels shows the cy5 median signal intensitys
of each of the three biological replicates A, B, C
versus their technical replicates 1,2,3. A1cy5 vs
A2cy5, A1cy5 vs A3cy5, A2cy5 vs A3cy5 as well
as B1cy5 vs B2cy5, B1cy5 vs B3cy5, B2cy5 vs 
B3cy5 and C1cy5 vs C2cy5.
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V. 2. 1. 2. Filtering of valid data points and normalisation 
 To rescue some data from this microarray experiment all unreliable (poorly 
correlated) points were extracted and excluded from the data set. In the best case the 
Cy5/Cy5 ratio between technical replicates should be around one. In contrast our 
results showed many outliers and in collaboration with Nick Schurch from the Data 
Analysis Group of the University of Dundee, the following criteria for validity of data had 
been set. If the Cy5/Cy5 ratio between technical replicates was greater than 1.3 or 
smaller than 0.7, the data point was invalid and assigned with a ‘0’ in the excel sheet. If 
it was within the defined range it was assigned with the median signal intensity value. 
Subsequently a filter was programmed, excluding all rows containing a ‘0’. All 
remaining data points therefore were valid and used for further analysis (Figure V. 5).  
 A more detailed description how invalid data points were excluded from further 
analysis can be found in Section II. 12. 3. 
 To account for the generally lower Cy5 labelling standard probes provided on 
the array were used for normalisation, the median Cy3/Cy5 ratios of those probes were 
calculated for each array (between 2.1 and 2.6) and subsequently the valid Cy3/Cy5 
ratios for each array were normalised by that value. 
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Figure V. 5. Method to exclude invalid data points. This Figure descibes how we dealt 
with the poor correlation between two technical replicates due to poor cy5 labeling in order to
gain knowledge from this cost intensive experiment. We excluded invalid data points based on
the criteria described in the text. A. Shows the cy3 vs cy3, cy5 vs cy5 and cy3/cy5 vs c3/cy5
plots from array C1 vs C2. The red triangles mark the areas containing anti-correlating data
points between two technical replicates. B. Shows the plots of A. after filtering invalid data
points. Those data points were used for further analysis.
The logical test is based on the required reproducibility between two technical 
replicates on one array. Figure V. 3 and 4 as well as the plots above show that the cy5 
rather then the cy3 labeling causes the poor reproducibility between cy3/cy5 ratios of 
technical replicates shown in Figure V. 2. Therefore the data was filtered based on the 
cy5/cy5 ratio between two technical replicates. If the ratio of for example C1cy5/C2cy5 
is greater then 1.3 or smaller then 0.7 the data point is invalid and assigned with a 0. If 
the ratio is within the range it is assigned with the median signal intensity value.
=IF(logical_test,[value_if_true], [value_if_false])
The data was then filtered simply by selecting the filter column with its zeros and value-
sand set the filter on “Does Not Equal” 0 thus excluding all invalid data points resulting 
in the quality plots below. About 50% of the ~50000 data points were valid and used 
togenerate the cy3/cy5 ratio (>4c/ 2c) plots for each array covering whole human 
genome (Figure V. 6-8).
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V. 2. 1. 3. Whole genome analysis of geminin depleted vs. control  
 By plotting the ratios for geminin depleted/ control cells (>4C/2C) over the 
whole genome (Figure V. 6-8) the data looked very promising. Only specific regions 
within the whole genome seemed to be amplified reproducibly between technical and 
biological replicates (compare Figures V. 6-8). This would suggest that re-replication in 
geminin depleted cells takes place at specific regions.  In those areas up to a 4-fold 
increase in copy number were observed, which were surrounded by areas showing no 
amplification at all (values around 1).  
 However, before these regions of amplification were further analysed by 
fluorescence in situ hybridsation (FISH) or quantitative PCR (qPCR) analysis, the data 
should be reproduced by an additional microarray, as the technical problems with the 
array that necessitated the removal of many data points raised doubts about the 
reliability of the data. No obvious reason for the low quality of Cy5 signal intensity could 
be found as the labelling quality as well as the concentration of the Cy5 labelled DNA 
sample was well in the range demanded by the manufacturer. Therefore Agilent 
Technologies kindly offered to run a 4x44K human genome array with >4C geminin 
depleted and 2C control DNA in their research facility in Germany to check 
reproducibility of this low quality array.  
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Figure V. 6. Whole Genome data for Array A2 and A3. The >4c/2c ratio of geminin depleted 
vs control depleted cells is shown for Array A2 and A3. A black dot represents one of  the 
remaining 28349 valid data points that represent distinct biological features covering the whole
human genome (array contains a total of 55077 distinct biological features).
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Figure V. 7. Whole Genome data for Array B1 and B3. The >4c/2c ratio of geminin depleted 
vs control depleted cells is shown for Array B1 and B3. A black dot represents one of  the 
remaining 26944 valid data points that represent distinct biological features covering the whole
human genome (array contains a total of 55077 distinct biological features).
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Figure V. 8. Whole Genome data for Array C1 and C2. The >4c/2c ratio of geminin depleted 
vs control depleted cells is shown for Array C1 and C2. A black dot represents one of  the 
remaining 27219 valid data points that represent distinct biological features covering the whole
human genome (array contains a total of 55077 distinct biological features).
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V. 2. 2. 4x 44K Human Genome CGH Microarray 
 
V. 2. 2. 1. Array setup and Quality Control 
 Because the problems we encountered with the 8x60K array were technical 
only, one biological experiment was performed for the 4x 44K array to generate DNA 
for four technical replicates (A1, A2, A3 and A4) (Figure V. 9). DNA was handled as 
described is Section V. 2. For each sample and each array, 500 ng input DNA was 
send to Agilent technologies. To obtain a better control for the labelling quality the 
array was setup as a dye swap experiment: for array A1 and A2 the >4C DNA was Cy3 
labelled while for array A3 and A4 it was Cy5 labelled and vice versa.  
 The Cy3/Cy5 or Cy5/Cy3 ratios of array A1 vs. A2 and A3 vs. A4 showed a 
good correlation with only a few outliers (Figure V. 10. upper panel), indicating good 
data quality. In agreement the plots of single wavelengths against each other (Cy3 vs. 
Cy3 and Cy5 vs. Cy5) also exhibited a highly correlated data distribution (Figure V. 10 
middle and lower panels). In contrast to the 8x 60K array it was not necessary to filter 
out invalid data points.  	  
V. 2. 2. 2. Geminin depleted vs. control whole genome analysis 
 In contrast to the 8x 60K results, the whole genome analysis of >4C/ 2C on the 
4x 44K array revealed no obvious areas of amplification.  On all 4 arrays the ~ 44000 
data points are distributed closely to the baseline of around one (Figure V. 11 - 12). 
This suggests that re-replication does not occur preferentially at specific origins and 
that re-firing of replication origins in G2 phase of the cell cycle occurs stochastically 
across the entire genome.  
However, given the fact that both microarray experiments gave opposite results, a third 
and different approach was chosen to allow a thorough conclusion.  
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Figure V. 9. Array setup for preparation by Agilent, Germany. U2OS cells were released from 
a double Thymidine block after prior treatment with either control or geminin RNAi, as in Figure 
IV. 2. 2. 48h later, cells were labeled with Hoechst 33342 for 30 min and indicated populations (2c, 
>4c) were seperated by FACS. Subsequently the DNA from each population of cells was isolated 
and quantified by agarose gel electrophorese and Nano Drop UV spectrophotometer. 500 ng 
input DNA was used per sample and per array.
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Figure V. 10. Quality control plots for the 4x44K microarray performed by Agilent.
The upper panel shows the cy3/cy5 (>4c/2c) ratio of Array 1 (A1) versus Array 2 (A2) and the 
cy5/cy3 (>4c/2c) ratio of A3 versus A4. The middle (cy3) and bottom (cy5) panels look at the 
single colors against each other to check technical reproducibility between the arrays.
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Figure V. 11. Whole Genome data for Array 1 and Array 2. The >4c/2c ratio of geminin 
depleted vs control depleted cells is shown for Array A1 and A2. A black dot represents one of 
the 42494 sequences that represent distinct biological features covering the whole human 
genome.
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Figure V. 12. Whole Genome data for Array A3 and Array A4. The >4c/2c ratio of geminin 
depleted vs control depleted cells is shown for Array A3 and A4. A black dot represents one of 
the 42494 sequences that represent distinct biological features covering the whole human 
genome.
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V. 3.  Solexa Deep Sequencing of geminin depleted 
  vs. control cells 
 
 Solexa deep DNA sequencing was chosen as an alternative approach to 
investigate copy number changes in geminin depleted U2OS cells. Although deep 
sequencing is fairly costly, it provides ~70x 106 usable mapped reads compared to  
~50x 103 probes from the microarray data. Thus the data resolution across the whole 
genome and therefore the reliability is much higher using the deep sequencing 
technique. 
 FACS was used to collect either 2C (control depleted) cells or >4C (geminin 
depleted) cells 48 h after double Thymidine release. The genomic DNA was isolated 
from biological triplicates and the six samples were analysed by deep DNA sequencing 
(http://genepool.bio.ed.ac.uk).  
 Figure V. 13. A shows the sequencing data as a circle plot, where each circle 
represents DNA from a single chromosome, shown as a running 1 Mb weighted-
average (red line). The deviation from exact circularity, which reflects differences in 
abundances of the sequenced DNA, is only slight. As an example, chromosome 10 is 
shown in more detail in Figure V. 13 B. In addition to the 1 Mb weighted-average data 
(red), data grouped with a 100 kb weighted-average (blue) is also shown. The 
abundance ratio typically remains very close to 1 with only minor deviations. Small-
scale (~10%) increases in the ratio are observed for some chromosomes for a few Mb 
surrounding the centromeres (notably chromosomes 4, 7, 10, 18 & 19) and telomeres 
(notably chromosomes 6, 10, 11, 12, 19 & 21). The raw data shows some strong, 
narrow (<10kb), ‘spikes’ which are associated with satellite repeats and are also seen 
in other genomic sequencing datasets (van Koningsbruggen et al., 2010). Analysis of 
the ~10% of sequencing reads that mapped to the repetitive chromosomal sequences 
gave almost identical ratios between control and geminin depleted samples (see 
Methods Section II. 13).  
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Figure V. 13. Re-replication occurs throughout the entire genome. Cells were released 
from a double Thymidine block after prior treatment with either control or geminin RNAi, as in 
Figure III. 2. 48 h after release from the 2nd Thymidine block, cells were sorted by FACS 
according to their DNA content. Cells with a 2c (G1) DNA content were collected from the control 
RNAi sample, and cells with a >4c (>G2) DNA content were collected from the geminin RNAi 
sample. DNA was isolated from the two samples and subjected to deep DNA sequencing. A total
of ~70x10  usable mapped reads covering the whole genome (3.04x 10   bases ) could be gener-
ated by sequencing. The number of reads in 1 Mb segments of the genome were derived for the 
two samples, and the ratioof read numbers in geminin-depleted/ control G1 samples were calcu-
lated. A. Geminin-depleted >G2 / control G1 ratio for all 23 chromosomes. Black brackets show 
the ratio scale from 0 to 2; the faint green line shows a ratio of 1. Purple boxes denote centrom-
eres. Ticks around the ring show chromosome position in Mb. B. Expanded data for chromosome 
10 as exemplar. The number of reads per segment is compared for 1 Mb (red lines) and 100 kb 
(blue lines) bins. Data for geminin depleted cells with >G2 DNA content (top), control G1 cells 
(middle), and their ratios are shown (bottom).
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 This indicates that repetitive DNA is not preferentially re-replicated in geminin 
depleted cells. Apart from the slight enrichment at centromeres and telomeres, the data 
therefore provide no evidence that any particular regions of the genome are 
preferentially re-replicated in response to geminin depletion. Consistent with the data 
from the 4x 44K microarray this implies that most re-replication occurs stochastically 
across the genome, rather than preferentially at specific loci.  
 
 
V. 4.  Summary 
 In this part of the Thesis the genomic consequences of geminin induced re-
replication have been investigated by comparative genomic hybridisation microarrays 
and Solexa deep sequencing. The aim was to determine whether re-replication occurs 
on preferential sites or randomly across the genome. CGH analysis of geminin 
depleted (>4C) versus control (2C) DNA revealed contrary results between two 
independent microarray experiments. The self-made 8x 60K microarray showed a low 
quality of Cy5 labelling resulting in a loss of ~45% of the data points. The remaining 
data indicated large regions of 2-4 fold amplifications across the genome. However, a 
4x 44K microarray performed by Agilent failed to reproduce those findings and instead 
showed no preferred sites of re-replication suggesting that re-firing of replication origins 
in G2 phase occurs stochastically across the human genome. In agreement with the 
Agilent data, deep DNA sequencing revealed no preferential re-replication of specific 
genomic regions after geminin depletion.  
 
V. 5.  Future Directions 
 Chapters III and IV of this PhD thesis investigated two distinct mechanisms 
inducing re-replication in U2OS cancer cells. Geminin depletion causes cells to re-fire 
replication origins after checkpoint mediated G2 arrest while MLN4924 mediated  
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stabilisation of Cdt1 seems to induce re-replication directly from within S-phase of the 
cell cycle. Microarray analysis and deep sequencing of geminin depleted cells showed  
that re-replication occurs stochastically across the entire genome rather than 
preferential on specific loci. It would be interesting to analyse the genomic 
consequences within the MLN4924 treated U2OS cells with by deep sequencing. Such 
analysis could clarify whether this second mechanism is as well random or locus 
specific. One approach could be to treat asynchronous cells with MLN4924 for 24 h 
and isolate the DNA for sequencing. Alternatively cells could be released from a double 
Thymidine block in the presence or absence of MLN4924 for approximately 18 h. The 
isolated DNA from the control population (no treatment) would have a mainly 2C DNA 
content as the majority of the cells would have replicated their genome normally and 
progressed into the next G1 phase. That would make it easier to compare with 
MLN4924 treated cells, which presumably have suffered massive re-replication of 
either specific or random loci.  
 Cdt1 over-expression or MLN4924 treatment of MCF7 cells (personal 
communication with Dimitris Xirodimas) causes inhibition of replication and G1/S-
phase arrest. Deep sequencing of DNA from Cdt1 over-expressing cells released from 
a double Thymidine block for 6 h could provide evidence for head to tail fork collision 
as it would show if multiple re-initiation events took place in certain regions and it would 
also show if re-replication initiated according to the replication timing program on early 
firing origins.  	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 Preventing re-replication of DNA in a single cell cycle is crucial for the 
maintenance of genetic stability, and defects in the regulation of the replication 
licensing system may contribute to genetic instability commonly seen in cancer cells 
(Blow and Gillespie, 2008a). In mammalian cells many regulatory mechanisms prohibit 
relicensing of replication origins once cells have entered S-phase, the most important 
of which are down-regulation of Cdt1 activity by proteolysis or Cdt1 inhibition via 
formation of a heterohexameric complex with geminin (Arias and Walter, 2007; Blow 
and Dutta, 2005; DePamphilis et al., 2006). Previous work has shown that inhibition or 
loss of geminin (Li and Blow, 2005; Melixetian et al., 2004; Zhu et al., 2004) or the 
over-expression of Cdt1 (Li and Blow, 2005; Maiorano et al., 2005; Nishitani et al., 
2004; Thomer et al., 2004; Vaziri et al., 2003) promotes re-replication of chromosomal 
DNA.  
The results presented in this thesis describe how loss of geminin and stabilisation of 
Cdt1 induce re-replication of chromosomal DNA via distinct mechanisms.  
 Geminin depletion in U2OS cells does not affect progression through the first S-
phase but triggers activation of the G2/M checkpoint. Cells arrested in G2 then 
undergo re-firing of origins randomly distributed across the genome, ultimately leading 
to inhibition of proliferation and cell death. Activation of the G2/M checkpoint amplifies 
small defects caused by geminin depletion, thereby creating an ‘all or nothing’ 
response to re-replication.  
 In contrast, stabilisation of Cdt1 by inhibition of its proteolysis causes re-
replication accompanied by checkpoint activation. In parallel, association of replication 
proteins such as PCNA, MCM2 and Cdt1 onto S-phase chromatin was observed, 
suggesting that in contrast to geminin depletion, re-initiation of replication origins takes 
place in S-phase leading to immediate re-replication of DNA. Very high levels of Cdt1 
over-expression mediated by transfection of Cdt1 expression constructs led to strong 
checkpoint activation and inhibition of replication with cells arresting in early S-phase. 
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Part VI. 1. Physiological Consequences of   
   chromosomal re-replication 
VI. 1. 1. Re-replication is lethal 
 Even when cells were treated with low concentrations of geminin siRNA, 
proliferation was decreased at least 10 fold compared to control cells. This is most 
likely a consequence of the 10-fold increase in cell death that can be observed after 
geminin depletion. A correlation between re-replication and apoptosis was observed in 
this study, suggesting that as a first response to geminin depletion cells start to re-
replicate DNA, while later on the levels of re-replication decline to the same extent than 
the levels of cell death increase. Two previous studies have already pointed out that 
geminin depletion causes re-replication and checkpoint activation in the presence of 
functional p53 (Melixetian et al., 2004; Zhu et al., 2004). However both studies only 
showed apoptosis in geminin depleted HCT116 cells after checkpoint abrogation. In 
this study activation of apoptotic signalling cascades can be detected without 
checkpoint abrogation as early as 16 h post 2nd Thymidine release in geminin depleted 
cells, as evident by increased levels of cleaved PARP. Consequently the appearance 
of apoptotic cells (<2C DNA content) can be observed between 72 h and 96 h post 2nd 
Thymidine release in geminin depleted populations. In agreement with these findings a 
recent study from the DePamphilis lab revealed that geminin depletion causes 
proliferation inhibition and selective killing of cancer cells due to massive re-replication, 
while non-cancer cells do not re-replicate and subsequently grow and survive (Zhu and 
DePamphilis, 2009).  
 
 Cdt1 stabilisation by inhibition of proteolysis by the Nedd8- activating enzyme 
inhibitor MLN4924 caused substantial amounts of re-replication apparently starting in 
S-phase. The time frame of this project did not allow long term analysis of cells treated 
with MLN4924, but previous studies showed induction of senescence (Jia et al., 2011; 
Lin et al., 2010) and selective killing (Lin et al., 2010; Milhollen et al., 2011; Soucy et 
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al., 2009) of cancer cells re-replicating upon MLN4924 treatment, making this drug a 
promising anti-cancer agent in clinical trials.  
 
 Although we were not able to recover cultures of geminin depleted cells that 
underwent re-replication to study specific genetic alterations, we cannot exclude that 
cells with only marginally reduced levels of geminin, might undergo only low amounts 
of re-replication and therefore might be able to survive. However re-replication 
detectable by FACS seems to be a cellular insult that does not allow cell survival. 
 
VI. 1. 2. Role of Cdt1 levels in initiation of re-replication 
 During anaphase and G1 phases, Cdt1 activity is high and geminin activity is 
low allowing origin licensing to take place (Figure VI. 1). During S-phase Cdt1 is 
degraded or inactivated by forming an inhibitory complex with geminin. Both Cdt1 
proteolysis and inhibition by geminin contribute to the prevention of re-licensing of 
replication origins after initiation of DNA replication. We show that synchronised U2OS 
cells progressing through their first S-phase in the absence of geminin exhibit no large-
scale defect in DNA replication or replication timing. In agreement with data provided 
by Ballabeni and colleagues (Ballabeni et al., 2004) we showed a decrease of Cdt1 
levels upon geminin depletion. Interestingly this decline is accompanied by a small 
increase in soluble PCNA levels in geminin depleted cells, suggesting that the lack of 
geminin, the low levels of Cdt1 or the presence of geminin unbound Cdt1 directly or 
indirectly mediate an accumulation or stabilisation of PCNA. This is a novel observation 
and cannot be explained by the current literature.  
 The decrease in Cdt1 could be a consequence of PCNA dependent 
degradation in response to DNA damage (Higa et al., 2003). Re-replication has 
recently been shown to activate the DNA damage induced PCNA dependent 
degradation of Cdt1 preventing origin licensing after DNA damage (Hall et al., 2008). 
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 However, Hall and colleagues (2008) showed enhanced PCNA dependent Cdt1 
degradation after detecting substantial re-replication and robust ATR-Chk1 checkpoint 
activation. In contrast we detected decreased levels of Cdt1 within the first S-phase 
after geminin depletion in the absence of measurable re-replication and DNA damage 
checkpoint activation. Therefore it seems more likely that Cdt1 proteolysis is increased 
upon geminin depletion as response to unbound Cdt1, being not in the inhibitory and 
protective complex with geminin as suggested by Ballabeni and colleagues (2004). 
Thus the steric hindrance is not provided by geminin allowing Cdt1 degradation, 
causing the decline in protein levels. Moreover geminin depletion was shown to reduce 
Cdt1 mRNA levels in Drosophila SD2 cells (Mihaylov et al., 2002) indicating that 
transcriptional down-regulation could also account for the Cdt1 decrease upon geminin 
depletion. 
 We postulate that in geminin depleted cells the low Cdt1 levels during the first 
S-phase are the reason why re-replication cannot occur before the levels build up 
during G2 phase. This suggests that the key role of geminin is to prevent re-licensing 
and re-replication in G2 phase (Figure VI. 1). 
In contrast, when Cdt1 proteolysis is suppressed by MLN4924, immediate origin 
re-firing and continuous incorporation of BrdU takes place resulting in significant re-
replication within S-phase (Klotz-Noack et al., 2012; Lin et al., 2010; Milhollen et al., 
2011; Soucy et al., 2009). The data provided so far suggests that the levels of Cdt1 
determine when re-replication can start and that the efficient proteolysis of Cdt1 
prevents substantial re-replication in S-phase when geminin is depleted. 
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Figure VI. 1.
Figure VI. 1. Cartoon of licensing control by Cdt1 and geminin. Activity levels of Cdks, Cdt1 
and geminin are shown throughout the cell cycle. This allows licensing to take place only during 
late mitosis and G1. In the absence of geminin, rising Cdt1 levels in G2 can promote re-licensing 
of replicated DNA, and in the presence of Cdk activity, can cause re-replication of DNA.
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VI. 1. 3. The role of re-replication in activation of cell cycle   
  checkpoints 
 Although geminin depletion does not cause major detectable problems in the 
first S-phase, 20 – 40% of geminin depleted cells were delayed or blocked in very late 
S-phase or G2. This appears to be due to activation of checkpoint kinases as the G2 
arrest was associated with phosphorylation of p53 and was abolished by treating cells 
with checkpoint inhibitors such as caffeine or the Chk1 inhibitor UCN-01.  
 Although it seems likely that activation of the G2/M checkpoint caused by 
geminin depletion is a consequence of a small amount of re-replication, we could find 
no evidence of significant amounts of re-replication having occurred at this stage. 
Similar results were reported by Liu et al, who showed that Cdt1 over-expression in a 
number of cell lines caused checkpoint activation in the absence of detectable re-
replication (Liu et al., 2007). It is not clear why a small amount of re-replication should 
cause checkpoint activation.  
 One mechanism by which re-replication induces checkpoint activation is a 
head-to-tail collision of replication forks after chasing one another along the same DNA 
template (Davidson et al., 2006). Under those circumstances the rear fork can run into 
the front fork causing fork stalling and checkpoint activation. If both forks in a 
replication bubble undergo this sort of collision, small double stranded DNA fragments 
would be generated (Figure VI. 2). In order for a head-to-tail collision to occur, re-
licensing and re-initiation must occur rapidly after a first initiation event and multiple 
rounds of re-replication are required. This seems incompatible with the undetectable 
levels of re-replication occurring in the first S phase after geminin depletion. However, 
head-to-tail fork collisions could explain the rapid inhibition of DNA replication occurring 
upon over-expression of Cdt1. Consistent with Davidson et al. moderate levels of Cdt1 
such as obtained by MLN4924 treatment caused re-replication of DNA while high 
levels caused inhibition of replication.  
	   
dsDNA 
fragment
A. Initial re-initiation
B. Further re-initiation
C. left fork collide and stall
D. right fork collide and stall- appearence of dsDNA fragments
activation of ATR / Chk1 checkpoint pathway
origin initiation and S-phase progression
Figure VI. 2. Head-to-tail fork collision model to activte cell cycle checkpoints in response 
to Cdt1 overexpression. A section of DNA with a replication origin is shown. The replication forks 
are indicated by green rings. A. Reinitiation at the replication origin forms a replication bubble. B. 
Further reinitiation events form a second replication bubble within the first bubble with the rear 
forks chasing the front fork. C. The left rear fork collides with the front fork. D. The right forks 
undergo head-to-tail fork collision releasing double stranded DNA fragments. Fork collision and 
the resulting fork stalling cause ATR / Chk1 checkpoint activation which inhibit further initiation and 
S-phase progression.
Figure VI. 2. 
modified from Davidson et al., 2006
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 In both studies phosphorylation of the Chk1 checkpoint kinase was observed, 
suggesting that head-to-tail fork collision took place after massive over-expression of 
Cdt1 thereby activating Chk1 kinase and consequently leading to replication inhibition 
and cell cycle arrest. The time frame of this project did not allow further investigation of 
Cdt1 over-expression to provide evidence for head-to-tail fork collision by checking the 
appearance of DNA fragments. 
 
 Liu and colleagues found that uncontrolled DNA unwinding by MCM2-7 protein 
upon deregulation of the licensing machinery results in accumulation of ssDNA and 
ATR checkpoint activation. In geminin depleted cells re-loading of MCM2-7 proteins 
can occur upon Cdt1 increase in late S-phase or G2 and could therefore result in 
uncontrolled DNA unwinding and the generation of DNA lesions together with 
activation of the ATR checkpoint pathway. If this is the case, why should re-loading of 
the MCM2-7 complex and re-initiation of DNA replication lead to uncontrolled DNA 
unwinding? One possibility is an incomplete assembly of the replisome, for example as 
a consequence of defective DNA polymerase activity (Walter and Newport, 2000) or a 
lack of other replisome components causing enhanced replication forks stalling (Byun 
et al., 2005).  
 Consistent with this interpretation, it has been shown in yeast that re-replicating 
forks may be particularly prone to collapse due to generation of DNA lesions produced 
by the re-replication itself (Green et al., 2010; Green and Li, 2005). However, it is not 
clear why re-replication would cause DNA damage that is not generated during 
‘normal’ replication thus activating checkpoints.  
 
 An alternative possibility is that replisomes performing re-replication are 
essentially normal and have the same probability of stalling as forks performing normal 
replication. However, it is likely that after geminin depletion, re-licensed origins on 
replicated DNA may be very sparse. If these forks stall, then they would be less likely 
to be rescued by initiation from nearby dormant origins than in case of the normal first-
 Chapter VI                        Discussion 
	   169 
round replication (Blow et al., 2011; Ge and Blow, 2010; Ge et al., 2007; Woodward et 
al., 2006). A lack of dormant origins under replicative stress would result in activation of 
Chk1 checkpoint kinase (Ge and Blow, 2010), which is consistent with ATR and the 
Fanconi Anaemia pathway being activated when geminin is lost (Liu et al., 2007; Zhu 
and Dutta, 2006).  
 
VI. 1. 4. The G2/M checkpoint mediates an ‘all or nothing’   
  response  
 I have shown that, paradoxically, activation of the G2/M checkpoint in response 
to loss of geminin actually promotes DNA re-replication. Only after being delayed in G2 
do geminin depleted cells undergo re-replication. This is likely because the PCNA-
dependent Cdt1 degradation pathway is no longer active in G2 and Cdt1 levels can 
start to accumulate. G2 is therefore the critical stage of the cell cycle where the 
presence of geminin is most important for preventing re-replication (Figure VI. 1). By 
holding cells at this stage, the G2/M checkpoint allows the amount of re-replication to 
increase, thereby amplifying the low levels of re-replication that may have initially been 
caused by geminin depletion. This could represent a protective mechanism to prevent 
small amounts of re-replication from accumulating in cells, by making re-replication an 
‘all or nothing’ response. Consistent with this idea, it was not possible to grow out 
colonies from cells that had already undergone re-replication. Therefore even modest 
amounts of re-replication ultimately led to cell death.  
  
 When the G2/M checkpoint was inhibited by Caffeine, cells were not arrested in 
G2 and progressed through mitosis into G1 without indications of substantial re-
replication. Interestingly, progression through G1 and S-phase was delayed in Caffeine 
treated and geminin depleted cells compared to control cells. One explanation is that a 
small degree of re-replication took place, causing activation of the G1/S checkpoint and 
G1/S delay. Alternatively, the low Cdt1 levels caused by geminin depletion could have 
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caused defects in licensing of replication origins, which would lead to impairments of 
DNA replication (Ballabeni et al., 2004).  
 Since Caffeine is known to inhibit ATM and ATR, either of these kinases could 
be responsible for the G2 delay in geminin depleted cells. Treatment with the ATM 
inhibitor KU55933 as well as depletion of p53 showed no impact on the levels of re-
replication or the ability of geminin depleted cells to progress through mitosis, 
suggesting that ATR kinase activity was responsible for the observed G2 delay. 
Moreover treatment of geminin depleted cells with the Chk1 inhibitor UCN-01 gave 
identical results to caffeine treatment.  
 Our conclusions are consistent with several previous studies showing that 
inhibition of checkpoint signalling or DNA damage response pathways in geminin-
defective cells leads to decreased levels of re-replication (Lin and Dutta, 2007; 
Melixetian et al., 2004; Zhu et al., 2004; Zhu and Dutta, 2006). These previous reports 
assumed that reduced levels of re-replication were due to increased apoptosis when 
DNA damage and checkpoint pathways were inhibited, but this could equally well be 
explained by reducing the period of time cells spend in G2, as we show here.  
 Consistent with our interpretation, re-replication induced by Cdt1 over-
expression is enhanced by inhibition of checkpoint kinases, since Cdt1-induced re-
replication occurs directly within S phase (no G2 delay is required) and checkpoint 
kinases suppress re-initiation of re-licensed origins (Davidson et al., 2006; Lee et al., 
2007a; Li and Blow, 2005; Liu et al., 2007; Vaziri et al., 2003).  
 Taken together our data suggest that re-replication can be induced by de-
regulation of geminin and Cdt1 and that depending on the cell cycle state, different 
checkpoint pathways play a role in preventing or enhancing re-replication.  
 A key example is the p53 checkpoint pathway, which seems to be activated in 
geminin depleted cells but plays little role in preventing re-replication (Melixetian et al., 
2004; Zhu et al., 2004). In contrast, re-replication induced by over-expression of Cdt1, 
Cdc6 and Cyclin A in p53-negative H1299 cells is inhibited by over-expression of p53 
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or p21 by inducing G1/S phase arrest (Vaziri et al., 2003). Recent studies showed that 
re-replication is induced by depletion of Forkhead box (FOX) proteins in human cells 
(Lo et al., 2010). FOX proteins are transcription factors that play a role in embryonic 
development, cell cycle progression and cell survival (Carlsson and Mahlapuu, 2002; 
Hannenhalli and Kaestner, 2009; van der Horst and Burgering, 2007). When FOX1 is 
depleted in HCT116 (p53-/-, p21-/-) cells re-replicate and apoptosis increases 
dramatically compared to wild-type cells, which arrest in G1/S-phase. Similarly re-
replication is enhanced when FOX1 and p53 are co-depleted in wild-type cells (Lo et 
al., 2012). It seems that the p53 checkpoint pathway plays an essential role in 
preventing initiation and S-phase progression when re-replication is induced in early S-
phase but is less important when re-replication is induced in G2 phase of the cell cycle.  
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Part VI. 2. Genomic Consequences of    
   chromosomal re-replication 
 To gain insight into genomic consequences of geminin induced re-replication of 
the human genome, the DNA content of cells that had undergone significant re-
replication was analysed via Comparative Genomic Hybridisation and Solexa deep 
sequencing. There are two different ways that re-replication could occur within the 
genome (Figure VI. 3). Origins could either re-fire reproducibly at preferential sites 
within the human genome causing detectable amplifications or re-initiate randomly 
across the genome resulting in no detectable copy number changes.  
 
 The initial 8x60K CGH microarray provided results that indicated re-replication 
of DNA may occur at preferential regions of the genome in geminin depleted cells. 
However, a second 4x44K CGH microarray and Deep sequencing revealed no 
amplification of specific regions across the whole human genome. The different results 
from both arrays are likely to be explained by technical problems with the first array. 
Although the Cy3 and Cy5 labelling quality was well in the range requested by the 
manufacturer, the quality plots clearly showed a very poor correlation of Cy5 signal 
intensity between technical replicates. Correspondence with Agilent technologies 
revealed that Cy5 has been shown to be sensitive to ozone degradation and levels as 
low as 10 µg/ m3 can compromise microarray results. Recently an updated version of 
the protocol includes stabilisation steps and an ozone-barrier slide cover to prevent 
degradation. Most likely ozone degradation could contribute to the bad quality of the 
array.  Due to the bad quality, invalid data points were filtered thus removing up to 40% 
of the data, which may generate the misleading results. However, the bad array quality 
raised sufficient doubts to immediately start reproducing the findings with a second 
array and deep sequencing.   
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Figure VI. 3. Refire option of replication origins in response to geminin depletion. Shown is 
a section of DNA with 4 licensed replication origins (A). One origin fires and the section is repli-
cated in S-phase (B). When rereplication is induced in G2 by geminin depletion two possibilities 
come in mind how refiring of origins takes place. The right panel illustrates how variable re-firing 
of origins or multiple variable re-firing would be visualised on CGH or deep sequencing analysis. 
When all origins have the same probability  to re-fire, no regions would appear amplified when 
DNA of a pool of cells is analysed. On the right panel the reproducible re-firing of one preferential 
origin  or multiple re-firing of one origin is presented. This scenario would show ampliefied regions 
of the genome if a pool of cells is analysed. The results presented in this work suggest that origins 
re-fire stochastically without preference for certain regins (light red box)
Figure VI. 3.
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 Deep Sequencing and the 4x 44K microarray did not provide any evidence for 
preferential amplification of any specific DNA sequences (Klotz-Noack et al., 2012). 
This is in marked contrast to studies in S. cerevisiae (Green et al., 2010; Green et al., 
2006) and Drosophila (Ding and MacAlpine, 2010) showing a preferred amplification of 
specific DNA regions after re-replication had been induced by de-regulation of the 
licensing system.  
 Green and colleagues designed an assay where re-firing of a specific origin 
could be achieved in G2/M phase in S. cerevisiae. They showed that non-allelic 
homologous recombination between repetitive elements took place leading to re-
replication induced gene amplification (RRIGA) in close proximity to the re-fired origin 
(Green et al., 2010). We cannot conclude that similar processes did not take place in 
our U2OS experiments but we can clearly say that they do not occur in the proximity of 
preferred origins (e.g. early or late origins), as this would result in amplified regions 
within the human genome which we did not observe by high resolution Solexa 
sequencing. It is currently unclear why our results differ from this mentioned report. It is 
hard to draw parallels between our results in human U2OS cells and results obtained in 
S. cerevisiae, since the mechanisms that suppress licensing in yeast are different from 
those in animal cells, and yeast even lacks geminin. 
  It is more surprising that our results differ from those results obtained by 
depletion of geminin in Drosophila, which preferentially showed re-replication of 
heterochromatin. Although we detected a small-scale (≈10%) increase in the re-
replication around some centromeres (chromosomes 4, 7, 10, 18 and 19) and 
telomeres (chromosomes 6, 10, 11, 12, 19 and 21), the increase was small and other 
known heterochromatic regions such as the p arms of chromosome 13, 14, 15, 21, and 
22 were not elevated. In addition to a differently used cell type, the Drosophila study 
used asynchronous cells (Ding et al (2010), and reached higher re-replication levels 
(~8C DNA content), though it is not obvious why these features would be critical for 
causing preferential re-replication of specific regions.  
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 We had initially expected re-replicating DNA to be enriched in sequences 
normally replicated early in S-phase, as these would be the first to replicate again 
following progression through mitosis and into the next cell cycle. However, a recent 
study in mouse cells revealed that G2 phase chromatin lacks any determinants of 
replication timing established during G1 phase of the cell cycle (Lu et al., 2010). When 
a complete genome re-duplication was induced in G2 phase cells, either by incubation 
in Xenopus egg extracts or following transient Cdk inhibition, replication did not follow 
any defined temporal sequence. Lu et al. used CGH analysis to compare the ratio of 
‘normal’ early versus late S-phase chromatin, which in a normal S-phase showed clear 
features of gain and loss according to early and late firing origins. During re-duplication 
of the genome starting from early G2 versus late S-phase chromatin clearly showed a 
ratio of approximately one, indicating that origins fire randomly if re-replication starts in 
G2 after timing information is lost. Taking this into consideration it would be expected 
that if geminin depletion induced re-replication predominantly from a G2 state, re-
replication would occur without any defined temporal sequence. Therefore all 
chromosomal domains have an equal probability of being re-replicated and DNA from a 
pool of >4C cells might not show preferential regions of re-replication.  
 As suggested by a previous report (Lin et al., 2010), it could be predicted that 
this would not be the case for re-replication induced by Cdt1 over-expression or 
MLN4924 treatment. When re-licensing of origins and consequently re-replication is 
induced in S-phase the timing pattern is present and replication starts at early 
replicating origins. Consequently re-replication would probably also start at early 
replicating origins as those would be re-licensed immediately by Cdt1 mediated MCM2-
7 re-loading. Consistent with this idea, Vaziri et al. (2003) showed that re-replication of 
human cells induced by over-expression of Cdt1 and Cdc6 generated heavy-heavy 
DNA that hybridised preferentially to early replicating regions on metaphase 
chromosome spreads (Vaziri et al., 2003). This is in contrast to the data presented in 
this thesis, but can be explained by the different experimental setup. Cdt1 stabilisation 
has been shown to induce re-replication in S-phase (Klotz-Noack et al., 2012; Lin et al., 
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2010; Milhollen et al., 2011; Soucy et al., 2009) while geminin depletion induces re-
replication from G2 (Klotz-Noack et al., 2012). These two pathways are likely to be 
different in terms of re-replication origins. It could well be that Solexa sequencing of 
MLN4924 treated cells would reveal that re-replication starts at early replication origins, 
simply because Cdt1 is active in S-phase and can facilitate the immediate re-licensing 
and re-firing of origins according to the replication timing programm. 
 Since MLN4924 is in trial as an anti-cancer agent, it would be interesting to 
know if different ways of inducing re-replication can be used to exploit different 
sensitivities between normal and cancer cells.  	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